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ABSTRACT
MOLECULAR CHARACTERIZATION OF HUMAN PAPILLOMAVIRUS
IN HEAD AND NECK TUMORS
Sujita Khanal
July 15, 2016
Head and neck cancers (HNCs) are common causes of cancer-related deaths
worldwide. An increasing incidence of subsets of HNCs is due to human papillomavirus
(HPV). Other subsets are associated with tobacco and alcohol use. Determination of
differential biomarkers and molecular mechanisms distinguishing HPV-associated and
unassociated HNCs should improve diagnostic and therapeutic strategies. This study was
designed to identify potential biomarkers for HPV detection, and to evaluate viral and host
genetic and epigenetic mechanisms involved in HPV-associated HNCs.
INK4a

Overexpression of a cellular protein, p16

, which is widely used as a surrogate

marker for HPV-positive HNC, is non-specific because some HPV-negative cancers can
INK4a

overexpress p16

. I found “mitosoid cells” and “HPV E7 serology”, respectively, as

histologic and serum biomarkers, which would improve diagnosis of HPV-positive head and
neck (HN) tumors. Mitosoid cells were not only observed in HPV-positive benign epithelial
hyperplasias but also abundantly present in subsets of pre-malignant tumors (high-grade oral
INK4a

epithelial dysplasia, hgOED). P16

could be used as an HPV-surrogate marker only in

Group 1 hgOED (containing diffuse mitosoid cells), but not in Group 2 (with focal mitosoid
cells) and Group 3 (lacking these cells). My study revealed that E7 seropositivity
INK4a

complements p16

overexpression in HNCs and a decrease in E7 serology potentially

predicts patients’ response to treatment. To evaluate genetic and epigenetic changes in HPVinduced malignancy, I assessed viral DNA- integration and -methylation, and viral-induced

v

methylation of host tumor suppressor genes (TSGs). Since viral DNA integration predicts
malignancy, my data showing integrated HPV in Group 1 and malignant tumors, suggest
greater malignant transforming potential of Group 1 than the other groups. Although viral
methylation is another regulatory mechanism for malignancy, the HPV epigenome was mostly
unmethylated in both premalignant and malignant HN tumors. Screening 38 host TSGs
identified EREG as a candidate gene, which may be epigenetically regulated, specifically in
HPV-positive HNC.
Overall, the present study found that mitosoid cells and E7 serology in combination
INK4a

with p16

overexpression are significant markers for HPV-associated head and neck

malignancy. HPV DNA integration and host EREG gene methylation, but not viral DNA
methylation, may play roles in HPV-associated head and neck carcinogenesis.
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CHAPTER I
INTRODUCTION ON HUMAN PAPILLOMAVIRUS AND HEAD AND NECK TUMORS

Human papillomavirus (HPV)

Papillomaviruses are small, non-enveloped, icosahedral DNA viruses that have a
diameter of 50–60 nm. Papillomaviruses (PVs) are species-specific, and can infect different
mammals, birds, and reptiles. Human papillomavirus (HPV) are PVs that infect human
epithelial cells (i.e. they are epitheliotropic in nature) (1). HPV is the most common sexuallytransmitted infection worldwide including the United States (2,3). HPVs are tissue-specific and
normally infect either cutaneous or mucosal tissue, although some are both cutaneous and
mucosotropic (1). In 1974, the German virologist Harald zur Hausen found that the skin wart
virus, HPV, contributes to the development of cervical cancers (4,5). Almost 10 years later,
his group isolated HPV type 16 DNA from a cervical squamous cell carcinoma (6). He was
awarded the Nobel Prize in Physiology or Medicine 2008 for this discovery. Presently, HPV is
known to cause virtually all cervical cancers. Recent studies have shown that HPV-associated
cancers are not just limited to the anogenital region. Instead, HPV is a highly prevalent human
pathogen and causes ~5% of all solid-organ cancers worldwide (7). During the past few
years, there has been considerable interest in the involvement of HPV in upper aerodigestive
sites and its etiologic role in causing head and neck tumors.

HPV genome

Papillomaviruses contain a circular, double-stranded DNA genome of approximately 8
kb. HPV genome contains a number of open reading frames (ORFs) classified as either early
or late depending on the timing of their expression after infection. The genome also includes a
long control region (LCR) or upstream regulatory region (URR), which lacks ORFs but
contains cis-responsive elements that govern viral replication and gene expression.

1

Figure 1 shows a genomic map of HPV type 16. The six early ORFs [E1, E2, E4 and E5
(in green) and E6 and E7 (in red)] are expressed from promoter either p97 or p670 (in the
case of HPV16) at different stages of epithelial cell differentiation. The late ORFs [L1 and L2
(in yellow)] are also expressed from p670. All the viral genes are encoded on plus (+) strand
of the double-stranded circular DNA genome.

Figure 1: HPV type 16 genomic map showing early genes (E1, E2, E4, E5, E6, and E7), late
genes (L1 and L2) and long control region (LCR) (Copyright permission obtained from John
Wiley and Sons).
The late genes encode for the structural proteins L1 (major capsid protein) and L2
(minor capsid protein), which are only expressed in productive infections. During this
productive infection, HPV genomes are packaged within the capsids for viral assembly and
release from keratinocytes. The early genes E1, E2, E4-E7 are expressed prior to initiation of
viral replication, but not the late genes. Among all genes, L1 and E1 genes are highly
conserved among all papillomaviruses (8).
E1, in combination with E2, has a regulatory function. E1 encodes a protein with
ATPase and helicase activities and is essential for viral replication (9). E2 gene encodes a
DNA-binding protein that binds to target sequences around the viral origin and recruits the E1
helicase which in turn is involved in replicating the viral genome by recruiting host replication
proteins (10). In addition to its role in viral DNA replication, the E2 protein functions as a

2

transcriptional repressor for the expression of E6 and E7 oncoproteins. The gene for the E4
protein overlaps the E2 ORF (10). E4 proteins are expressed relatively late during infection
before the expression of L2 and L1 and help in the maturation of viral particles (11,12). While
a definite oncogenic role of E5 is not clear, it is thought to augment oncogenic activities of E6
and E7 proteins, and allow the continuous proliferation of the host cell delaying differentiation
(12,13).
E6 and E7 are the main oncoproteins of high-risk HPVs. The E6 and E7 proteins bind
and promote the degradation of the host p53 and retinoblastoma (pRb) tumor suppressor
proteins, respectively (14) (Figure 2). Since most HPV-positive cancer cells harbor wild-type
TP53 and Rb tumor suppressor genes, these cells have intact but dormant tumor suppressor
pathways due to the continuous expression of E6 and E7 genes (15). E6 binds the tumor
suppressor protein p53 and promotes ubiquitin-mediated proteasomal degradation of p53.
Hence, HPV-infected cells do not undergo apoptosis or cell cycle arrest even if DNA is
damaged. E6 also activates the expression of hTERT, the catalytic subunit of telomerase and
increases telomerase activity, contributing to cell immortalization (16,17). E7 is another major
oncoprotein. E7 binds with pRb protein and its family proteins, p107 and p130, and disrupts
their ability to form complexes with E2F transcription factors, resulting in increased expression
of E2F-responsive genes, many of which are required for cell cycle progression. In addition,
the E7 protein accelerates degradation of hypophosphorylated pRb family members.
INK4a

Inactivation of pRb by E7 can be monitored by overexpression of p16
often used as a surrogate marker of HPV infection (18).
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(Figure 3), which is

Figure 2: The combined effects of HPV E6 and E7 oncoproteins in malignant transformation.
E7 and E6 inactivate tumor suppressor proteins pRb and p53, respectively. E6 also increases
telomerase activity (Copyright permission obtained from Elsevier)
The long control region (LCR), also called upstream regulatory region (URR)
regulates the transcription of viral genes, particularly oncogenes E6 and E7. The LCR
contains viral promoters, enhancers, the replication origin and binding sites for several viral
and cellular transcription factors, which are important for viral replication and gene expression
(10).
The expression of HPV E6 and E7 proteins is inhibited by the viral E2 protein through
its interaction with the early promoter p97 located in the LCR. This promoter harbors four
specific E2-binding sites (E2BSs) sharing the consensus sequence 5′-ACCG(N)4CGGT-3′
(19) (Figure 3). The three sites proximal to the TATA box, importantly E2BS2, E2BS3, and
E2BS4, have been shown to be involved in E2-mediated repression of the promoter activity
(20). Binding of E2 protein to E2BS inhibits the docking of transcription activators, such as
specificity protein 1 (Sp1) and TATA-binding protein (TBP), from their binding sites, leading to
a repression of E6 and E7 expression from the early promoter (21) (Figure 3). The integration
of viral DNA in high-risk forms of HPV has been described as a key step in carcinogenesis
since it generally results in the disruption of the E2 ORF (22). Additionally, DNA methylation
on LCR region is shown to inhibit binding of the transcriptional repressor (E2), resulting in the
overexpression of viral oncoproteins, leading to malignant transformation (23,24).

4

Figure 3: HPV long control region (URR) showing E2 and other transcription factor binding
sites. Binding of E2 to E2BS causes repression of E6 and E7 expression.

Classification of HPV types

Papillomaviruses (PVs) belong to the family Papillomaviridae. Each PV has
traditionally been referred as “type”. An HPV type is defined as an HPV isolate where the
nucleotide sequence of the highly conserved viral L1 gene is at least 10% different from any
known HPV type (25,26). More than 150 PV types are capable of infecting humans and thus
are referred to collectively as human papillomaviruses (HPVs).
Isolates of the same HPV type are referred to as “variants” or “subtypes” when the
nucleotide sequences of the L1 gene differ by less than 10%. An HPV variant contains a
unique combination of single nucleotide polymorphisms (SNPs) mainly in E6 and/or LCR
gene (27). Names of HPV variants are derived from the geographical origin of the human
populations in which they are most prevalent. For example, HPV type 16 variants have been
classified into 4 major lineages: European-Asian, African 1, African 2, and Asian
American/North American (28,29).

HPV types fall into 5 genera (namely- Alpha, Beta, Gamma, Mu, and Nu) based on
sequence comparisons of L1 genes (members of the same genus share >60% nucleotide
sequence identity between L1 genes). Many types of HPV, especially those of the Beta and
Gamma genera, cause asymptomatic infections without the apparent disease. The most
clinically significant group is the Alpha genus which includes HPV types that infect cutaneous
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or mucosal sites. Cutaneous types include HPV2 and HPV57, which cause common warts
and HPV3 and 10, which cause flat warts. Mucosal HPV types are sub-divided into low-risk
types and high-risk types depending on the strength of their association with carcinogenesis,
Table 1 (4,30). High-risk HPV mucosal types (such as HPV16 and 18) are highly associated
with the development of precancerous and cancerous lesions while low-risk types (such as
HPV6 and 11) cause benign conditions such as genital warts and respiratory papillomatosis
(30). HPV is so common that nearly all sexually active people will have it at some point in
their lives (2). However, only persistent infections with specific subsets of high-risk HPVs are
responsible for the development of cancer (31). Among the high-risk HPV types, HPV16 and
18 are frequently found to be associated with malignancy. Between these two HPV types,
HPV16 is the most prevalent carcinogenic HPV (32).
Table 1: High-risk and low-risk HPV types, based on their oncogenic potential
High-risk HPV

16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59

Putative high-risk HPV

23, 53, 66, 67, 68, 73,82

Low-risk HPV

6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, CP6108

Strategies for HPV detection, their strengths, and limitations
An ideal test for HPV would be highly sensitive, specific, cost-effective, and simple in
the application so that it could be easily employed in routine diagnostic pathology practice.
But none of the currently used HPV testing strategies completely satisfy all of these criteria.
Depending on the technique used, the results of HPV detection can vary widely.
Polymerase chain reaction (PCR)-based method of detecting a well-conserved HPV L1
gene is very sensitive and can detect a large number of HPV types. However, this method is
relatively more expensive and is not readily available in the routine pathology laboratory, and
turnaround time is also longer. Also, because of the very high sensitivity, this method requires
proper handling and processing of samples to avoid a false positive result due to crosscontamination (33). Another method of detecting HPV DNA is in situ hybridization (ISH).
Although ISH is more specific, it is less sensitive than PCR and requires technical expertise to
interpret results (33,34). Also, ISH method cannot detect all HPV types using commercially
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available HPV probe cocktails. Both PCR and ISH- based HPV DNA detection method are
unable to detect transcriptionally active HPV (i.e. E6/E7 expression).
As HPV-driven tumor growth is caused by E6 and E7 expression, PCR detection of
E6/E7 mRNA is the best method to detect transcriptionally active HPV (34). However, this is
technically challenging to be used in clinical laboratory and can’t be performed effectively on
formalin-fixed, paraffin-embedded (FFPE) tissues (35). A recently developed technique, RNA
in situ hybridization is effective in FFPE tissues and is highly sensitive and specific for
detecting E6/E7 mRNA (36-42). As this technique is technically cumbersome and is not yet
commercially available (34), other techniques are often used in clinical practice. For example,
INK4a

immunohistochemical detection of p16

expression in tumor tissue sections is commonly

used in the clinic as surrogates for HPV status (43). This is based on the premise that HPV
infection leads to the production of the E7 oncoprotein, which inactivates pRb tumor
INK4a

suppressor protein and releases p16
overexpression of p16

INK4a

gene from transcriptional inhibition thereby causing

in HPV-associated cancers, Figure 4 (34,44,45).
INK4a

Immunohistochemistry (IHC) for p16

is inexpensive, highly sensitive and can be

performed in virtually any histology laboratory with very quick turnaround (34,46).
Overexpression of p16

INK4a

is often used as a surrogate marker of HPV infection in

oropharyngeal cancers, while its use in oral cavity cancers is not well established, even
though both are subgroups of HNC (46,47). Current studies show that other non-viral
INK4a

mechanism can also increase p16

expression, making it a non-specific marker for HPV

infection, Figure 5 (18,46,48). This warrants the need for reliable and appropriate biomarkers
to precisely diagnose HPV status in head and neck tumors or to determine HPV-associated
cancer progression.
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Figure 4: Presence of high-risk (HR)-HPV causes overexpression of p16
INK4a

p16

INK4a

; as such

immunohistochemistry is used as a surrogate marker of HPV infection. The

functional inactivation of pRb by HPV oncoprotein E7 results in the release of the
transcriptional factor E2F from the pRb–E2F protein complex and lead to the release of the
INK4A

p16

gene from its transcriptional inhibition.

INK4a

Figure 5: p16

is not always a surrogate marker of HPV infection. p16

INK4a

is also

overexpressed via non-viral mechanisms

HPV-associated clinical lesions in head and neck region
In the head and neck region, the majority of HPV-associated clinical manifestations
occurs in squamous epithelium and includes benign lesions, premalignant dysplasia, and
carcinomas.

1. Benign Lesions of the head and neck
There are many different types of benign oral tumors. In this study, I focused on two types
of benign lesions of the oral cavity - Multiple Epithelial Hyperplasia (MEH) and squamous
papilloma.
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a. Multiple epithelial hyperplasias: MEH is an HPV-associated benign proliferation of oral
squamous epithelium. It is also known as Heck’s disease or focal epithelial hyperplasia
(FEH) (49). It commonly occurs in Native Americans in the US but is rare among
Caucasians. It usually presents in children/adolescents or HIV-infected adults and is
typically associated with HPV type 13 or 32. It occurs as multiple slightly elevated and
minimally keratinized papules located mainly on labial and buccal mucosa. A prominent
feature of MEH is the mitosoid cell; an enlarged cell with a fragmented nucleus
resembling atypical mitotic figure (50,51). These cells are consistently observed in MEH.
Although asymptomatic and self-limited in its course, the distinction of MEH from another
benign oral lesion (for example, squamous papilloma) is important since these lesions
may have overlapping clinical and histologic features.
b. Squamous papilloma: Squamous papillomas are common benign epithelial lesions of
the head and neck region. It has been suggested that many of these lesions have a viral
origin but the etiology is still controversial. Several reports have demonstrated the
presence of HPV in squamous papillomas (52,53). However, the presence of HPV in
these types of lesions varies from one study to another (53-56). Of note, squamous
papilloma may show some clinical and histologic overlap with MEH.

2. Premalignant lesions of the head and neck
Dysplasia is defined as an abnormality in maturation of epithelial cells. In other words,
squamous dysplasia is the precancerous state referring to metaplastic alterations of the
surface epithelium prior to the invasion of the subepithelial tissues. These changes include
abnormal cellular organization, increased mitotic activity, and nuclear enlargement with
pleomorphism. Although terminology varies, atypia limited to the lower one-third of the
epithelium is generally referred to as mild dysplasia, atypia limited to the lower two-thirds as
moderate dysplasia, and atypia involving the full thickness of the epithelium as severe
dysplasia/carcinoma in situ. With progression, the carcinoma in situ breaks through the
basement membrane and invades the subepithelial connective tissue (57).
In this study, I focused on high-grade oral epithelial dysplasia (i.e. severe
dysplasia/carcinoma in situ). These are pre-cancerous lesions which often develop into oral
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squamous cell carcinoma (SCC), a subset of head and neck SCC (58). Studies of HPVassociated cervical carcinogenesis have looked at clearly defined stages, including
asymptomatic infection, cervical intraepithelial neoplasia (CIN) stages I to III, and cancer (59),
whereas HNC studies conducted to date have mainly focused on primary cancers. As such,
there are few studies evaluating the presence of HPV in the pre-cancerous lesions.

3. Head and neck squamous cell carcinoma
The majority of the cancers in the head and neck region develop from thin, flat cells
called squamous cells. Cancer that starts in the layer of squamous cells is called squamous
cell carcinoma. Head and neck squamous cell carcinoma (HNSCC) or head and neck cancer
(HNC) is the sixth most common cancer and eighth leading cause of cancer-related deaths
worldwide and it represents about 3% of all cancers in the United States (60,61). It develops
in the mucosa of the upper aerodigestive sites including oral cavity, oropharynx, hypopharynx
or larynx (62). Because of anatomic locations associated with the ability to look, talk, eat and
breathe, these cancers can highly affect the quality of life. There are two major risk factors for
the development of HNC: exogenous carcinogens (namely tobacco and alcohol exposure)
and infection with HPV. Cancer-related death ranges widely from 20-60% in patients
presenting with locally advanced forms of HNC. While many tobacco-related cancers are on
the decline owing to decreases in smoking among Americans, the number of HPV-related
HNC cases appears to be increasing (62).
HPV-associated and unassociated HNCs display differences in clinical outcome:
patients with HPV-positive HNC respond better to chemo/radiotherapy and have higher
overall survival rates (63,64). Because of this, many clinicians advocate for a reduction in
treatment intensity for patients with HPV-induced cancers to minimize post-treatment
morbidity (65). However, a reduction in treatment intensity risks the possibility of undertreatment, tumor progression, and metastasis in patients who are HPV negative and may
have responded to current high-intensity treatments (66). So, a detailed understanding of
HPV status of HNC patients is warranted to determine appropriate therapies.
The molecular profiles of HPV-positive HNC are distinct from those of HPV-negative
cancers. In HPV-positive cancers, HPV oncoproteins E6 and E7 promote the degradation of
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INK4a

p53 and pRb tumor suppressors, respectively, and p16
Overexpression of p16

INK4a

protein is upregulated.

protein is the result of the effect of the viral E7 protein in

suppressing the function of pRb. In contrast, in HPV-negative HNC, TP53 is frequently
INK4a

mutated and p16

is under-expressed. HPV-negative HNCs are reported to accumulate a

large number of cellular mutations compared to HPV-positive HNCs (67,68). These molecular
differences are suggested to be the reasons behind better prognosis of HPV-positive HNC.
However, the specific mechanisms responsible for improved prognosis/survival in HPVpositive patients have not been fully elucidated. For these reasons, the knowledge of
differential mechanisms distinguishing HPV-positive and -negative HNC is very important;
which may underlie the molecular basis of improved prognosis for HPV-induced cancer as
well as provide opportunities for new therapeutic development.

Figure 6: Pictorial representation of the anatomy of the head and neck cancer showing
different subgroups (Copyright permission obtained from Terese Winslow LLC, U.S. Govt).

There are different subgroups of HNCs based on anatomic locations (69) (Figure 6).
HNCs driven by tobacco and alcohol use can occur anywhere throughout the upper
aerodigestive tract while cancers driven by HPV appear to be mostly localized to the
oropharynx (34).
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Oropharyngeal squamous cell carcinoma (OPSCC or OPC): The incidence of OPC
is increasing as smoking-related cancers decrease (43). This increase is due to HPV, which
has emerged as the primary etiologic factor in OPC, surpassing tobacco and alcohol as risk
factors in this type of HNC (70). Cohort studies from the 1990s suggested that approximately
50% of oropharyngeal cancers were attributable to HPV, while more recent studies suggest
that HPV accounts for 70 to 80 % of cases in North America and Europe (71).
An oropharyngeal subsite of the head and neck region most affected by HPV includes
the soft palate, base of tongue, tonsils, throat walls and oropharynx (72). More specifically,
HPV infection is most commonly associated with the palatine and lingual tonsils (62).
Oral cavity squamous cell carcinoma (OCSCC): The possible role of HPV in the
etiology of OCSCC is currently not well-defined. The role of HPV in carcinogenesis of the oral
cavity is further obscured by discordant findings between p16

INK4a

IHC and HPV testing in

these tumors. While HPV is detected in relatively few OCSCC tumors, the majority of these
INK4a

tumors exhibit overexpression of p16

INK4a

(58,73). Reports show that the majority of p16
INK4a

positive OCSCC were negative for HPV (74-76), suggesting that p16

-

is not always an

absolute marker to detect HPV. In OCSCC, non-viral mechanisms appear to stimulate
INK4a

p16

overexpression, making it relatively non-specific and therefore an increasingly

unreliable surrogate marker for HPV detection in OCSCC (74-76).
Other HNC types are nasopharyngeal, laryngeal and hypopharyngeal carcinoma
where tobacco and alcohol are the main risk factors/ primary etiologic agents. These types of
cancers in head and neck region are found to be less likely to be associated with HPV (77).

Biology of HPV infection

HPV infections are most frequently seen in the epithelia of the uterine cervix and
head and neck region. The biology of HPV infection in cervical cancers has been welldocumented but there is less information available for HNCs.
In cervical cancer, HPV virions attach to the basement membrane and preferentially
infect basal cells in cervical transformation zone, located in the boundary between the
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squamous epithelium of ectocervix and the columnar epithelium of endocervix (called
squamocolumnar junction) (4). Viruses are known to use the host cell machinery for
replication. As the HPV-infected keratinocytes differentiate and move toward the epithelial
surface, different viral genes are expressed, allowing high viral genome amplification and the
expression of the late region genes that encode the viral capsid proteins necessary to
complete viral life cycle (78). As the cells reach the surface, the HPV episomes are packaged
within the capsids for final viral assembly and release (called lytic infection) (79). Abnormal
cell growth in the lower 1/3 of the cervical epithelium is classified as HPV infection or cervical
intraepithelial neoplasia 1 (CIN1) and 2/3 of the way from the basal layer as CIN2. These
CIN1 and CIN2 lesions typically disappear within a few months by the immune system (80).
However, the persistent infection causes abnormal cell growth to penetrate the entire
thickness of cervical epithelium causing CIN3 or carcinoma in situ. When abnormal cells
invade the basal membrane and spread into the tissues beneath, the condition becomes
cervical cancer (81).
The biology underlying HPV infections in the head and neck region is largely
unknown, particularly in areas other than the oropharynx. Oropharyngeal tissues do not
contain squamocolumnar junctions. However, the palatine and lingual tonsils are lined with
stratified squamous epithelium and contain numerous tonsillar crypts that extend through the
full thickness of the tonsil (82,83). These crypts are lined with specialized reticular epithelium
that has a porous basal cell layer and disrupted basement membranes. It has been proposed
that the structural porosity of the tonsillar reticulated crypt epithelium allows HPV access to
the basement membrane and infection of basal cells without the associated trauma observed
in cervical cancer (57).
Since tumorigenesis in oropharynx often occurs deep within the crypts, it is difficult to
identify premalignant precursors on the tissue surface (47). Unlike oropharyngeal cancers
(OPC), oral squamous cell carcinoma (OSCC) often develops from a clinically apparent
leukoplakia (84) that shows microscopic evidence of oral epithelial dysplasia. Therefore, oral
cavity pre-malignant lesions may provide an in vivo model to study the development of head
and necks involving an HPV etiology.
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Molecular events associated with HPV malignancy

Studies in cervical cancer, the most widely characterized HPV-associated
malignancy, indicate that HPV-driven malignant conversion is associated with specific
molecular events. HPV-associated carcinogenesis requires continuous overexpression of the
two main viral oncoproteins E6 and E7, which interact with many cellular proteins leading to
the induction and maintenance of a transformed phenotype in infected cells (15). E6 and E7
expression are regulated by the viral E2 protein through the early promoter (termed p97 for
HPV16) located in the LCR of the viral genome. Overexpression of E6 and E7 is caused
either by disruption of E2 gene via HPV genome integration or by inhibition of E2 protein
binding to the LCR via methylation of viral DNA. Therefore, the integration and methylation of
viral DNA are considered as two main regulatory mechanisms for malignant transformation,
mainly in the cervical region (85). Additionally, DNA hypermethylation of host genes was
frequently detected in advanced forms of cervical cancer (86-90). In contrast, molecular
events culminating in malignant transformation of the HPV-infected head and neck cells are
largely unknown.

HPV DNA integration

HPV DNA may exist in the episomal (extra-chromosomal) form and/or become
integrated into the host genome (Figure 7A). HPV DNA integration into the host genome has
been considered to be an important molecular event during HPV-induced cervical
carcinogenesis (91,92), (Figure 7B). In most invasive cervical cancers, high-risk HPV
genomes are integrated into the host genome mainly via mechanisms that disrupt the E2
reading frame (93-95). Lack of E2 results in up-regulation of the viral oncogenes E6 and E7,
thereby promoting tumorigenesis (Figure 7). In addition to invasive cervical cancers,
integration of HPV DNA was also found in premalignant cervical intraepithelial neoplasia
(CIN2/3). In contrast, in benign and low-grade cervical lesions the predominant form of HPV
DNA is episomal (96,97). Accordingly, different patterns of HPV DNA integration are currently
used to monitor cancer progression in cervical cancer patients (98,99).
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While viral integration is thought to play an important role in cervical carcinogenesis
(92), the relevance of viral DNA integration is controversial in head and neck tumors (100).
Some studies suggest that viral DNA integration in the head and neck sites plays an
important role in carcinogenesis (83,101-105), while other studies suggest that episomal HPV
alone contributes to the development of most HNCs, in contrast to what is observed in
cervical cancers (100,106-108). Therefore, more research needs to be done to better
understand the role of HPV DNA integration in head and neck malignancy.

HPV DNA methylation

Methylation of DNA is facilitated by a family of DNA methyltransferases (DNMTs) that
catalyze the addition of methyl group to cytosine located in CpG dinucleotides. Like the
human genome, the HPV genome is subject to epigenetic regulation through alterations in
DNA methylation. There are 15 CpG sites in the LCR of HPV16 genome (Figure 8).
Methylation of these 15 CpG sites (mainly 5 sites) inhibits the binding of E2 protein to E2BS,
in turn, leads to an overexpression of E6 and E7 from the early promoter, Figure 8.
Methylation of the five CpGs located in the E2BS3 and E2BS4 and Sp1-binding site (Sp1BS)
has been suggested as biomarkers for cervical cancer progression (23,24). Such
hypermethylation has been reported in cervical cancers or high-grade cervical dysplasia
compared with low-grade CIN (23,109,110). But it is unknown whether or not viral methylation
in HNC has a similar association with malignancy, although recent studies have suggested
that there may be some similarities between cervical cancers and HNCs with respect to viral
methylation (111). In contrast, a large study reported hypomethylation of the LCR of the viral
genome in oropharyngeal cancers (112). Therefore, more research remains to be done to
clarify a role of viral methylation in HPV-associated HNCs.
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A.

B.

Figure 7: (A) Episomal and integrated forms of HPV DNA. Integration of HPV DNA is
associated with loss or disruption of E2, and subsequent upregulation of E6 and E7 oncogene
expression. (B) HPV-DNA integration- mediated progression to cervical cancer.
HPV infects basal cells in the cervix. Low-grade cervical intraepithelial lesions (CIN) support
productive viral replication. The progression to high-grade CIN and invasive cancer is
associated with the integration of the HPV genome into the host chromosomes (red nuclei)
from episomal HPV (dark blue nuclei). (Copyright permission obtained from Nature Publishing
Group)
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Figure 8: Upstream regulatory region of HPV16. Methylated E2BS inhibits the binding of E2
transcriptional repressor and in turn, increases E6 and E7 transcription. Fifteen CpG sites are
shown along with their respective nucleotide positions using an Asian-American variant of
HPV16 (Genbank accession number: AF402678.1) as a reference sequence.

Host genomic epigenetic changes

DNA methylation is one of the most intensely studied epigenetic modifications in
humans. In normal cells, DNA methylation plays a role in maintaining genome stability and in
regulating the expression of genes involved in signal transduction cascade pathways, cell
cycle regulation, angiogenesis, apoptosis, and DNA repair (113). Methylation of DNA typically
occurs on cytosines located in CpG dinucleotides, which are usually concentrated in large
clusters called CpG islands. The methylation of cytosine residues is mediated by a class of
enzymes called DNA methyltransferases (DNMTs) that catalyze the transfer of the methyl
group from S-adenosyl-methionine to the carbon 5 position of cytosine (Figure 9A). DNA
methylation often leads to gene silencing after chromatin structure remodeling (114). MethylCpG-binding proteins (MBD) associates with methylated CpG that, in turn, recruits histone
deacetylases (HDAC). As a consequence, chromatin becomes compacted and gene
expression is inhibited (113), (Figure 9C).
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Figure 9: Mechanism of gene silencing mediated by DNA methylation. A) Cytosine
methylation catalyzed by DNMT in the presence of S-adenosyl-methionine (SAM). B)
Unmethylated CpGs within the promoter region allows gene expression while methylated
CpGs causes silencing of genes. C) DNA methylation occurs through the recruitment of
methyl-CpG-binding proteins (MBD) and histone deacetylases (HDAC) resulting in compacted
chromatin and gene inhibition (Copyright permission obtained from Elsevier)

Aberrant methylation of gene promoters, particularly of tumor suppressors can lead to
their transcriptional repression, thereby resulting in the pro-carcinogenic environment
(115,116). Recent studies have identified epigenetic alteration, most importantly aberrant
DNA methylation, as a possible cause of progression of various cancers (116-118). In
addition, recent evidence revealed that HPV16 induces DNA methylation in infected cells by
up-regulating DNMTs (DNMT1 and DNMT3a) (119,120). Different studies related to
epigenetic alterations have been largely investigated in cervical cancers, where
hypermethylation of viral and host genes was frequently detected in advanced cancers (8690). In addition to cervical cancers, aberrant promoter hypermethylation also has been
identified in the progression of HNCs (121,122). However, the differences in epigenetic
anomalies between HPV-positive and HPV-negative HNCs are not well-defined (123-125). A
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better understanding of these abnormalities will help to know the epigenetic mechanism
regulated by the presence of HPV in HNCs.

Dissertation Overview

Overall Goal
The information summarized above suggests that understanding molecular events
involved in HPV-associated head and neck cancer progression will have diagnostic and
prognostic significance. Therefore, it is crucial to study HPV-associated potential biomarkers
and molecular events that occur early in head and neck cancer progression in order to
enhance detection. The ability to document an HPV etiology for HNCs can affect therapeutic
decision-making, factor into a patient’s long-term prognosis, and identify new therapeutic
targets.
Hypothesis and Research Aims
The overall aim of my dissertation is to identify potential biomarkers and ascertain
underlying molecular mechanisms associated with HPV-positive head and neck malignancy. I
hypothesized that head and neck tumors display distinct HPV-associated biomarkers and
oncogenic mechanisms for malignancy, which differ from that of HPV-negative head and neck
tumors.
My dissertation includes three major areas of investigation outlined in chapters 2, 3,
and 4. In chapter 2, I analyzed tumors of the head and neck for the presence of HPV and
found that HPV-positive tumors were molecularly and histologically distinct. In chapter 2 and
3, I identified potential clinical biomarkers for the detection of HPV-associated head and neck
malignancies. Finally, in chapter 4, I focused on the role of HPV DNA integration, HPV
methylation and host gene methylation in tumors of the head and neck to identify genetic and
epigenetic mechanisms involved in HPV-mediated malignancy.
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CHAPTER II
HISTOLOGIC VARIATION IN HEAD AND NECK TUMORS WHEN ASSOCIATED WITH
HUMAN PAPILLOMAVIRUS

Chapter Overview

Recently, HPV has been found to be increasingly implicated as a causative agent in
different types of tumors in the head and neck region. In this chapter, I determined the
involvement of HPV in pathologically distinct tumor specimens of the head and neck and
identified potential histological biomarkers which could be used to detect HPV infection.
This chapter is divided into three sub-headings, based on the study conducted on
different head and neck tumor specimens:
1. Benign oral lesions (126)
2. Premalignant oral lesions (127)
3. Carcinoma of head and neck

1. Benign oral lesions

Introduction
Multifocal epithelial hyperplasia (MEH) or Heck’s disease is a benign oral condition
that occurs in Native American children/adolescents or HIV-infected adults in the United
States but is rare among Caucasians and HPV-negative adults. It is typically associated with
low-risk HPV infections typically involving HPV type 13 or 32 (49). Histologically, MEH lesions

[A study of benign oral lesions was published in 2015 (126) and copyright permission was obtained from
Elsevier to reuse in this dissertation. A manuscript regarding premalignant lesions is currently under revision for
publication in Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology; an abstract published in 2016 (127)]
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are characterized by mild hyperkeratosis and thickening of the epithelium with elongated rete
ridges. A prominent feature is the presence of a mitosoid cell, an enlarged cell with
atypical/fragmented nucleus resembling a mitotic figure (50,51). Mitosoid cells are atypical
mitotic figures, which are usually seen in well-differentiated upper epithelial layers of
hyperplastic oral mucosa (128).
Recently, we have identified oral lesions that mimic MEH microscopically but occur in
adult Caucasian patients who are not known to be HIV positive. Oral squamous papillomas
are another HPV-associated benign lesion which shows clinical & histological overlap with
MEH but do not occur in the clinical setting expected for Heck’s disease (i.e. children/
adolescents) (52). It is important to distinguish different forms of MEH from one another and
from squamous papilloma. HPV genotyping could potentially contribute to differentiating
between these different lesions. Herein, I performed HPV genotyping of oral lesions
microscopically consistent with MEH and compared these results with those derived for
squamous papilloma.

Experimental Procedures
Patient’s biopsy sample collection: This study was approved by the Institutional Review
Board (IRB) at the University of Louisville. MEH (N=22, 17 patients) and squamous papilloma
(N=9, 9 patients) samples were selected based on well-defined histologic criteria.
Histologically, MEH should have thickening of the epithelium (acanthosis) with elongated rete
ridges and mitosoid cell(s) within the well-differentiated upper epithelial layer called spinous
cell layer (Figure 10). The histologic inclusion criteria for squamous papilloma were:
keratinized stratified epithelium with finger-like surface projection and without the presence of
any mitosoid cell(s).
Genomic DNA extraction and HPV detection: Formalin-fixed, paraffin-embedded (FFPE)
specimens were deparaffinized using xylene, followed by an ethanol wash. DNA was
extracted using DNAeasy Blood & Tissue kit (Qiagen, USA) as per manufacturer’s
instructions. HPV DNA detection was performed by PCR amplification using conventional
degenerate MY09/11 and GP5+/GP6+ consensus primers to a well-conserved HPV L1 gene.
Both primers can detect a wide range of HPV types. The reaction conditions were as follows:
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50-100ng of template DNA, HiFi PCR buffer, 50mM MgSO4, 10mM dNTPs, 20µM of each
primer and 1U of HiFi Taq polymerase (Invitrogen) in a total volume of 20μl reaction mixture.
PCR reaction consisted of an initial 94°C incubation for 2 min, followed by 44 cycles of
denaturation at 94°C (45 sec), annealing step at 56°C (for MY product) or 48°C (for GP
product) for 45 sec, and 68°C (45 sec) and a final elongation step of 1 min at 68°C in a MJ
Research Peltier Thermal Cycler PTC-200. The PCR amplified products were analyzed by
electrophoresis on a 3% agarose gel stained with ethidium bromide and observed under
ultraviolet light. PCR products on gels were purified using QIAquick Gel Extraction Kit
(Qiagen, USA) and sent for DNA sequencing to the DNA Core Facility at the University of
Louisville. Sequences obtained were analyzed using NCBI BLASTn database and
MegAlign®. DNASTAR software (Version 12.0, Madison, WI), and type of HPV was identified.
The quality of the extracted DNA was checked by amplification of internal control (β-globin).
For a patient who showed two types of HPV in his/her lesions, HPV-type specific PCR was
employed (which detects the presence of the E7 region of specific HPV type) to test the coinfection of HPV6 and 32 in lesions.
Statistical Analysis: Distributions of the discrete lesion and subject characteristics were
summarized by frequency and percentage. Fisher’s exact tests were applied to examine
differences between the MEH cases and squamous papilloma. These studies also assessed
the types of HPV associated with the MEH lesions in this patient cohort. Means, standard
deviation, and p-values from Student’s t-tests were reported. All data analyses were
®

conducted by SAS /STAT Software (Version 9.4.,SAS Institute Inc., Cary, NC, USA).

Results

Clinical and histologic features of MEH and squamous papilloma lesions
MEH lesions presented as a well-circumscribed, white plaque or nodule with a finely
stippled/papillary surface. There was significant differences between MEH and squamous
papilloma cases in distributions of the number (p=0.006) and site (p<0.0001) of lesions (Table
2). According to my data, MEH lesions occurred more frequently at multiple anatomic sites
than squamous papillomas (66.7% vs. 0.0%). The MEH cases were less likely to appear in
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the soft palate/oropharynx than squamous papillomas (0.0% vs. 55.6%) and were more likely
to appear in both keratinized oral sites and the labial/buccal mucosa than squamous
papillomas. Of the MEH lesions that were HPV positive 13/19 (68.4%) occurred on the
labial/buccal mucosa.
MEH lesions presented with characteristic histologic features: acanthosis with
elongation of the rete ridges (Figure 10a) and occasionally altered nuclei typical of mitosoid
cells in the spinous cell layer (Figure 10b). Squamous papilloma cases, on the other hand,
showed multiple fingerlike surface projections covered by hyperkeratotic stratified squamous
epithelium supported by fibrovascular connective tissues. While typical mitotic cells are often
seen in these lesions they are confined to the basal and parabasal cell layers (Figure 11b).

HPV status of MEH lesions and squamous papillomas
Figure 12 shows images of agarose gels of 9 representative samples. When the
amplicons of MY and GP primers were sequenced, 8 cases were HPV6, and 11 cases were
HPV32, while one sample was HPV40. Other samples, which did not produce any bands and
of an inappropriate size for both MY and GP amplicons, were classified as negative for HPV
DNA. Altogether, 19/22 MEH samples and 1/9 squamous papilloma cases were HPV positive.
The presence of HPV differed significantly between MEH and squamous papilloma
specimens (p=0.0002, Table 2). The MEH lesions were more likely to have HPV than the
squamous papillomas (86.4% vs. 11.1%), especially those involving HPV type 6 (36.4% vs.
0%) and type 32 (45.4% vs. 11.1%).
HPV status in MEH lesions
Analysis of MEH lesions revealed that the number of oral lesions was significantly
different depending on the HPV type detected (p=0.002). HPV32 lesions occurred
significantly more often as multiple lesions than HPV6, HPV40, and HPV negative lesions
(Table 3). Marginal differences in race, HIV status, and duration of the lesion were observed
across HPV types in MEH cases. A higher proportion of African Americans were observed
with HPV32 lesions than HPV6, HPV40, and HPV-negative lesions. Subjects who were
reported as HIV positive had HPV32 but none of the other HPV types. In addition, HPV32 was
most frequently associated with lesions occurring for a longer duration.
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I examined more than one lesion, biopsied from different sites, per patient from four
MEH subjects. All lesions were biopsied from different sites on the same day except in the
case of patient #15. Three MEH patients were positive only for HPV32 in all of their lesions. In
contrast, one patient (ID #15) with 3 lesions had HPV6 in two lesions and HPV32 in the other,
as detected by MY/GP primer-based PCR. In one instance (case #35) sequencing based on
HPV-type specific primers (HPV6 E7 and HPV32 E7) revealed co-infection with HPV6 and 32.

A
.

B
.

Figure 10: Photomicrographs of MEH lesion showing (A) acanthosis and elongation of
anastomosis of the rete ridges, H&E 100X; and (B) a mitosoid cell (arrow) in the spinous cell
layer, H&E 200X magnification

A
.

B
.

Figure 11: Photomicrographs of squamous papilloma showing (A) the characteristic
hyperkeratosis and finger-like projections, H&E 100X, and (B) normal mitoses in the basal
and parabasal cell layers, H&E 400X magnification
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Table 2: Clinical variables of MEH cases and squamous papillomas
Squamous papillomas
(9 Subjects, 9 Lesions)
Variable*
Gender
Female
Male
Race
African American
Caucasian
Unknown*

MEH Lesions
(17 Subjects, 22 Lesions)

p-value

n

%

n

%

3
6

33.3
66.7

5
12

29.4
70.6

1.00

1
8
0

11.1
88.9
0.0

3
12
2

17.6
70.6
11.8

1.00

Age (Mean ± SD)

46.9 ± 23.9

52.4 ± 16.9

<40 years
40-59 years

3
4

33.3
44.4

5
7

29.4
41.2

≥60 years

2

22.2

5

29.4

HIV
Negative
9
100.0
13
76.5
Positive
0
0.0
3
17.6
0
0.0
1
5.9
Unknown*
HPV
Absent
8
88.9
3
13.6
6
0
0.0
8
36.4
32
1
11.1
10
45.5
40
0
0.0
1
4.5
Number of Lesions
Single
7
100.0
7
33.3
Multiple
0
0.0
14
66.7
2
22.2
1
4.5
Unknown*
Site of Lesion
Soft palate
5
55.6
0
0.0
Keratinized oral sites
0
0.0
4
18.2
Labial/buccal mucosa
0
0.0
14
63.3
Tongue/floor of mouth
4
44.4
4
18.2
Duration of Lesion
≤6 months
2
22.2
6
27.3
>6 months
0
0.0
6
27.3
7
77.8
10
45.5
Unknown*
Size of Lesion
≤3 mm
6
66.7
10
45.5
4-6 mm
2
22.2
6
27.3
>6 mm
1
11.1
5
22.7
0
0.0
1
4.5
Unknown*
*unknown: clinical information that could not be retrieved from biopsy requisition sheets
†
Negative (absent) vs. positive (HPV6, 32, and 40)
‡
The unknown value was omitted for analysis.
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0.50
1.00

0.28

‡

0.0002

0.006

†

‡

<0.0001

0.47

0.76

‡

‡

Figure 12: HPV DNA detection in benign oral samples by PCR using MY and GP primers
showing amplified products of 450bp and 150bp, respectively. Amplified β-globin represents
the loading control to check the quality of extracted DNA.

MEH lesions in HIV-positive subjects
In the MEH group, 3 subjects (17.6%) had HIV compared to 0 subjects in the
squamous papillomas group, although no significant difference was observed between HIVstatus and the groups, Table 2. HIV status was marginally associated with HPV genotyping
(p=0.07, (Table 3). All 3 HIV-positive MEH patients (total of 5 lesions) were HPV32 positive
(Table 3). Therefore, HPV6 was not detected in known HIV positive patients. Interestingly, I
found that one MEH case in an HIV positive patient was on the skin side of the commissure.
To our knowledge, HPV32 has never been reported in the skin. Since clinical pictures of
specimens were not available to rule out the possibility that skin infection might be an
extension from the oral mucosal side, I cannot substantiate my result as the first report of
HPV32 on the skin surface.
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Table 3: Clinical variables of MEH lesions based on HPV status
HPVnegative
MEH

Variable

HPV-positive MEH cases

HPVpositive
MEH

HPV6

HPV32

HPV40

n

%

n

%

n

%

n

%

n

%

Female

2

66.7

6

31.6

2

25.0

4

40.0

0

0.0

Male

1

33.3

13

68.4

6

75.0

6

60.0

1

100.0

0

0.0

5

26.3

0

0.0

4

40.0

1

100.0

Caucasian

3

100.0

12

63.2

6

75.0

6

60.0

0

0.0

Unknown

0

0.0

2

10.5

2

25.0

0

0.0

0

0.0

Age
<40 years

0.0

p-value*

Gender

Race
African American

0

0.0

8

42.1

5

62.5

3

30.0

0

40-59 years

1

33.3

7

36.8

3

37.5

4

40.0

0

0.0

≥60 years

2

66.7

4

66.7

0

0.0

3

30.0

1

100.0

3

100.0

13

68.4

7

87.5

5

50.0

1

100.0

Positive

0

0.0

5

26.3

0

0.0

5

50.0

0

0.0

Unknown

0

0.0

1

5.3

1

12.5

0

0.0

0

0.0

Single

2

66.7

5

26.3

4

50.0

0

0.0

1

100.0

Multiple

0

0.0

14

73.7

4

50.0

10

100.0

0

0.0

Unknown

1

33.3

0

0.0

0

0.0

0

0.0

0

0.0

Skin

0

0.0

1

5.3

0

0.0

1

10.0

0

0.0

Keratinized oral sites

2

66.7

2

10.5

1

12.5

1

10.0

0

0.0

Labial/buccal mucosa

0

0.0

13

68.4

6

75.0

6

60.0

1

100.0

Tongue/floor of mouth

1

33.3

3

15.8

1

12.5

2

20.0

0

0.0

≤6 months

1

33.3

5

26.3

4

50.0

0

0.0

1

100.0

>6 months

1

33.3

5

26.3

1

12.5

4

40.0

0

0.0

HIV
Negative

0.62

0.08

0.13

0.07

Number of Lesions
0.002

Site of Lesion
0.36

Duration of Lesion

Unknown

1

33.3

9

90.0

3

37.5

6

60.0

0

0.0

Size of Lesion
≤3 mm

1

33.3

9

47.4

3

37.5

6

60.0

0

0.0

4-6 mm

0

0.0

6

31.6

4

50.0

2

20.0

0

0.0

>6 mm

2

66.7

3

15.8

1

12.5

1

10.0

1

100.0

Unknown

0

0.0

1

5.3

0

0.0

1

10.0

0

0.0

*analyses between HPV types and variables
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0.07

0.20

Discussion

I studied two types of benign oral lesions (MEH, multifocal epithelial hyperplasia, and
squamous papilloma) and found a significant difference in HPV infection in these lesions. The
most important finding from my study is the demographic presentation of MEH lesions.
Although seen throughout the world, MEH is predominantly seen in Native Americans
children/adolescents or HIV-infected adults and is typically associated with HPV types 13 and
32. However, my study demonstrated a novel presentation of MEH with HPV6, 32 and a
unique type HPV40 in middle-aged to older (31-82 years of age), HIV-negative Caucasian
adults. Of note, the most widely and frequently published HPV in MEH, i.e. type 13, (49) was
not detected in any samples in this study. Future HPV detection protocols should include
HPV32 as it may be currently overlooked. Another benign lesion i.e. squamous oral
papilloma, which showed histologic overlap with MEH, was found to be mostly HPV negative.
Interestingly, different HPV types were noted in a patient with recurrent lesions. This
patient had an initial HPV6-positive lesion, followed 15 months later by a lesion with HPV6
and another lesion co-infected with both HPV6 and HPV32. This indicates that more than one
HPV type may be present in MEH lesions in the same patient.
Although MEH is asymptomatic and can regress spontaneously without surgical
intervention, diagnosis of MEH is important to ensure differential diagnosis from other benign
lesions since these lesions may have overlapping clinical and histologic features. Here I have
shown that HPV genotyping complements histologic characterization of benign oral lesions
that are suspected of harboring HPV.

2. Premalignant oral lesions

Introduction

In the head and neck, high-risk HPV infection is most often seen in oropharyngeal
cancer (OPC), a subset of head and neck cancer that is increasing in incidence worldwide
(62). While HPV is strongly associated with OPC, the relationship of HPV to oral squamous
cell carcinoma (OSCC), another subgroup of HNC (58), and its premalignant precursor, high-
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grade oral epithelial dysplasia (hgOED), is still not clearly defined. While some reports have
indicated that HPV is not commonly found in OSCC (73,129); others indicated ~25%
prevalence of HPV16/18 in oral dysplasia (130). More recently, a subset of hgOED was
shown to be strongly positive for high-risk HPV (131,132). In these studies, the authors
indicated that diffuse atypical mitotic-like structures (herein referred to as “mitosoid” cells) and
apoptotic cells are unique histologic features warranting the designation “high-risk HPVassociated oral dysplasia”(132) or “HPV-associated Oral Intraepithelial Neoplasia (HPVOIN)”(131).
In our laboratory, we have also noted hgOED cases that show the widespread
mitosoid and apoptotic cells recently described (Group 1 for this study) but in compiling such
cases we have also noted that hgOED may also show focal mitosoid and apoptotic cells
(Group 2 for this study) while other cases completely lack these features (Group 3). Herein, I
explore the association of high-risk HPV in these potential subsets of hgOED with the addition
INK4a

of HPV genotyping. I hypothesize that a high prevalence of high-risk HPV and strong p16

expression will be seen in Group 1 cases with intermediate and lower associations for these
variables in Group 2 lesions and Group 3 respectively.

Experimental Procedures

Biopsy sample selection: This study was approved by the IRB at the University of Louisville.
Reports of biopsies accessioned into the University of Louisville Oral Pathology Laboratory
were searched for keywords and/or phrases that could be associated with HPV infection (i.e.
virus, viral, HPV, mitosoid, Bowen, koilocy-, apopto-, multinucleated keratinocyte). All
retrieved cases whose diagnosis reported premalignant changes (i.e. dysplasia or carcinoma
in situ) were then evaluated microscopically for the Group 1 histologic inclusion criteria as
previously reported (near full thickness mitosoid and apoptotic cells) (131). Group 2 included
cases which had focal mitosoid cells above the basal layer and occasional apoptotic cells (i.e.
in at least one or more high power fields but not diffusely through the specimen), suggesting a
possible early or isolated infection of those cells with high-risk HPV. Group 3 cases (N=10)
lacked these features altogether in the histologic sections studied.
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Genomic DNA extraction and HPV detection: The microscopic and clinical information for
all cases were blinded before performing HPV genotyping. Genomic DNA extraction and HPV
genotyping were performed as described in previously. Type-specific E7 HPV primers were
used to confirm the presence of HPV6, 16, 33 and 45.
INK4a

Immunohistochemistry (IHC) for p16

INK4a

: Immunohistochemistry for p16

expression in

FFPE specimens was performed by the Special Procedures Laboratory (University of
INK4a

Louisville) using an antibody to p16

(CINtec Histology Kit, Roche laboratories). The Leica

Bond Polymer Refine Detection (DS9800) system and the Leica BOND III automated IHC
INK4a

stainer were used for histological staining. Staining for p16

was rated according to criteria

used by McCord et al (132): grade 2 (strong and diffuse nuclear and cytoplasmic staining of at
least the half depth of the epithelial thickness); grade 1 (patchy staining with unstained
epithelial cells interspersed among positive cells); and grade 0 (negative, no staining or
staining of scattered single cells). This system was modified such that if patchy staining was
observed but it included >70% of the dysplastic areas, then it was categorized as grade 2.
Also, grade 1 and grade 2 cases were classified as positive for p16

INK4a

expression, rather

than grade 1 cases being “equivocal,” and grade 0 cases were categorized as negative.
Statistical analysis: Fisher’s exact tests were conducted to evaluate differences between (1)
all groups, (2) Group 1 vs. Group 3 lesions, (3) Group 2 vs. Group 3 lesions, and (4) Group 1
vs. Group 2 lesions. As pair-wise intergroup comparisons would produce prohibitively small
sample sizes, statistical significance was reported for differences across all 3 groups. As
Group 2 and Group 3 were more similar histologically than Group 1, their results were pooled
together for some comparisons and are designated as Group 2/Group 3, where applicable.
For continuous characteristics, means, standard deviations, and p-values from one-way
ANOVA or Student’s t-tests comparing groups are reported. To determine if high-risk HPV
INK4a

presence correlated with p16

status (negative vs. positive), stratified exact conditional

logistic regression was conducted. Predictor test variables [histologic features alone (Group 1,
Group 1 and 2) and in combination with positive p16

INK4a

expression] of high-risk HPV

presence were evaluated for sensitivity, specificity, positive predictive value (PPV) and
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negative predictive value (NPV). Statistical analyses were conducted in SAS Version 9.4
(SAS Institute Inc., Cary, NC, USA).

Results
Clinical characteristics of hgOED lesions
The typical clinical appearance for each group consisted of a white or red/white patch
or plaque with a variably rough/papillary surface texture which most commonly affected the
lateral tongue or floor of the mouth (Figure 13). Table 4 depicts comparisons among all three
groups and between Group 1 and Group 2/Group 3. While the lateral tongue and floor of the
mouth were most commonly affected in all groups, this location was nearly exclusively
involved in Group 2/ Group 3 (95.8%) whereas Group 1 lesions affected other sites in 37.5%
of cases (p=0.01). Group 1 lesions were significantly smaller than the Group 2/Group 3
lesions with the latter tending to be >6mm (p=0.03); although, there were many cases for
which size data was not available. Patients in Group 1 were typically younger than Group
2/Group 3 patients by 8 years on average (p=0.03).

Histologic features of hgOED lesions
Group 1 hgOED presented with characteristic histologic features as described
previously (131,132): abundant mitosoid and apoptotic cells throughout the full thickness of
epithelium (Figure 14). Group 2, on the other hand, showed only focal apoptotic and
mitosoid cells (Figure 15). Group 3 showed typical dysplastic features but lacked the
combination of mitosoid and apoptotic cells (Figure 16).

Figure 13: Clinical photograph showing a similar white patch/plaque on the floor of mouth for
each group. A) Group 1. B) Group 2. C) Group 3 lesions.
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Figure 14: Group 1 hgOED H&E- stained section showing diffuse apoptotic cells (red arrows)
and mitosoid cells (black arrows) at A) 200x and B) 400x magnification.

Figure 15: Group 2 hgOED H&E- stained section showing A) a focal apoptotic cell (red
arrow) and mitosoid cells (black arrows) at 200x, and B) at 400x magnification.

Figure 16: Group 3 hgOED H&E- stained section showing dysplastic epithelial features which lack
mitosoid or apoptotic cells at 200x magnification.
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HPV status in hgOED lesions
Statistical significant differences among all groups were observed for HPV presence
(p=0.02), Table 4. High-risk HPV was found significantly more often in Group 1 (81.3%)
versus Group 2 (57.1%) and Group 3 (20.0%), (overall p=0.01). HPV16 was seen in all
except one HPV-positive case (being HPV33) in Group 1, comprised 7 of 9 (77.7%) of the
HPV-positive cases in Group 2 (HPV6 and HPV45 seen in the other 2 cases respectively) and
was the only HPV type seen in the Group 3 (2 cases). When Group 2 and Group 3 were
combined, Group 1 was significantly more associated with high-risk HPV (p=0.02) and the
odd ratio of HPV presence were 5.12 (95% CI 0.99, 33.9) times greater for Group 1 lesions
than combined Group 2/Group 3 lesions.

Immunohistochemical (IHC) staining for p16
INK4a

IHC results for p16
INK4a

and diffuse p16

INK4a

expression

expression between groups are reported in Table 5. Strong

staining (grade 2) was more common in Group 1 cases (75%) than in
INK4a

Group 2 (14.3%) or Group 3 (11.1%), (overall p= 0.0008). Similarly, p16

positive cases

(grade 1 and 2, as depicted in Figure 17) were significantly higher in Group 1 (93.8%) than in
INK4a

Group 2 (42.9%) or Group 3 (33.3%) (overall p=0.001). The odd ratio of p16

positive

status was 23.3 times greater for Group 1 than Group 2/Group 3 (Table 4).

Figure 17: p16

INK4a

immunohistochemistry. (A) Grade 2 (strong and diffuse) staining from

Group 1. (B) Grade 1 (patchy) staining from the Group 3 group, at 200x magnification.
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Association of p16

INK4a

status with HPV presence

Stratified logistic regression analysis (Table 5) showed a significant association
between p16 expression and high-risk HPV status (p=0.04). Expression of p16 combined with
high-risk HPV positivity was seen frequently in Group 1 (13/16, 81.3%) compared to Group 2
(5/13, 38.5%) and Group 3 (1/9, 11.1%). All high-risk HPV-positive Group 1 and Group 3
samples expressed p16 whereas only 5 of 8 (62.5%) high-risk HPV-positive samples in Group
2 expressed p16

INK4a

. In Group 2/Group 3 samples, there was a variable association of the
INK4a

presence of high-risk HPV and p16

expression.

Prediction of high-risk HPV presence in hgOED
INK4a

Analyses of the use of histologic features either alone or combined with p16 p16

expression to predict HPV presence in hgOED are shown in Table 6. Histologic features of
Group 1 and 2 combined (i.e. mitosoid and apoptotic cell(s) diffusely or focally present) were
91.3% sensitive (95% CI: 72.0%, 99.0%) and 47.1% specific (95% CI: 23.0%, 72.2%) for
detecting high-risk HPV with a positive predictive value of 70.0% and negative predictive
value of 80.0%. Analysis of Group 1 histologic features alone to predict for the presence of
high-risk HPV was more specific at 82.4% (95% CI: 56.7%, 96.2%) but showed a large
decrease in sensitivity to 56.5% (95% CI: 34.5%, 76.8%).
INK4a

The combination of p16

expression and the histologic features of Group 1 lesions

were 100% sensitive (95% CI: 75.3%, 100.0%) in predicting the presence of high-risk HPV
with a positive predictive value of 86.7% (95% CI: 59.6%, 98.4%), though specificity was only
33% (95% CI: 0.84%, 90.6%), Table 6. When Group 1 and 2 were combined then the
INK4a

addition of p16

expression was 81.8% sensitive (95% CI: 59.7%, 94.8%) and 62.5%

specific (95% CI: 24.5%, 91.5%) in predicting the presence of high-risk HPV.
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Table 4: Clinical variables of hgOED
Group 1
(N=16)
Variable
Gender

N

Male
Female
Race
Black
Caucasian
Unknown

ǁ

Age (median ±
IQR)

%

Group 2
(N=14)
N

%

Group 3
(N=10)
N

%

Odds Ratio

p-value

Group1 vs.
Group2/Group 3
Group1 vs.
(95% CI)
Overall Group2/Group 3

13
3

81.3
18.8

11
3

78.6
21.4

9
1

90.0
10.0

0.88

1.00

0.87 (0.12,
6.93)

3
8

18.8
50.0

2
7

14.3
50.0

0
7

0.0
70.0

0.72

0.60

2.63 (0.24,
36.4)

5

31.3

5

35.7

3

30.0

51.1 ± 10.3

59.0 ± 12.3

59.3 ± 8.5

<40 yrs

1

6.3

1

7.1

0

0.0

40-55 yrs
>55 yrs

10
5

62.5
31.3

4
9

28.6
64.3

3
7

30.0
70.0

Current
Non

7
3

43.8
18.8

5
6

35.7
42.9

4
5

40.0
50.0

Previous
ǁ
Unknown

3
3

18.8
18.8

2
1

14.3
7.1

1
0

10.0
0.0

4
5
1

25.0
31.3
6.3

3
1
1

21.4
7.1
7.1

2
4
0

20.0
40.0
0.0

6

37.5

9

64.3

4

40.0

3
0

18.8
0.0

5
1

35.7
7.1

8
0

80.0
0.0

Type 16

12

75.0

7

50.0

2

20.0

Type 33

1

6.3

0

0.0

0

0.0

Type 45
HPV risk
Low-risk HPV

0

0.0

1

7.1

0

0.0

0

0.0

1

7.1

0

0.0

High-risk HPV

13

81.3

8

57.1

2

20.0

Negative

3

18.8

5

35.7

8

80.0

12

75.0

2

14.3

1

11.1

grade 1

3

18.8

4

28.6

2

22.2

grade 0

1

6.3

8

57.1

6

66.7

15

93.8

6

42.9

3

33.3

1

6.3

8

57.1

6

66.7

10

62.5

13

92.9

10

100.0

3

18.8

0

0.0

0

0.0

0.09

†

0.03

†

0.38 (0.10,
1.30)*

Smoking

Alcohol
Current
Non
Previous
Unknown
HPV
Negative
Type 6

ǁ

0.65

0.21

2.85 (0.46,
‡
21.4)

0.50

0.78

0.80 (0.09,
‡
6.76)

0.02

0.03

N/A

0.01

0.02

5.12 (0.99,
§
33.9)

0.0008

0.0001

7.06 (2.31,
31.2)*

0.001

0.001

23.3 (2.50,
1,050)

0.13

0.01

N/A

INK4a

p16
grading
grade 2

INK4a

p16
status
Positive
Negative
Site
Tongue/ Floor of
mouth
Buccal/ labial
mucosa
Soft palate

1

6.3

1

7.1

0

0.0

Hard palate/
gingiva

2

12.5

0

0.0

0

0.0
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Size
>6mm
4-6mm
<4mm
ǁ

Unknown
Duration
>2 months
≤2 months
ǁ
Unknown

4

25.0

10

71.4

5

50.0

5
1

31.3
6.3

1
0

7.1
0.0

0
1

0.0
10.0

6

37.5

3

21.4

4

40.0

4
3
9

25.0
18.8
56.3

5
0
9

35.7
0.0
64.3

4
1
5

40.0
10.0
50.0

0.09

0.03

0.24 (0.03,
,
1.14) *

0.56

0.36

0.15 (0.00,
2.83)

Abbreviations: IQR, interquartile range; N/A, not applicable; CI, confidence interval
*Odds ratio computed assuming variable is ordinal
†
Wilcoxon rank-sum test p-value
‡
§
ǁ
Current vs. Non; Positive vs. Negative; Unknown level omitted for analysis

INK4a

Table 5: Association between p16

(p16) and high-risk HPV (HR-HPV) in hgOED

Group 1 (N=16)

Group 2 (N=13*)

Group 3 (N=9)

P16 | HR-HPV

Positive

Negative

Positive

Negative

Positive

Negative

p16 positive

13
(81.25%)

2
(12.5%)

5
(38.46%)

1
(7.69%)

1
(11.1%)

2
(22.2%)

p16 negative

0
(0.0%)

1
(6.25%)

3
(23.07%)

4
(30.77 %)

0
(0.0%)

6
(66.67%)

p†
value

0.04

*

One low-risk HPV-positive sample omitted for analysis

†

Stratified exact conditional logistic regression score test mid-p.
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Table 6: Prediction of the presence of high-risk HPV (HR-HPV) in hgOED
Predictor variables for
HR-HPV presence

Sensitivity %
(95% CI)

Specificity %
(95% CI)

PPV %
(95% CI)

NPV %
(95% CI)

56.5
(34.5, 76.8)

82.4
(56.7, 96.2)

81.3
(54.4, 96.0)

58.3
(36.7, 77.9)

91.3
(72.0, 99.0)

47.1
(23.0, 72.2)

70.0
(50.6, 85.3)

80.0
(44.4, 97.5)

100.0
(75.3, 100.0)

33.3
(0.84, 90.6)

86.7
(59.6, 98.4)

100
(2.5, 100.0)

81.8
(59.7, 94.8)

62.5
(24.5, 91.5)

81.0
(58.1, 94.6)

55.6
(21.2, 86.3)

Histologic features alone
Group 1*
Group 1 and 2

†

Histologic features with p16 expression
Group 1*

Group 1 and 2

†

PPV, positive predictive value; NPV, negative predictive value; CI, confidence interval
*Comparison of Group 1 with Group 2/Group 3
†

Comparison of Group 1/Group 2 with Group 3

Discussion

The present study analyzed histologically distinct high-grade oral epithelial dysplastic
(hgOED) lesions based on the distribution of mitosoid/apoptotic cells: Group 1 hgOED with
diffuse mitosoid cells, Group 2 with focal mitosoid cells and Group 3 hgOED lacking these
histologic features. This study is the first study to perform HPV genotyping in histologically
distinct hgOED lesions and show significant differences in both the presence of high-risk HPV
INK4a

and p16

expression between these lesions. In previous studies (131,132), researchers

employed in situ hybridization (ISH) technique using cocktails of low-risk and high-risk HPV
probes, which could not identify the specific HPV types as done by PCR-based HPV
genotyping.
My data confirm the previous findings (131,132) that high-risk HPV is strongly
associated with forms of hgOED with widespread mitosoid and apoptotic cells (Group 1).
Though not statistically significant, an intermediate level of high-risk HPV was detected in
Group 2 lesions (57.1%) as compared to Group 1 (81.3%) and Group 3 (20%). HPV16 was
the most predominant HPV type present in 12/16 (75%) of Group1, 7/14 (50%) of Group 2
and 2/10 (20%) of Group 3. The focal changes in Group 2 cases could be due to early
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proliferation of high-risk HPV that could expand throughout the epithelium over time to
eventually become widespread as in Group 1 lesions. Correlation of these specific histologic
changes in the presence of high-risk HPV with gene and protein expression profiles could
help reveal how high-risk HPV infection influences the histologic progression of dysplasia and
risk for malignant transformation.
INK4a

In this study, I showed a significant association between high-risk HPV and p16
expression in Group 1 lesions. Expression of p16

INK4a

was 100% sensitive for detecting highINK4a

risk HPV in Group 1 lesions with a positive predictive value of 86.7%. So, p16

overexpression is a reasonable surrogate marker for high-risk HPV infection in hgOED where
INK4a

widespread mitosoid cells and apoptotic cells are noted. However, 2 cases were p16

positive but negative for high-risk HPV, resulting in only 33.3% specificity (95% CI: 0.84%,
90.6%). Therefore, p16

INK4a

expression may not be specific for high-risk HPV in hgOED cases

that show these unique histologic changes and direct testing for HPV by PCR or in situ
hybridization (ISH) may be warranted in these instances. My data also show that when these
INK4a

unique histologic features are focal or absent (Group 2 and Group 3 respectively), p16

is

not predictive of the presence of high-risk HPV in hgOED.
On combining Group 1 and Group 2 lesions, the sensitivity of these histologic
features for detecting high-risk HPV was improved; point estimates for sensitivity increased
from 54.2% to 91.7%. However, this was at a cost to specificity—point estimates for
specificity decreased from 81.3% to 50.0%. Practically speaking, when a pathologist
evaluates a case of hgOED and sees either diffusely distributed or focally dispersed mitosoid
and apoptotic cells, there is a high likelihood that high-risk HPV is present and warrants direct
testing for HPV. Whether focal changes seen in Group 2 lesions are a precursor to more
widespread changes observed in Group 1 lesions requires further study.
While a causative role of high-risk HPV is clearly implicated in OPC, its role in OSCC
is still largely unknown (74) and even less is understood about its role in the development of
pre-malignancy and subsequent malignant transformation. An initial challenge to studying
HPV-associated disease progression is to identify high-risk HPV infection in the premalignant
state. For OPC, tumorigenesis often occurs deep within the crypts without a surface
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premalignant precursor (47) whereas OSCC often develops from a clinically apparent lesion
(84) with microscopic evidence of dysplasia. Also, there is no reason to clinically evaluate the
tonsillar crypts unless there are symptoms (e.g. neck mass, sore throat), which do not occur
until cancer has already developed. In contrast, routine oral examination (as performed in the
dental care) allows detection of early oral premalignant lesions thus providing the unique
opportunity to study how HPV infection may initiate dysplastic changes or propel them
forward to malignancy. While the mechanisms of HPV-driven neoplasia in the oropharynx
compared to the oral cavity likely differ, the study of these oral cavity lesions may be the best
in vivo opportunity to study the evolution of head and neck HPV-associated neoplasia.

3. Carcinoma of the head and neck

Introduction

Head and neck cancers are malignant tumors that develop in the upper aerodigestive
epithelium. A subset of head and neck cancers (HNCs), mostly oropharyngeal cancer, has
been found to be strongly associated with HPV infection, particularly high-risk HPV types 16
and 18. Other risk factors for HNC are tobacco and alcohol use (61). Although the prevalence
of smoking is decreasing in the United States, there has been a recent increase in the
incidence of HPV-positive oropharyngeal cancers (62). About 72% of oropharyngeal cancers
are caused by HPV in the United States (62). It is estimated that around 2,400 and 9,400 new
cases of HPV-associated oropharyngeal cancers are diagnosed in women and men,
respectively, each year in the US. HPV-associated oropharyngeal cancers now outnumber
the cases of these cancers attributable solely to smoking or alcohol use (133).
Immunohistochemical analysis (IHC) for p16

INK4a

expression is frequently used to
INK4a

determine HPV status in the clinic, but many reports have shown that p16

is not always a

good surrogate for HPV infection (18,46,48). This study assessed the presence of HPV by
using the PCR-based method to detect HPV DNA and compared the HPV-positive status with
INK4a

cancer anatomic site and p16

expression.
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Experimental Procedures

Tissue Samples: This study was approved by the IRB at the University of Louisville. Patients
who attended the Head and Neck multidisciplinary clinic for evaluation of their cancer were
asked to provide written consent. HNC specimens were classified into one of five categories
according to anatomical subsites: a. Oral cavity (includes lip, anterior tongue, gum, floor of
mouth, hard palate); b. Oropharynx (includes the base of tongue, lingual tonsil, soft palate,
uvula, tonsil, and oropharynx); c. Hypopharynx (includes pyriform sinus, hypopharynx); d.
Larynx (includes glottis, supraglottis, subglottis); and e. Other unspecified cases (includes
sites which were not within one of the categories listed above and those of unknown primary
cancer). This categorization is based on The International Classification of Diseases (134),
and the method used by Hashibe et. al (135). The clinical stage of each cancer was
determined using the TNM staging system, 7th edition (136). Demographic and disease
characteristics of patients were collected from the deidentified database and researchers
were blinded to the HPV status of the patients before serological analysis.
Genomic DNA extraction and HPV detection: DNA was extracted from fresh frozen or
formalin-fixed, paraffin-embedded (FFPE) specimens using DNAeasy Blood & Tissue kit
(Qiagen, USA) as per manufacturer’s instructions with RNAase (20µl of 20 mg/ml) treatment.
FFPE samples were deparaffinized using xylene and washed before DNA extraction. HPV
detection and genotyping were performed, as described previously. β-globin amplification was
done used for an internal control.
INK4a

p16

immunohistochemistry: Immunostaining was performed using standard protocols in
INK4a

the UofL pathological laboratory. IHC for p16

was considered positive if there was strong

and diffuse staining present in >70% of the malignant cells. The results of the p16

INK4a

IHC for

malignant specimens were provided by the Cancer Database and Specimen Repository
(CDSR) at the James Graham Brown Cancer Center, University of Louisville. There were
INK4a

cases in which p16

IHC was not performed as part of a patient’s standard diagnostic

workup and hence were unavailable at the time of analysis.
Statistical analysis: Distributions of discrete lesion characteristics were summarized by
frequency and percentage. Fisher’s exact tests or Students t-tests were conducted to
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evaluate differences between variables using SigmaPlot Version 12.5 (Systat Software, Inc.,
San Jose California, USA).

Results

Demographic Information of HNC Patients
Summary on the distribution of 54 HNC specimens is shown in Table 7. Age ranged
from 35-87 years and 81.5% of patients were males with two exceptions. HPV-positive HNC
patients were about 6 years younger than patients whose tumors were HPV-negative
(p<0.05). No significant difference in cancer stages was found between HPV-positive and
HPV-negative HNC.
HPV-positive HNC patients
HPV DNA was detected in 18 out of 54 HNC specimens (Table 7). When the MY and
GP amplicons (Figure 18) were sequenced, 16 were genotyped as HPV16 and other two
were HPV18 and HPV33. Results were further verified using HPV type-specific primers. Of
note, there were many samples, which produced a band around the size of MY amplicon, but
were not detected to have HPV DNA after sequencing.
Correlation of HPV positivity with HNC anatomic sites and p16

INK4a

status

HPV-positive cases were significantly associated with oropharyngeal cancer (Table
7), p<0.001. In this study, only 16.7% of total HPV-positive patients had oral cavity cancers.
INK4a

Positive HPV status was also significantly correlated with positive p16
(p<0.001).
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IHC staining

Figure 18: HPV DNA detection in HNC samples by PCR using MY09/11 and GP5+/GP6+
consensus primers. β-globin was used as the loading control.

Table 7: Demographics of HPV positive and HPV negative HNC patients
Category

HPV DNA positive

HPV DNA negative

(N=18)

(N=36)

n

%

n

%

Male

16

88.9

28

77.7

Female

2

11.1

8

22.2

p-value

Gender

Age (years)

55.11± 8.4

61.1 ± 10.8

NS

0.022*

Anatomic site
Oropharynx

11

61.1

3

8.3

Oral cavity

3

16.7

11

30.6

Others (Hypopharynx, larynx)

4

22.2

22

61.1

I

0

0.0

1

2.8

II

1

5.6

12

33.3

III

4

22.2

13

36.1

IVA

9

50.0

4

11.1

IVB

0

0.0

0

0.0

IVC

0

0.0

0

0.0

4

22.2

6

16.7

13

72.2

3

8.3

0

0

10

27.8

5

35.7

23

63.9

<0.001*

Stage

Unknown
INK4a

p16

†

NS

status

Positive
Negative
Unknown

†

*Significant values, NS: non-significant
†

Unknown values omitted during analysis
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<0.001*

Discussion

In this study, an initial characterization of the malignant specimens was done and the
obtained data was used for their further analysis in subsequent chapters. Malignant tissue
samples from different histological sites of the head and neck (oropharynx, oral cavity,
hypopharynx, and larynx) were examined. The median age of HPV-positive HNC patients was
significantly younger than HPV-negative patients. A similar trend is seen in HPV-positive OPC
and OSCC patients in younger patients compared to those with HPV-negative cancers
(62,137). When cases were stratified according to location, the data showed that
oropharyngeal sites (tonsils, posterior tongue, and oropharynx) were the most common sites
affected in patients who were HPV-positive. My results were consistent with the increasing
incidence of HPV infection in oropharyngeal cancers (60%-100%) (62,133,138,139). HPVnegative cancers were mainly from non-oropharyngeal cancers of the head and neck region.
Further, the data showing only 16.7% (3/18) of HPV-positive OSCC samples supports the
findings of previous studies that HPV prevalence is lower in OSCC (13-47%) (58,140,141). As
expected, HPV type 16 was the predominant type found in our specimens, which was also
reported in the majority of other studies (69,82,138,142). Other high-risk types- HPV18 and
HPV33 were also observed. While HPV16 is the most common type detected in OPC, HPV33
and HPV18 have shown to be rare but significant factors in OPC (32,143,144).
Results indicated that HPV-positive cancers are significantly associated with positive
INK4a

p16

expression, confirming the finding of previous reports, particularly in OPCs (48).

Studies also suggest that factors/mechanisms other than HPV infection likely stimulate
INK4a

p16

expression, mainly in OSCC (46,74,76). 72.2% of the HPV-positive cancers showed
INK4a

positive p16

INK4a

staining, though most could not be evaluated for p16
INK4a

of HPV-negative OSCC was p16
INK4a

positive p16

status. The majority

negative. Out of 3 HPV-positive OSCC, two showed

staining (the other could not be determined). These data did not reveal any
INK4a

obvious results towards positive or negative p16

status in OPC and OSCC because of

small sample size and limited available data.
In summary, my study is in agreement with previous results showing a clear
association of high-risk HPV with HNCs, particularly oropharyngeal cancers. In addition to
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INK4a

HPV genotyping and p16

staining, characterization of mitosoid cells would be useful. In

earlier sections of this chapter, I have shown that mitosoid cells are strong biomarkers of HPV
infection in benign MEH and distinct subset of pre-malignant oral tumors. It was not possible
to characterize mitosoid cells in malignant specimens due to unavailability of histological
slides. Further studies characterizing mitosoid cells in cancerous tissues of the head and neck
would be useful to determine whether these histological features are consistently present
during premalignant to malignant transformation. In addition to histologic biomarkers,
identification of HPV-associated serum biomarker would be non-invasive and early method to
diagnose HPV etiology in HNCs (discussed in Chapter III). Also, detailed molecular studies
are needed to determine mechanism how HPV influences malignant transformation in HNCs
(discussed in Chapters IV and V).
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CHAPTER III
POTENTIAL SERUM BIOMARKER FOR DETECTION OF HPV-ASSOCIATED
HEAD AND NECK MALIGNANCY

Chapter Overview

HPV-related head and neck cancer incidence is increasing rapidly worldwide
including the United States, but there are no standard non-invasive ways to detect HPV in
INK4a

these cancers. Although p16

overexpression in tumor tissues is widely accepted as a

surrogate marker for HPV positivity, studies reported that non-HPV cancers also express
INK4a

p16

. In chapter II, I have shown that mitosoid cells could serve as a strong histologic
INK4a

biomarker of HPV infection in the head and neck tumors. Detection of both p16

expression and mitosoid cells require cancer tissues specimens. Therefore, there is a need to
identify serum biomarker of HPV infection that could carry the potential of earlier and noninvasive methods of viral detection. Therefore, in this chapter, I determined whether titers for
antibody to the HPV E7 protein could also be used as a suitable biomarker for head and neck
malignancies associated with HPV. To this end, HPV E7 antibody titer was analyzed together
INK4a

with p16

staining and HPV genotyping in tumor tissues to access their potential uses as

biomarkers for the presence of HPV. My data represent the first report that the combination of
E7 serology and p16

INK4a

staining represents a strong diagnostic marker for underlying HPV

etiology in HNCs (145).

Introduction
Evidence of an etiologic role for HPV in head and neck squamous cell carcinoma has
been accumulating, with high-risk HPV16 (and to a lesser extent HPV18) detected in
INK4a

carcinomas in this region. The p16

protein is overexpressed in HPV-positive tumors as a

result of the HPV oncoprotein E7 inactivating the tumor suppressor pRb protein. This
inactivation leads to increased expression of downstream genes like p16

INK4a

normally

[This study was published in 2015 (145) and copyright permission was obtained from Elsevier to reuse
in this dissertation]
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repressed by pRb. HPV DNA detection (by in situ hybridization or PCR) and p16

INK4a

immunohistochemistry are currently used to determine HPV status. Both of these tests
require cancer tissues samples. Novel diagnostic techniques using serum samples could
carry the potential of earlier and non-invasive methods of detection.
Studies have been done to evaluate serologic markers of HPV infection in HNC. HPV
serology studies have focused on detecting HPV16 antibodies and have focused mostly on
the L1 protein (146-149), with few studies involving E6 and E7 oncoproteins (149-152) or
E1/E2 proteins (152). Antibodies to HPV16 E6 and/or E7 are suggested to be more specific
for HNC than L1 antibodies (149,150). The presence of HPV L1 and E2 antibodies may
indicate benign infection whereas E6 and E7 antibodies are more specific for premalignant
and malignant lesions (i.e. transcriptionally active HPV infection). Antibodies against E6 and
E7 proteins are largely HPV type specific. HPV18 DNA has been also detected in HNCs but
only a few studies have examined the seroprevalence of HPV18 in HNCs (153,154). Some
studies have suggested a correlation between HPV16 E6/E7 seropositivity and clinical
outcome of HNC patients (155-157).
My study examined the presence of HPV16 and 18 specific antibodies to E7
oncoprotein in sera of HNC patients and compared the seropositive status with anatomic site
INK4a

of cancers, p16

IHC positivity, HPV tumor DNA, smoking status and treatment outcome.

Currently, there are no standard commercially available serologic tests that detect HPVantibodies against any HPV proteins. Although HPV serological studies have been reported;
most of them have focused on HPV16 antibodies (not HPV18) and fewer have conducted
serology both before and after treatment of HNC patients.

Experimental Procedures

Serum samples: This study was approved by the IRB at the University of Louisville. Blood
was collected from pathologically confirmed HNC patients during the period from 08/27/2009
to 07/30/2014. Blood samples were kept at room temperature for 30 minutes to clot and then
were centrifuged at 3,000 rpm for 10 min to obtain serum. Serum aliquots were obtained from
the Cancer Database and Specimen Repository (CDSR) at the James Graham Brown Cancer
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Center (JGBCC). I analyzed 92 de-identified serum samples (including 17 follow-up sera)
from 75 patients. HNC was classified into anatomical subsets, as described previously in
chapter II. Sera from two cervical cancer patients who were seropositive for HPV16 or HPV18
were used as positive Group 3.
E7 proteins of HPV16 and 18: Previously, E7 oncoproteins of HPV16 and 18, fused with
MBP (maltose-binding protein), were expressed in E.coli and purified on amylose column
(158). These fusion proteins were employed as antigens for ELISA in this study.
Serological Analysis by ELISA: Total IgG antibody against E7 oncoproteins of HPV16 and
HPV18 were examined by direct ELISA using recombinant E7 proteins as antigens. Briefly,
500ng protein/ well in 100μl of 50mM bicarbonate buffer (pH 9.6) was coated onto Immulon

TM

ELISA microplates (Thermo Scientific, USA) using an overnight incubation at 4°C. After three
washings with 200μl of PBS, wells were blocked with 100μl of 5% PBS-A (PBS containing 5%
bovine serum albumin) and incubated for 1 h at 37°C. Wells were then washed three times
with 200μl of PBS. Sera diluted to 1/100 in 1% PBS-A was added for 1 h at 37°C followed by
the alkaline-phosphatase-(AP-) conjugated goat anti-IgG of human at 1/1,000 dilution in 1%
PBS-A for 1 h at 37°C. After the addition of 100μl of the AP-chromogenic substrate (Sigma104 p-nitrophenyl phosphate substrate; Sigma, St Louis, MO), the absorbance was measured
at 405 nm using Gen5 Microplate Reader and Imager Software in Synergy™ HT Multi-Mode
Microplate Reader (BioTek Instruments, Inc., VT, USA).
All serum samples were analyzed at the same time to avoid experimental variations.
ELISA for all samples was performed at least three times. Human sera, which had been
previously tested as positive for HPV16 or HPV18 E7 oncoproteins, were used as positive
controls for each experiment. Wells without antigen or serum was used as negative control
and wells containing the only substrate were used as background control.
HPV DNA detection in HNC tissues: FFPE tumor samples with corresponding serum
specimens were available HPV DNA detection and genotyping in 11 of the HNC cases. DNA
was extracted and HPV genotyping was performed, as described previously in chapter II.
HPV DNA status of the tumor tissues was then correlated with HPV E7 seropositivity.
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INK4a

p16

immunohistochemistry (IHC): Immunostaining for p16

results were obtained

from a deidentified database of the Cancer Database and Specimen Repository (CDSR) at
the James Graham Brown Cancer Center. IHC for p16

INK4a

expression was considered

positive if there was strong and diffuse staining present in >70% of the malignant cells.
INK4a

p16

result was then correlated with HPV E7 seropositivity.

Statistical Analysis: The seropositive and seronegative groups were determined by two
different methods regarding the distribution of absorbance values. In the first method,
seropositivity was defined as samples whose absorbance values were 2 standard deviations
(SD) from the mean value. We noticed that there was no difference in demographics for HPV
seropositivity for both 2 and 3 SD of the mean. In the second method, absorbance values
were observed based on quintile plots and two different slopes on the plots were determined
using the non-linear procedure (158). Thresholds of the seropositive group were determined
by the cross points of two slopes on the plots, and the samples whose absorbance values
were greater than or equal to the threshold values. Both methods used to define seropositivity
were in agreement. The ELISA values greater than the cut-off (1.04 and 0.905 for HPV16 E7
and HPV18 E7, respectively) were considered seropositive. Once the seropositive group was
determined, the associations were examined between the seropositive group and all available
variables using Chi-square test for discrete variables and independent t-test for continuous
variables at p=0.05. All data analyses were conducted by SAS 9.3 and Microsoft Office Excel.

Results

Demographic Information of HNC Patients
Summary on the distribution of 75 HNC and 25 seropositive patients is shown in
Table 8. All groups (total, seropositive and seronegative) were the average age of 57 years.
None of the seropositive cases were less than 40 years.
HPV E7 Seropositivity of HNC Patients
Antibodies against E7 oncoproteins of HPV16 and 18 were examined by ELISA in 92
serum samples, including 17 follow-up samples (Figure 19). Of the 75 patients, 14 and 8
patients were seropositive for the oncogenic E7 proteins of HPV16 and HPV18, respectively.
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Three patients were cross-reactive for E7s of both HPV types. Four follow-up sera were
seropositive (2 for HPV16 E7, 1 for HPV18 E7 and 1 was cross-reactive for both HPV types)
(Figure 19).
Correlation of E7 Seropositivity with HNC anatomic sites and p16

INK4a

status

I evaluated the association between serology and HNC anatomic sites. Seropositive
cases were strongly correlated with oropharyngeal cancer (Table 8). Positive HPV serology
INK4a

was also significantly associated with positive p16
INK4a

serology with p16

IHC (Table 8). I further compared HPV

IHC in oropharyngeal cancer as compared to other anatomic sites of
INK4a

the head and neck (Table 9). Only patients whose p16

IHC results were known were
INK4a

included, excluding unspecified cases. The association between E7 serology and p16

IHC was significant in oropharyngeal carcinoma as well as in other HNC sites (Table 9).
Although the sensitivity of E7 serology as a diagnostic marker in HPV-driven HNC (as defined
INK4a

by positive p16

IHC) was only 62.5%, E7 serology showed a high specificity and positive

predictive value (94.7% and 95.2% respectively) (Table 10). Isolating only oropharyngeal
cancers, where the role of HPV is much more clearly defined, the positive predictive value
was 100%.
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Table 8: Demographics of 75 HNC and 25 HPV E7 seropositive patients
Category

Total HNC

Seropositive

Seronegative

patients (N=75)

(N=25)

(N=50)

Gender

0.186

Male

67 (89.33%)

24 (96%)

43

Female

8 (10.67%)

1 (4%)

7

57 ± 10

57.56 ± 7.75

56.60 ± 11.12

< 40 yrs

4

0

4

40 - 59 yrs

43

16

27

≥ 60 yrs

28

9

19

Age

Anatomical sites
Others (Oral cavity,
Hypopharynx, Larynx)

39 (52%)

20 (80%)

19

36 (48%)

5 (20%)

31

Stage

0.674

II

4

1

3

III

15

7

8

IVA

48

15

33

IVB

2

1

1

IVC

3

0

3

Undetermined

3

1

2

p16

0.7002

0.0006*

Oropharynx

INK4a

p-value

status

<0.001*

Positive
Negative
Unspecified

†

32 (42.1%)

20 (80%)

12

19 (25.33%)

1 (4%)

18

‡

24 (31.57%)

4 (16%)

20

Smoking status

0.3556

Past or current
smokers (>10 pack-

55(73.33%)

20 (80%)

35

20 (26.67%)

5 (20%)

15

years)
Never-smokers
Treatment response

0.45

Complete response

33

13

20

Partial response

10

4

6

Progression

11

2

9

Not assessed

21

6

15

*Significant values
†

INK4a

Unspecified p16

‡

INK4a

p16

status was not considered during statistical analysis

IHC results were unavailable for 4 seropositive cases.
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Figure 19: Scatter plot of HPV16 and HPV18 E7 antibody titers of 92 serum samples
from 75 HNC patients. Cut-off lines were drawn at 1.04 for HPV16 E7 and 0.905 for
HPV18 E7. The values that were higher than the cut-off were considered seropositive.

INK4a

Table 9: E7 serology and p16

status in oropharyngeal and other HNCs

INK4a

p16

E7 serology

Site

(HPV16, HPV18 or both)

status

Positive

Negative

Oropharynx

Seropositive (N=17)

17

0

(N=34)

Seronegative (N=17)

10

7

Total

27

7

Others

Seropositive (N=4)

3

1

(N=17)

Seronegative (N=13)

2

11

Total

5

12

INK4a

*Unspecified p16

status was not considered during statistical analysis
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p-value*

0.0030

0.0221

INK4a

Table 10: Diagnostic measures based on E7 serology and p16

Sensitivity

Specificity

PPV*

NPV*

(%)

(%)

(%)

(%)

Site
Total (n=51)

status

62.5 (20/32)

94.7 (18/19)

95.2

60

Oropharynx (n=34)

63

100

100

41.2

Others (n=17)

60

91.7

75

84.6

* PPV and NPV denote positive predictive value and negative predictive value respectively

Figure 20: HNC patients (N=11) showing negative HPV16 and HPV18 E7 antibody titers both
before and after treatment.
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Figure 21: HNC patients who showed positive antibody titers before treatment revealed a
significant decrease in titer values after treatment, except in one case (HPV004). Five of
patients who showed decrease in antibody titer had complete/partial response to treatment

Correlation of E7 Seropositivity with treatment response
Seventeen follow-up serum samples were available for analysis. Sera (N=11) that
were seronegative before treatment, also revealed negative serology after treatment (Figure
20). I evaluated antibody status of the remaining 6 follow-up samples and compared with
respective seropositive pretreatment samples (Figure 21). Follow-up samples were collected
at a median of 96 days post-treatment (range 87-170 days). Treatment response at this time
point was supplied by the biorepository database and was determined clinically and in some
cases, radiographically, when imaging was available. Post-treatment serum antibody titer
against HPV16 and 18 E7 decreased significantly compared to those at pretreatment (p
<0.01) in 5 patients, who had a complete or partial response to treatment. One case
(HPV004) whose titer was decreased, but not significantly, also showed a complete response
to treatment. Three patients (HPV011, HPV032, and HPV038) became seronegative during
follow-up (Figure 21).
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Correlation of E7 Seropositivity with HPV DNA
Eleven HNC tissues were available for HPV detection and genotyping (Figure 22).
When the MY and GP amplicons of these seven samples were sequenced, 6 were genotyped
as HPV16 and 1 sample as HPV33. A sample (HN027) showing HPV33 was confirmed by
another PCR using HPV type 33- specific primers against oncogene E7. One sample
(HN021), which produced a band around the size of MY amplicon, was not detected to have
HPV DNA after sequencing. Samples (HN013, HN019, and HN025), which did not produce
bands consistent with MY or GP, were negative for HPV DNA. Altogether, HPV DNA was
detected in 7 samples out of 11 HNC tissues. Positive HPV DNA in cancer tissue was mainly
from the oropharynx.
I correlated HPV DNA status with the HPV serology of the patients whose tissues
were available for DNA extraction and HPV genotyping. The association of HPV16 E7
serology was strong among the samples tested positive for HPV16 DNA (N=6), except in one
case. This exceptional case (HN014) was seronegative in repeated assays even though it
was HPV16-DNA positive. I verified that detected HPV DNA was not a result of sample
contamination. There were two cases (HN013 and HN021) in which HPV-DNA was not
detected in their tissue, but sera were positive for HPV-16 E7. The reason behind this might
be due to multiple HPV infections in a single patient, that makes MY/GP- PCR method
inefficient and subsequent typing by sequencing is fraught with difficulties in revealing multiple
types. The sample (HN027), which was positive for HPV33 DNA, was HPV18 E7 seropositive,
which might be due to the cross-reactivity between epitopes of HPV33 E7 and 18 E7 proteins.
A sample (HN025) was negative both for HPV DNA and E7 serology. In overall, the sera of
86% of HPV DNA-positive patients (6 of 7) gave positive ELISA results.

Correlation of E7 Seropositivity with smoking status
I assessed the association of seropositivity with smoking status. I defined “smokers”
as the past and current smokers who smoked 10 or more pack-years. 73% of the total HNC
patients were smokers, indicating the high smoking prevalence in our population, regardless
of HPV positivity. Also, seropositivity did not significantly correlate with smoking status (p
>0.05), Table 8. Only 20% (5 out of 25) seropositive cases were never smokers.
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Figure 22: HPV–DNA detection in HNC tissue samples using MY and GP consensus
primers. β-globin was used as the internal control.

Discussion

This study evaluated serological biomarkers for clinical assessment of the role of
HPV in HNC. Although studies have been done to detect HPV L1 (VLPs) (146-149) and E1/
E2 antibodies (152), these antibodies mostly indicate early benign HPV infection or
vaccination. Since cancer usually develops after years of persistent HPV infection; detection
of antibodies for E6/E7 oncoproteins may be helpful in the serological diagnosis of malignant
lesions.
Serial monitoring of HPV serology may also be useful in predicting a patient’s
response to treatment. The decline of anti-HPV16 E6 and/or E7 antibodies after treatment
has been shown in cervical cancers (159-161) and with a few studies in HNC (156,157). From
our laboratory, Drs. Jenson and Ghim had followed cervical cancer patients with E7
serological tests and found profound IgG response against E7, which was associated with
tumor stability or dormancy (162). In a small subset of patients, I observed a significant
decline in HPV E7 antibodies after treatment, except for one patient. I also observed that sera
that were seronegative before treatment remained so after treatment of patients. In addition,
some studies have suggested that HPV16 E6/E7 seropositivity is prognostic of a favorable
clinical outcome of HNC patients (156,163). HPV status as defined by positive E6/E7 serology
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INK4a

and positive tumor HPV status (HPV DNA and p16

) is suggested to correlate even more

strongly with favorable prognosis than tumor HPV status (HPV DNA and p16

INK4a

IHC) alone

(163).
When seropositive cases were examined, I observed a statistically significant
correlation with oropharyngeal cancer, but not with other anatomic sites of HNC. My results
were consistent with the increasing incidence of HPV infection in oropharyngeal cancers. I
demonstrated that HPV serology correlates well with routine methods of testing of HPV status
INK4a

(HPV DNA detection and p16

IHC) as 86% (6 of 7) of HPV DNA positive HNC patients

also displayed positive serology. Further, E7 antibody titer in patients’ sera was strongly
INK4a

correlated with p16

positivity in HNC tissue samples. Also, among HNC samples that

tested positive for HPV16 DNA, the association of HPV16 E7 serology was strong.
In the present study, HNC patients were of the average age of 57 years, regardless of
HPV positivity. This population of patients demonstrated a high prevalence of tobacco use,
INK4a

with 74% of patients with p16

-positive HNC reporting >10 pack-years. Previous studies

have suggested that this intermediate risk group has inferior survival compared to nonsmokers with HPV-induced HNC. HPV E7 seropositivity did not correlate with smoking status
in our study population, possibly secondary to the strikingly high smoking prevalence. Indeed,
some cases of HNC may be caused by a combination of tobacco and HPV (164).
In this study, I also found that E7 antibody levels declined with response to treatment
of a patient, though post-treatment serum was available in a limited subset of patients. This
study was done with only a single follow-up sample per patient. Therefore, further studies in a
larger sample size, including longitudinal follow-up of patients could help to identify if serial
monitoring of E7 serology may be useful in predicting a patient’s respond to treatment.
In summary, HPV-specific E7 antibody levels in the sera of patients with
oropharyngeal cancer are complementary to the well-established HPV histological detection
INK4a

methods. Given the high positive predictive value of E7 serology for p16

positivity,

particularly in cancers of the oropharynx, HPV serology may be particularly useful in cases
when insufficient tissue is available to carry out p16

INK4a

immunostaining for detection of HPV-

associated disease. Further comparisons between potential tissue and serum biomarkers i.e.
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expression of p16

, presence of mitosoid cells and positive E7 serology, would be useful

to identify the best HPV-associated biomarker in head and neck tumors.
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CHAPTER IV
HPV DNA INTEGRATION AND VIRAL GENE METHYLATION DURING HEAD AND NECK
CANCER PROGRESSION

Chapter Overview

In order to better understand the progression of HPV infection in premalignant lesions
to head and neck cancers, I aimed to characterize HPV-associated genetic and epigenetic
alterations involved in head and neck carcinogenesis. Studies in cervical cancer indicate that
HPV-linked malignant conversion is associated with the specific molecular events i.e. HPV
integration and HPV methylation. In contrast, little is known regarding malignant progression
in HPV-linked head and neck cancers. Therefore, frequencies of HPV DNA integration and
methylation were profiled in the premalignant and malignant head and neck tumors and
underlying mechanisms associated with head and neck carcinogenesis were studied.

Introduction

Head and neck cancer (HNC) comprises squamous cell carcinoma (SCC) of the oral
cavity (oral squamous cell carcinoma, OSCC), oropharynx (oropharyngeal squamous cell
carcinoma, OPC), hypopharynx and larynx. In addition to excessive tobacco and alcohol
consumption, the human papillomavirus (HPV) infection has been established as an
etiological factor for HNCs, particularly OPC. Patients with HPV-associated cancers display
better treatment response and survival than patients whose tumors are HPV-negative,
independent of treatment strategy (63,64). While HPV is strongly associated with OPC, the
relationship of HPV to OSCC and its premalignant precursor (high-grade oral epithelial
dysplasia, hgOED) are not clearly defined. Our group (127) and few others (131,132) have
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recently reported that HPV is strongly associated with a certain histologic subset of hgOED. In
this chapter, I aimed to further characterize these premalignant lesions and their relationship
with malignant lesions to better understand the underlying molecular mechanisms in HPVassociated head and neck carcinogenesis.
The major viral oncogenes E6 and E7 are generally thought to be responsible for
HPV-associated malignancy, as shown in Figure 2. Their expression is mainly regulated by
viral protein E2, which is a transcription factor that binds to the early promoter p97 at specific
E2-binding sites (E2BSs) located within the long control region (LCR) of HPV and can repress
the expression of HPV E6 and E7 oncogenes (20,21), Figure 3. Overexpression of E6 and
E7 can be caused either by disruption of E2 gene via HPV genome integration or by inhibition
of E2 protein binding to the LCR via HPV methylation (85). Therefore, viral integration and
methylation are considered as two main regulatory mechanisms for malignant transformation
(23,24,91,92), Figure 7 and Figure 8.
Integration of HPV into the genome of an infected host cell has been extensively
characterized in cervical cancers that are the widely acknowledged as HPV-associated
cancers (96,97). In HNC, studies are mostly limited to cancer cell lines with few studies in
patient specimens (83,100-105) and data on premalignant lesions are limited. While viral
integration is thought to play an important role in cervical cancer (92), the relevance of viral
integration is controversial in head and neck carcinogenesis (100). My first objective in this
chapter is to address the role of viral integration in the development of cancers of the head
and neck by determining the integration status in histologically distinct premalignant and
malignant lesions.
Methylation of the HPV genome, which contains 15 CpG sites in the long control
region (LCR), has been suggested as a biomarker for cervical cancer progression (23,24).
Hypermethylation within HPV-LCR has been reported in cervical cancers or high- grade
cervical dysplasia compared with low-grade CIN (23,24). In cervical cancer, it is shown that
methylation of HPV inhibits binding of the transcriptional repressor (E2), resulting in
overexpression of viral oncoproteins and leading to malignant transformation. However, very
few studies have evaluated HPV methylation status in HNC specimens and their results are
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inconsistent (111,112). To date, there is no information about the methylation pattern in
premalignant hgOED lesions. My second objective in this chapter is to address the role of
HPV DNA methylation in malignant transformation in head and neck tumors.
Toward these ends, I analyzed the physical integration of HPV DNA into the host
chromosomes and presence of potential DNA methylation sites in the HPV epigenome in
patients with premalignant and malignant tumors of the head and neck. Profiling of these
genetic and epigenetic events may help to better understand the complex mechanisms of
HPV-mediated head and neck carcinogenesis.

Experimental Procedures

Tissue specimens and cell lines: This study was approved by the IRB at the University of
Louisville. Premalignant specimens from 40 patients were obtained from Biorepository of
University of Louisville Oral Pathology Laboratory (as mentioned in Chapter II). HNC
specimens from 50 patients were collected from Cancer Database and Specimen Repository
at the James Graham Brown Cancer Center (as mentioned in Chapter II subheading 3). HNC
cell lines were established at the University of Michigan and carry the heading, University of
Michigan Squamous Cell Carcinoma (UMSCC). The HPV-negative cell line (UMSCC-1) and
HPV-positive cell lines (UMSCC-47 and UMSCC-104) were purchased from EMD Millipore
Corporation (Temecula, CA, USA), and cultured using standard protocols. Cervical cancer
cell lines, CaSki and SiHa, were cultured as suggested by American Type Culture Collection
(ATCC, Manassas, VA, USA).
DNA extraction and HPV detection: DNA was extracted from fresh frozen or FFPE
specimens using DNAeasy Blood & Tissue kit (Qiagen, USA) as per manufacturer’s
instructions with RNAase (20 µl of 20mg/ml) treatment. FFPE samples were deparaffinized
and washed before DNA extraction. HPV detection and genotyping were performed, as
previously described (126). β-globin was used as an internal control. Sixteen of the 50 HNC
specimens were HPV16 positive (Table 7 for demographics). In premalignant lesions, HPV16
DNAs were present in 12/16 of Group 1, 7/14 of Group 2 and 2/10 of the Group 3. HPV type
16 is known to be the most common carcinogenic HPV type in cervical cancer development.
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Similarly, HPV16 was the predominant form of HPV in specimens and cell lines derived from
head and neck tumors. I used HPV16-positive premalignant and malignant samples for
further analysis.
HPV integration and viral load by quantitative PCR: I employed a previously described
real-time quantitative PCR assay to evaluate viral load and integration in cell lines and HNC
specimens (165). The primers and probes were designed for specific amplification of the E2
hinge regions which are known to be disrupted most frequently during the process of viral
integration (165). E6 primers and probes were also designed accordingly. β-globin was used
as an internal control. In a total volume of 20 µl, the final primer, probe and DNA template
concentrations were 0.3 µM, 0.1 µM, and 20 ng respectively. TaqMan™ Universal Master Mix
II, with UNG (Uracil-N-glycosylase), was used according to the manufacturer’s instructions
(Thermo Fisher Scientific, USA). HPV16 plasmid cloned in a pBR322 vector (300 pg to 0.3
pg) was used to plot a standard curve. The relative viral load was estimated by calculating the
ratio of a copy of E6 found in the specimen to copy of E6 present in SiHa cell because SiHa
cells are known to contain a well-defined viral copy number (165). HPV integration status was
evaluated using E2/E6 ratio. The ratio of E2 to E6 equal or greater than 1 indicates the
presence of HPV DNA in the episomal state with no integrated forms of viral DNA. An E2/E6
ratio of 0 indicates HPV DNA in an integrated state with no episomal forms of viral DNA. An
E2/E6 of 0.5 shows the presence of equal copies of integrated and episomal forms of HPV
DNA. Samples were categorized as predominantly integrated if the E2/E6 ratio was less than
0.5 and predominantly episomal if the ratio was greater than 0.5. Cervical cancer cell lines
(CaSki and SiHa) were used as positive controls for studying HPV genome integration in HNC
cell lines and different head and neck tumor lesions. Water controls were included in each
run. All experiments were performed in duplicates at least three times.
Determination of E2 Gene Integrity: The integrity of the E2 gene was determined by
amplification of the full-length E2 ORF (nucleotide 2755 to 3852 of NC_001526.2; primers
16E2a and E2b listed in Table 11). Disruption of this region was defined as an absence of the
full-length E2 amplicon on agarose gel electrophoresis and positive signals of parallel β-actin
amplification. Positive signals for amplification of the ~1 kb full-length E2 amplicon from CaSki
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DNA were used as a control because CaSki cells are known to carry an intact E2 gene. Also,
amplification of first half of E2 (primers 16E2a and 16E2c) and last half of E2 region (primers
16E2d and 16E2b) was performed for further confirmation of E2 integrity.
Bisulfite-sequencing: Purified genomic DNA was bisulfite converted using an EpiTect ®
Plus Bisulfite Kit (Qiagen, CA, USA) according to the manufacturer’s protocol. In this
treatment, unmethylated cytosine residues are converted to uracil whereas 5-methylcytosine
is unaffected. Target DNA is then amplified by PCR in which uracil residues are converted to
thymine. The DNA methylation status of HPV DNA was then evaluated by the direct
sequencing of PCR products. Because HPV type 16 have different variants (categorized
based single nucleotide polymorphisms present in LCR and/or E6), an Asian-American
variant of HPV type 16 (Genbank accession number: AF402678.1) was used as reference
HPV16 sequence for primer design and further analysis. The bisulfite-treated DNA was
amplified by PCR using different sets of primers designed to target the 15 CpG sites in LCR
region of HPV (Figure 8, Table 11). Primers were designed within the consensus sequences
among different variants of HPV16 (Genbank accession numbers: AF402678.1, AF125673.1,
AY686584.1, NC_001526.2, and KF954093.1). Different secondary primer sets were adopted
in cases where PCR amplification was negative using primary primers. As an internal control
for the presence of bisulfite-modified DNA, primers specific to a modified region of the β-actin
(ACTB) gene containing no CpG sites was used. PCR reaction mixtures consisted of 10X HiFi
PCR buffer, 50mM MgSO4, 10 mM dNTPs, 20 µM of each primer and 1 U of HiFi Taq
polymerase (Thermo Fisher Scientific, USA) in a total volume of 20 µl. PCR conditions were
95°C (2 min); 45 cycles of 45 sec at 95°C, 45 sec at 52°C and 45 sec at 68°C, followed by 10
min at 68°C. PCR products were run on 3% agarose gel and extracted using QIAquick Gel
Extraction Kit (Qiagen, USA) and sent for sequencing to the DNA Core Facility at the
University of Louisville. Amplified products were directly sequenced using the same primers.
Sequencing data was analyzed using NCBI BLAST database and SeqMan Pro program
(Lasergene 12, DNAstar Inc., Wisconsin).
RNA extraction and qRT-PCR analysis: Total RNA was isolated from cultured UMSCC-1,
47 and 104 cells by using PureLink® RNA Mini Kit (Thermo Fisher Scientific, USA), with
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DNase I treatment, according to manufacturer's instructions. Single-stranded complementary
DNA (cDNA) was synthesized from 1 μg of total RNA using SuperScript® VILO cDNA
Synthesis Kit (Thermo Fisher Scientific, USA) according to the manufacturer's instructions.
Quantitative real-time reverse transcription–polymerase chain reaction (qRT-PCR) was
performed in separate 20-μL reaction volumes to evaluate the expression of HPV16 E6, E7,
and E2 genes, and cellular genes p16 (CDKN2a/INK4a), EGFR and β-actin. To investigate
the expression of E2 gene, primers were designed near the 5’ end and upstream of the
frequent E2 breakpoint to monitor the relative expression of truncated E2 mRNA. qRT-PCR
was performed in triplicate using 100 ng of cDNA as template, the gene-specific forward and
reverse primers (0.3 μM each) (Table 11), and the Power SYBR® Green Supermix (Thermo
TM

Fisher Scientific, USA) in an Applied Biosystems VIIa

7 Real-Time PCR detection system

(Thermo Fisher Scientific, USA). The amplification program for all primer sets was 95°C for 3
minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 60 seconds. Real-time
PCR amplification data were analyzed and threshold cycle (Ct) numbers were automatically
TM

determined by VIIa

7 software v1.2.4 (Thermo Fisher Scientific, USA). The relative

expression of each mRNA was calculated by the ΔCt method (166,167). Endogenous β-actin
mRNA levels were used for normalization of RNA expression. Due to the small amounts of
RNA recovered from clinical biopsies, qRT-PCR was only performed on cell lines and not on
clinical biopsy samples.
Statistical analysis: Comparisons were performed using Student’s t-test or Fisher’s exact
test or Mann-Whitney Rank Sum Test. SigmaPlot Version 12.5 (Systat Software, Inc., San
Jose California, USA) and Microsoft Excel 2013 (Microsoft Corporation, Redmond WA) were
used for data computation and statistical analysis. Statistical significance was established at
p-value ≤0.05 (*p<0.05; ** p<0.01; ***p<0.001).
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Table 11: List of primers employed to detect HPV DNA, HPV integration, E2 gene integrity,
bisulfite sequencing and qRT-PCR.
Target
HPV detection
L1

Primer
*

MY09 (For)
*
MY11 (Rev)
L1
GP5+ (For)
GP6+ (Rev)
β-globin
GH20 (For)
PC04 (Rev)
HPV integration by qPCR
E2
16E2F
16E2R
16E2probe
E6
16E6F
16E6R
16E6probe

Sequence (5’-3’)
CGTCCMARRGGAWACTGATC
GCMCAGGGWCATAAYAATGG
TTTGTTACTGTGGTAGATACTAC
GAA AAATAA ACTGTAAATCATATTC
GAAGAGCCAAGGACAGGTAC
CAACTTCATCCACGTTCACC
AACGAAGTATCCTCTCCTGAAATTATTAG
CCAAGGCGACGGCTTTG
(FAM)-CACCCCGCCGCGACCCATA-(TAMRA)
GAGAACTGCAATGTTTCAGGACC
TGTATAGTTGTTTGCAGCTCTGTGC
(FAM)-CAGGAGCGACCCAGAAAGTTACCACAGTT(TAMRA)

E2 gene Integrity
16E2a (For)
16E2b (Rev)
16E2a (For)
E2 (first half)
16E2c (Rev)
16E2d (For)
E2 (last half)
16E2b (Rev)
Bisulfite sequencing
(2F+3R) For
5’-LCR, enhancer
(2F+3R) Rev
enhancer
(4F+4R) For
(4F+4R) Rev
promoter
(5F+5R)For
(5F+5R) Rev
5’-LCR and
BSP-6 (For)
enhancer
BSP-6 (Rev)
β-actin
mACTB (For)
mACTB (Rev)
Gene expression by qRT-PCR
E6
For
Rev
E7
For
Rev
E2
For
Rev
INK4a
p16
For
Rev
EGFR
For
Rev
β-actin
For
Rev
IPO8
For
Rev
E2 (full length)

ATGGAGACTCTTTGCCAACGTT
TCATATAGACATAAATCCAGTAGAC
ATGGAGACTCTTTGCCAACGTT
TTATTCTTTGATACAGCCAGTGTTG
CCTCACTGCATTTAACAGCTCA
TCATATAGACATAAATCCAGTAGAC
GTGTATGTGTTTTTAAATGTTTGTGT
CACAATATACATAATAATTCAATAATTAC
GTAATTATTGAATTATTATGTATATTGTG
CACACACCCATATACAATTTTACAA
TTGTAAAATTGTATATGGGTGTGTG
ACAACTCTATACATAACTATAATAACT
TAAATTATATTTGTTATATTTTGTTTTTGT
TAATTAACCTTAAAAATTTAAACCTTATAC
TGGTGATGGAGGAGGTTTAGTAAGT
AACCAATAAAACCTACTCCTCCCTTAA
CAGCAATACAACAAACCG
GCAACAAGACATACATCG
CAGAGGAGGAGGATGAAATAG
AGGTCTTCCAAAGTACGAATG
TGATAGTACAGACCTACGTGACCATATAGA
CCCATTTCTCTGGCCTTGTAAT
CATAGATGCCGCGGAAGGT
CCCGAGGTTTCTCAGAGCCT
GGAGAACTGCCAGAAACTGACC
GCCTGCAGCACACTGGTTG
CCATCGTCCACCGCAAAT
GCTGTCACCTTCACCGTTCC
CAGTGCATTCCACTCTTCGT
ACGAAGCTCACTAGTTTTGACC
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Results

Frequency of viral DNA integration in HNC cell lines
HPV16 DNA integration into the host genome is known to be strongly associated with
HPV-induced cancer progression, and different integration patterns were reported in two
cervical cancer cell lines (168). In this study, using an absolute quantification method with
qPCR confirmed 2 copies of HPV16 DNA from SiHa cell line as previously reported (169).
SiHa cells were then used as a reference for estimating the relative viral copy number in other
cell lines and human tissue specimens (165). I found 325 copies of HPV16 DNA in CaSki,
although different HPV DNA copy numbers (60–600) were previously reported in this cell line
(169).
Integration of HPV16 DNA in the HNC cell lines and tumor tissues was examined
using a method that was designed to provide a ratio of E6 to E2 gene copy number (165).
The disruption of the E2 gene upon viral integration is known to be associated with HPVinduced cancer malignancy and was, therefore, the major focus of this study. The E2/E6 ratio
was 0.0 in SiHa, indicating that both copies of HPV16 DNA were integrated into chromosomal
DNA on this cell line as reported previously (169). CaSki cells showed the E2/E6 ratio of 0.12,
indicating that the majority of HPV DNA in this cell line is integrated. These results were
further confirmed by amplifying E2 ORF with nested PCR primers (Table 11). No full length of
E2 was found in SiHa while small 3’- or 5’- E2 fragments were amplified (Figure 23C). In
CaSki, both full length and small fragments of E2 ORF were amplified confirming the
presence of mixed forms of intact and disrupted E2 DNAs (Figure 23).
UMSCC-47 and 104 cell lines, originated from tumors of the anterior tongue and floor
of the mouth, respectively, were classified as oral cavity cancers according to the anatomybased classification of HNCs (170,171). HPV16 DNAs were detected from both cell lines
while no DNA was found from the cell line UMSCC-1, which also originated from an oral
cavity tumor. Relative to SiHa, the number of viral copies in HPV16-positive HNC cell lines
(UMSCC-47 and UMSCC-104) was 2 (Figure 26). However, no full length of E2 was
amplified in both cell lines, suggesting both contained only integrated HPV16 DNA (Figure
23). HPV DNA integration was confirmed by evaluating E2/E6 ratio from these cell lines.
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E2/E6 ratio values obtained from UMSCC-47 and UMSCC-104 (0.0 and 0.045 respectively)
suggested that in both cell lines contained integrated HPV as the predominant species
(Figure 26).

Characterization of HNC cell lines with integrated HPV DNA
Because the disruption of the E2 gene upon HPV DNA integration causes robust and
chronic expression of the viral E6 and E7 oncogenes in cervical cancer, the expression of E2,
E6, and E7 genes was profiled in HNC cell lines. Quantitative RT-PCR assays showed that
E6/E7 mRNA levels varied considerably between the two HPV-positive HNC cell lines studied
(Figure 24). E7 expression was significantly higher in UMSCC-104 compared to UMSCC-47
(p<0.001); however the latter showed higher E6 expression than the former (p<0.05).
Expression of E2 was analyzed using the primers designed to anneal upstream of the
frequent E2 breakpoint and both cell lines showed similar levels of E2 expression.
INK4a

Additionally, the expression of p16

and EGFR has been associated with HNCs (172,173),

so their expression was also examined in HNC cell lines. The expression of p16

INK4a

was

similar in HPV-positive HNC cell lines and significantly higher than that in the HPV-negative
UMSCC-1 cell line. EGFR expression was relatively higher in UMSCC-104 than UMSCC-1,
but was not significantly different between UMSCC-47 and UMSCC-1 (Figure 24).
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Figure 23: Determination of E2 gene integrity (A) by using HPV16 E2 primers (16E2 a, b, c,
and d, Table 11) which detect intact and disrupted E2 gene. (B) Agarose gel image showing
the full length of E2 in CaSki and disrupted E2 sequences in SiHa, UMSCC-47, and UMSCC104. (C) Schematic representation of integrated HPV DNA in CaSki, SiHa, UMSCC-47 and
UMSCC-104 cell lines.
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Figure 24: Relative expression of E6, E7, E2, p16 and EGFR in UMSCC-47 and UMSCC-104
head and neck cell lines (Significance level at *p<0.05 and **p<0.01)
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Differential HPV16 DNA integration rates in head and neck tumors collected at the
different stages of malignant progression
In chapter II, I classified three different groups of premalignant oral samples based on
their histological features. Briefly, Group 1 contained diffuse mitosoid/ apoptotic cells while in
Group 2 and Group 3, histological features were focal or lacking. Group 1 was found to be
INK4a

strongly associated with the presence of HPV and higher levels of p16

expression when

compared with specimens in Group 2 and Group 3. Here, I evaluated HPV copy number and
integration status to determine if there was a relationship between these parameters in the
differently staged groups. HPV copy number was detected at variable levels in premalignant
lesions and was significantly higher in Group 1 lesions compared to Group 2 (p <0.001) and
Group 3 (p= 0.04, Mann-Whitney test, Figure 25). Relative to SiHa, the HPV copy number in
Group 1 lesions ranged from 1-47 with one exception of 0.1 copies. In contrast, all
premalignant samples in Group 2 and Group 3 groups showed relative viral loads less than
0.1 (Figure 25). When I analyzed the integration state of HPV genome in HPV16 positive
premalignant lesions, I observed a significant difference in the physical state of the viral DNA
among the study groups (p=0.006, Table 12). The specimens in Group 1 contained a
significantly higher level of integrated HPV DNA (90.9%) compared to Group 2 (28.6%) and
Group 3 (0%). In contrast to Group 1, where integrated DNA was the predominant species,
both episomal and integrated forms of HPV DNA were found in samples in Group 2.
HPV DNA copy number and integration status were also analyzed in 16 HNC
specimens (malignant forms) and compared with those of premalignant tumors. Relative to
SiHa, variable viral loads between 0.1 and 205 copies/cell (two cases had less than 0.1) were
found in malignant specimens (Figure 25). 75% of these HNC specimens had integrated HPV
as the predominant species, whereas only 6.25% of these HNC specimens had episomal
DNA as the predominant species (Table 12). The patterns of HPV genome integration were
similar between malignant and premalignant lesions of Group 1. Similarly, there was also no
significant difference in viral load between Group 1 premalignant lesions and malignant
specimens (p= 0.79).
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Figure 25: Box plot showing viral load in malignant (N=16) and different groups of
premalignant [Group 1 (N=11), Group 2 (N=7) and Group 3 (N=2)] tumors, expressed in a
number of times the level in SiHa cells. The bottom and top of the box show the first and third
quartiles respectively, the solid line inside the box is the second quartile (i.e. the median), and
the dashed line shows the mean value. Whiskers in the box plot represent the highest and
lowest values excluding outliers as shown by dots. Long whisker in the case of the malignant
specimen shows high variability in HPV copy number. In the case of Group 2 and Group 3
tumors, the values for mean, median and quartiles were almost same, so only solid lines are
seen in the plot. (Significance level *p<0.05, **p<0.01, NS- non-significant, Mann-Whitney
Rank Sum Test)
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Figure 26: Assessment of HPV16 DNA integration by analyzing E2/E6 ratio in (A)
premalignant (Group 1, Group 2 and Group 3) tumors and (B) cancer cell lines (cervix-CaSki
and SiHa; and head and neck, UMSCC-47 and 104), and malignant head and neck tumor
specimens.

71

Table 12: HPV DNA integration in HPV16 positive premalignant hgOED and HNCs
Premalignant hgOED
HNC
Overall (malignant)

HPV DNA integration status
Group 1

Group 2

Group 3
p-value

Solely or predominantly integrated

10 (90.9%)

2 (28.6%) 0 (0.0%)

Episomal or predominantly
episomal

1 (9.1%)

3 (42.9%) 1 (50%)

Both episomal and integrated

0 (0.0%)

2 (28.6%) 1 (50%)

12 (75%)
0.006

1 (6.25%)
3 (18.75%)

Table 13: Methylation pattern of HPV16 cervical and HNC cell lines and HNC specimens*

%

Sample* |

E2BS1

Enhancer

E2BS2

SP1

E2BS3 E2BS4

7862

31

37 43 52 58

Methyla
tion

7428

7434

SiHa

0

U

U

U

U

U

U

U

U

U

U

U

U U U

U

CaSki

93.33

M

M

M

M

M

M

M

M

M

U

M

M M M

M

76.92

M

mutated

M

M

M

M

U

U

M

U

mutated M M M

M

0

U

U

U

U

U

U

U

U

U

U

U

U U U

U

HN08-T

93.33

M

M

M

M

M

M

M

M

M

U

M

M M M

M

HPV037

60.0

M

M

M

M

U

U

U

U

U

U

M

M M M

M

HN022

26.67

U

U

U

U

U

M

U

U

U

U

M

U U M

M

CpG sites

UMSCC-47

†

UMSCC-104

7455 7461 7535 7553 7676 7682 7694

U denotes unmethylated; M denotes methylated.
*The remaining 13 HNC and 20 premalignant hgOED specimens were unmethylated at
all 15 CpG sites.
†
UMSCC-47 only has 13 CpG sites due to two point mutations at nucleotides 7434 CG>CA
and 31 CG>TG.
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HPV LCR methylation in head and neck malignant progression
Methylation of the HPV genome has emerged as a biomarker for cancer progression
in cervical cancer (23,24). To determine the role of HPV methylation in head and neck
carcinogenesis, I first localized CpG sites within the HPV16 LCR. This region contains a
promoter for transcription of viral early genes that includes E2 binding sites (E2BS) 1 to 4 and
an SP-1 binding site (Figure 8 and Table 13). There were 15, 15, 13 and 15 CpG sites in
SiHa, CaSki, UMSCC-47 and 104 LCRs, respectively. UMSCC-47 had less CpG numbers
than other cell lines tested because of its two point mutations [nucleotide (nt.) 7434 CG>CA
and nt. 31 CG>TG], as reported previously (174). A variety of methylation patterns on the
promoter within the LCR were found in four HPV cancer cell line derived from HPV16
infections. CaSki and UMSCC-47 cells showed hypermethylation (93.33% and 76.92% of
available CpGs, respectively). The CpG at nt.7862 within E2BS-2 was unmethylated in both
cell lines. UMSCC-47 had additional unmethylated CpGs at nucleotides 7676 and 7682. In
contrast, UMSCC-104 and SiHa cell lines showed unmethylated CpG at all 15 sites within
LCR. Consequently, two different HPV cancer cell lines (CaSki and UMSCC-47) showed
hypermethylation and the other two (SiHa and UMSCC-104) showed hypomethylation
patterns.
The methylation patterns on viral LCR were then profiled in premalignant and
malignant lesions of the head and neck in specimens where DNA integration rates were
analyzed (Table 13). The methylation patterns of CpG were not different among premalignant
specimens between the histologically distinct groups. Indeed, all CpG sites within the LCR
were unmethylated in all premalignant specimens. Moreover, all HNC specimens were
predominantly unmethylated, except three malignant samples which contained methylated
CpG (93.33%, 60%, and 26.67% methylation, respectively). From these results, I observed
overall hypomethylation pattern of HPV epigenome from samples of HNC patients.

Discussion

The molecular determinants of HPV-associated HNC development and progression
are not well-defined. Viral integration and methylation could potentially play a role in HPVinduced head and neck carcinogenesis as seen in HPV-associated cervical cancer. However,
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limited studies have addressed this highly relevant issue and are mostly done using HNC cell
lines with few studies in patient tumor samples and even fewer in pre-malignant specimens.
In this study, I have analyzed histologically characterized HPV-positive tumors, collected at
different stages of malignancy, with a goal of elucidating mechanisms of HPV-associated
head and neck malignancy.
I used cervical and head and neck cancer cell lines to collect reference data that are
useful for the analysis of clinical samples. HNC cell line UMSCC-47 contained integrated HPV
with disruption of the E2 gene, similar to SiHa. Further, UMSCC-104 showed a low E2/E6
ratio with no amplified product for the full length of E2 (Figure 23), indicating that HPV had
integrated (Figure 26). These results were consistent with data from other researchers (168) .
However, one study suggested the presence of only episomal HPV in UMSCC-104 (175).
This discrepancy might be due to the use of a different set of primers that do not target fulllength E2. According to Akagi et. al, in UMSCC-104, the integration breakpoint is at the far 3’
end of E2 gene, which differs from the frequent breakpoint site as seen in SiHa and UMSCC47 (168). This unexpected location of the breakpoint likely explains why this was missed by
Olthof et. al (175).
Methylation is another mechanism by which expression of the HPV oncogenes can
be reduced and contribute to malignant progression (176-179) , therefore I also studied
promoter methylation in HPV cell lines and patient samples. I began by studying promoter
methylation in HPV-positive HNC cell lines (UMSCC-47 and -104) and compared with that in
cervical cancer cell lines (CaSki and SiHa). The SiHa cell line where HPV DNA had integrated
was hypomethylated within the LCR, whereas CaSki containing both integrated and episomal
HPVs was hypermethylated (Table 13, Figure 23 and Figure 26). Surprisingly, the pattern of
methylation and its correlation with integration status showed exactly the opposite in the two
HNC cell lines: UMSCC-47 with only integrated DNA (similar to SiHa) showed
hypermethylation pattern (resembling CaSki), and UMSCC-104 containing predominantly
integrated HPV DNA showed hypomethylation pattern (Table 13, Figure 23 and Figure 26).
Therefore there was no correlation between integration status and promoter methylation of
HPV DNA between the different cancer cell lines used in this study.
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As mentioned earlier, viral integration and methylation are considered as two different
mechanisms to interfere with E2 function thereby increasing oncogene expression and
potentially leading to malignant transformation. Both HPV- positive HNC cell lines used in this
study showed integrated HPV DNA, therefore it was not possible to correlate viral oncogene
expression with integration status. However, the UMSCC-104 cell line which was derived from
a recurrent tumor showed significantly higher E7 expression compared to UMSCC-47. In
contrast, the UMSCC-47 cell line with hypermethylated HPV showed higher E6 levels than
UMSCC-104, which contained hypomethylated HPV DNA. These data show no clear pattern
relating promoter methylation to oncogene expression, except to possibly suggest that there
may be differences between oncogenes in this regard. More studies are necessary to
determine whether changes in methylation patterns in the LCR influence the expression of the
HPV oncogenes, E6 and E7.
Overexpression of p16
INK4a

As expected, p16

INK4a

has been correlated with HPV-positive cancers (172,173).

expression was significantly higher in both HPV- positive HNC cell lines

compared to HPV-negative UMSCC-1 cell line. EGFR is also frequently overexpressed in
HNC independent of HPV etiology (180,181). Overexpression of EGFR is considered a poor
prognostic factor in HNCs (182). Accordingly, compared to UMSCC-1 (which is HPV-negative
HNC cell line), I found significantly higher EGFR expression in UMSCC-104 cells which was
isolated from an HPV-positive tumor that did not respond to treatment (170).
Integration of high-risk HPV DNA into host cells in severe dysplasia or carcinoma in
situ of the cervix has been suggested as the first epidemiological marker of malignancy (183186). Therefore, for the first time, I analyzed HPV integration status in HPV16-positive
samples collected at different malignant stages of tumors from the head and neck region,
mainly by incorporating pre-malignant lesions in the study. I found that HPV integration status
differed significantly between histologically distinct premalignant hgOED groups. Although the
consequences of HPV DNA integration in oral dysplastic cells remains unexplored, I found
that Group 1 (having diffuse mitosoid/ apoptotic cells) was more likely to have integrated HPV
DNA (90.9%) than Group 2 and Group 3 (where histological features were focal or lacking).
Group 1 had mostly integrated HPV DNA, which may confer higher malignant transformation
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potential of Group 1 to HPV-associated cancer than Group 2 or Group 3. Therefore, the
presence of an abundance of mitosoid cells in any premalignant squamous lesion could
indicate the potential development of an HPV-associated oral cancer, though further research
is warranted to confirm this hypothesis. In the malignant specimens, I also observed
integration of HPV DNA in a significant proportion of HPV-positive HNCs, which was as
expected based on the results from cell lines. These observations obtained from malignant
specimens were also consistent with the results from other studies (104,105).
In the case of cervical cancerous and pre-cancerous lesions, higher CpG methylation
in E2BS was seen in samples containing only episomal HPV16 compared to those with
integrated HPV16 genomes (178). So, HPV LCR methylation was considered as an
alternative mechanism to HPV integration for cervical malignancy. However, HPV epigenome
of head and neck tumors was mostly hypomethylated in contrast to what was observed in
cervical lesions (23,24). This is also in contrast with a small study consisting of 3 HPVpositive HNCs, which showed hypermethylation in LCR regions (111). However, a study in a
large number of malignant samples reported hypomethylation of LCR in OPSCC (112), which
is consistent with the results obtained in this study. Moreover, my analyses showed no
significant differences in the methylation pattern between head and neck premalignant and
malignant specimens with or without integration. In malignant specimens containing
predominantly episomal HPV DNA, I didn’t find any methylation for CpG sites. Additionally,
since all 15 CpG in premalignant specimens were unmethylated, I could not find any
difference in methylation pattern among 3 groups, although they varied in integration status.
Consequently, my results indicated that integration status of tumor lesions of the head and
neck did not seem to correlate with HPV methylation pattern. This warrants further extensive
research to determine the relationship of HPV genome methylation and integration in head
and neck carcinogenesis.
Overall, this is the first study to show differential HPV integration pattern in
histologically distinct premalignant samples. This study revealed that HPV DNA integration
might play a role in the process of HPV-induced head and neck carcinogenesis but not HPV
methylation.
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CHAPTER V
HOST EPIGENETIC CHANGES BY HPV INFECTION

Chapter Overview

DNA methylation is an important epigenetic modification in human cells. Both viral
genomic and host chromosomal DNA can undergo methylation. In chapter IV, I found that
promoter methylation of HPV DNA (HPV epigenome) gave no consistent patterns in head and
neck cancer. In this chapter, I focused on characterization of host epigenetic changes to
better understand cancer progression driven by HPV infection in the head and neck. For this
study, an array of tumor suppressor genes was selected based on the data available from
PubMed that seem to be implicated in HPV carcinogenesis. Results of my study showed that
EREG is a candidate target gene for epigenetic regulation by HPV in HNC cells.

Introduction

Epigenetic modification, such as DNA methylation, histone modification, chromatin
remodeling and microRNA, are essential for normal cellular differentiation, development and
gene expression (187). Therefore, abnormal epigenetic modifications may contribute various
pathological states. In particular, gene silencing through aberrant promoter methylation is
considered as an important cause of tumorigenesis (118,188). Unmethylated cytosines in
CpG island within the promoter region allows gene expression while methylated CpG causes
silencing of genes. Methylated CpG binds with methyl-CpG-binding proteins and in turn,
recruit histone deacetylases, resulting in transcriptional inactivation and loss of gene
expression, as described in Figure 9 (113,189). Methylation of DNA is catalyzed by a group
of enzymes called DNA methyltransferases (DNMTs), Figure 9A. DNMT1 is mainly
responsible for maintenance methylation in which the methylation pattern is transmitted
during cell division (190). The DNMT3 group of methyltransferases, particularly DNMT 3a and
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DNMT3b performs de novo methylation in which previously unmethylated cytosines are
modified (113). There is growing evidence that the DNA methylation is a target for epigenetic
changes induced by HPV E7 and E6 oncogenes (119,191). It has been shown that HPV16
infection is associated with an up-regulation of DNMT1 and DNMT3a (119). Therefore,
different studies related to epigenetic alterations have been largely investigated in cervical
cancers, where hypermethylation of viral and host genes were frequently detected in
advanced cancers (86-90,192). Accordingly, epigenetic alteration (particularly, promoter
hypermethylation of the tumor suppressor genes) are known to play a major role in the
development of HNCs (121,122,125,193,194). Although studies have shown epigenetic
modulation in HNCs (121,122,195), it is unknown the extent to which these changes
contribute to HPV-mediated carcinogenesis and progression. A better understanding of the
epigenetic differences between HPV-positive and HPV-negative HNCs will help to identify
molecular signatures involved in HPV-mediated HNC carcinogenesis.
In order analyze the methylation status of tumor suppressor genes (TSGs) and
identify epigenetic changes specific for HPV-positive HNCs, I surveyed publicly available
resources- NCBI Epigenomics and PubMed literature. Thereby, I selected 38 candidate TSGs
thought to be hypermethylated and repressed on cervical cancers and HNC (125,193-210).
There were only a few reports on the relationship between HPV infection and methylation of
host genes in HNCs (104,195,211-215) and results varied among studies. Herein, I
hypothesized that presence of HPV infection leads to methylation of host genes and thereby
reduces expression of distinct unique tumor suppressor genes in HNCs.

Experimental Procedures

Cell culture: Head and neck cancer cell lines; UMSCC-1 (HPV-negative) and UMSCC-47
(HPV-positive); were purchased from EMD Millipore Corporation (Temecula, CA, USA) and
cultured as per manufacturer’s instructions. UMSCC-1 and -47 originated from the floor of the
mouth and anterior tongue, respectively, such that they are classified as oral cavity cancers
(subsets of HNCs).
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DNA isolation: DNA was isolated from cultured UMSCC-1 and 47 cells using DNAeasy®
Blood & Tissue kit (Qiagen, USA) as per manufacturer’s guidelines. The same method was
applied to isolate DNA from 5-aza-2′-deoxycytidine treated cells.
RNA isolation and cDNA synthesis: Total RNA was extracted from all samples by using
PureLink® RNA Mini Kit (Thermo Fisher Scientific Inc, USA), with DNase I treatment,
according to manufacturer's instructions. To detect mRNA expression, single-stranded
complementary DNA (cDNA) was synthesized from 1 µg total RNA by using SuperScript®
VILO cDNA Synthesis Kit (Thermo Fisher Scientific Inc, USA) according to the manufacturer's
guidelines.
Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) Analysis: Quantitative
RT-PCR was conducted on a ViiA7 Real-Time PCR system (Applied Biosystems, Thermo
Fisher Scientific Inc, USA). Expressions of DNMTs were quantified using Power SYBR Green
PCR Master Mix (Thermo Fisher Scientific Inc, USA) and normalized against expression of a
β-actin housekeeping gene. Each sample was measured two times at least and fold changes
in mRNA expression levels were calculated using the comparative threshold (Ct) cycle
method. Expressions of DNMTs were also measured using pre-designed TaqMan primers
and probes in TaqMan array plate. Results were consistent from both Sybergreen assay and
TaqMan array assay plate.
Quantification of global DNA methylation: DNA was isolated as described previously in
earlier chapter II. Global methylation levels were assayed using Methylamp™ Global DNA
Methylation Quantification Ultra Kit (Epigentek) following the manufacture’s protocol. In this
assay, DNA is immobilized to the well which is specifically coated with DNA binding
substance. The methylated fraction of DNA is recognized by 5-methylcytosine antibody and
quantified through an ELISA-like reaction.
Selection of endogenous control for Taqman gene expression studies: TaqMan®
Human Endogenous Control array (Applied Biosystems, Thermo Fisher Scientific Inc, USA)
was used to identify appropriate endogenous controls that are invariably expressed in
different samples being compared (i.e. 5-aza-dc treated and untreated UMSCC-1 and
UMSCC-47 cells). This array card contains a panel of 16 endogenous control gene
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candidates (probe/primer sets preloaded into the array card), Table 14. cDNA from each
sample were synthesized from 1 µg total RNA and equal concentration (200 ng in each well)
were loaded in triplicates into the endogenous control array card according to manufacturer’s
specifications, centrifuged and run on a ViiA7 Real-Time PCR system (Applied Biosystems,
Thermo Fisher Scientific Inc, USA). Accordingly, three genes- namely 18S rRNA, GAPDH,
and IPO8 were selected (since their standard deviations were less than 0.5 Ct) and added in
TaqMan custom array plate.
Customized TaqMan® Array Plate: Assorted from various previous studies, 38 tumor
suppressor gene (TSG) candidates that showed to be hypermethylated with decreased
expression in cervical and HNCs were selected and added in custom array plate (Table 15).
In addition, the plate also contains three DNMTs (DNMT1, DNMT3a, and DNMT3b); four
INK4a

HPV-affected genes (TP53, RB1, p16

, EGFR) and three internal control genes (18S,

GAPDH, IPO8; which was selected from TaqMan Endogenous Control Arrays). Relative
changes in gene expression in UMSCC-47 versus UMSCC-1 and relative changes on 5-azadc treatment as compared to untreated (DMSO treated) control cells was analyzed using
normalization with IPO8.
5-aza-2′-deoxycytidine (5-aza-dc) treatment: The de-methylation reagent 5-aza-dc
treatment assay was used to analyze the functional effect of gene methylation on its
expression in HNCs. 5-aza-dc (Sigma Aldrich Inc., St. Louis, MO) was dissolved in DMSO to
make a stock solution of 20 mM and stored in aliquots at −80°C until use. From the stock
solution, it was diluted directly in the culture medium to obtain desired final concentrations.
Cells were treated with 5-aza-dc at different concentrations (0.5–30 μM) for 96 h. The culture
medium containing freshly prepared 5-aza-dc was replaced every 24 h. Control cells were
treated in parallel with DMSO only. Cell viability and global methylation were tested to
determine optimal 5-aza-dc concentration for each cell type. Cells were harvested, and DNA
and RNA were isolated.
Cell viability: Cell viability before and after 5-aza-dc treatment was assessed by crystal violet
staining method. Briefly, cells were seeded in each well of a 24-well plate and were allowed to
grow for 24 h or 70 % confluence before treatment. Cells grown in monolayer were treated
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with various doses of 5-aza-dc for 96 h. After treatment, cells were washed with PBS, fixed
with ice-cold methanol and stained with 0.5% crystal violet (prepared in 50% methanol) for 15
mins and then washed with PBS and air-dried for 10 mins. Cells were then destained with
10% acetic acid for 5 mins in the rocker. Absorbance was measured at 595nm using Gen5
Microplate Reader and Imager Software (BioTek Instruments, Inc., VT, USA). For the
evaluation of cell viability, the average absorbance of the control (5-aza-dc untreated) wells
was regarded as 100%, and the percentage of cell growth in each well was calculated (% of
control).
Promoter Methylation Detection: DNA samples were subjected to bisulfite treatment using
an EpiTect ® Plus Bisulfite Kit (Qiagen, CA, USA) following the manufacturer’s protocol. In
this treatment, methylated cytosine remains unaffected whereas unmethylated cytosine
residues are converted to uracil, which gets converted to thymine during PCR amplification.
Methylation-specific PCR (MS-PCR) was performed to identify promoter methylation of
EREG, GRB7, SMG1, RUNX3, and CHFR in HNC cell lines. Ensemble database was used to
find and retrieve promoter sequences of these genes. Nucleotide sequences from ~1 kbp 5'flanking sequence to ~500 bp downstream of the transcription initiation site (TSS) of the gene
was entered into MethPrimer program (http://www.urogene.org/methprimer/) (216). Primers
specific for methylated sequences and unmethylated sequences of the gene were designed
using MethPrimer program (Table 16). To control for the presence of bisulfite-modified DNA,
primers specific to a modified region of the β-actin (ACTB) gene containing no CpG sites were
used (mACTB Forward primer: TGGTGATGGAGGAGGTTTAGTAAGT and Reverse primer:
AACCAATAAAACCTACTCCTCCCTTAA). The amplified products were resolved on 3%
agarose gel and visualized under Bio-Rad ChemiDoc™ imaging system using ChemiDoc™
XRS software. Results of promoter methylation of SMG1, RUNX3 and CHFR are included in
an appendix so as not to distract from the focus of the study.
Statistical analysis: Data was analyzed by Students t-test or Analysis of Variance (ANOVA).
One-way ANOVA or Student’s t-test was employed to test the effect of treatment on
expression of each gene on each cell line individually. Two-way ANOVA was done to test the
effect of treatment across the two cell types for each gene (i.e. the interaction between
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“Treatment” and “Cell type”). Bonferroni p-value correction was designed to test the
interaction effect across seven genes and to correct the Type 1 error rate (i.e. false positive
result) for multiple comparisons. The analysis was performed using SigmaPlot Version 12.5
(Systat Software, Inc., San Jose, CA, USA), GraphPad Prism Version 7 (GraphPad Software,
Inc., La Jolla, CA, USA) and Microsoft Excel 2013 (MS Corp, Redmond WA). P values ≤ 0.05
were considered statistically significant (*p<0.05, **p<0.01 and ** p<0.001). Error bars
represented standard deviations of the mean fold change.
Table 14: Endogenous control genes contained on Applied Biosystems (ABI) Human
Endogenous Control Array
Gene symbol with ABI
Gene name

product reference number

Eukaryotic 18S rRNA

18S-Hs99999901_s1

Actin, beta

ACTB-Hs99999903_m1

Beta-2-microglobulin

B2M-Hs99999907_m1

Glyceraldehyde-3-phosphate dehydrogenase

GAPDH-Hs99999905_m1

Glucuronidase, beta

GUSB-Hs99999908_m1

Hydroxymethylbilane synthase

HMBS-Hs00609297_m1

Hypoxanthine phosphoribosyltransferase 1

HPRT1-Hs99999909_m1

Importin 8

IPO8-Hs00183533_m1

Phosphoglycerate kinase 1

PGK1-Hs99999906_m1

Polymerase (RNA) II polypeptide A, 220kDa

POLR2A-Hs00172187_m1

Peptidylprolyl isomerase A (cyclophilin A)

PPIA-Hs99999904_m1

Ribosomal protein, large, P0

RPLP0-Hs99999902_m1

TATA box binding protein

TBP-Hs99999910_m1

Transferrin receptor (p90, CD71)

TFRC-Hs99999911_m1

Ubiquitin C

UBC-Hs00824723_m1

Tyrosine 3-monooxygenase/tryptophan 5monooxygenase activation protein, zeta polypeptide
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YWHAZ-Hs00237047_m1

Table 15: Genes present in the custom TaqMan Array Plate including three endogenous
controls (18S, GAPDH and IPO8)

Table 16: Methylation-specific PCR primers

Genes

Primers for methylated sequence

Primers for unmethylated sequence

Amplicon size (bp);
(Methylated, M;
Unmethylated, U)

EREG

Met-Forward

UnMet-Forward

154 (M) and 153 (U)

GTTTTTTAGTTATTGTCGCGAGTTC

TTTTTAGTTATTGTTGTGAGTTTGT

Met-Reverse

UnMet-Reverse

TTATCTCCTCTTTAAAACGACCG

TTATCTCCTCTTTAAAACAACCAAA

Met-Forward

UnMet-Forward

TTTTTTATTATTTGTAGAGAAGCGG

TTTTTTATTATTTGTAGAGAAGTGG

Met-Reverse

UnMet-Reverse

GRB7

CSF3

AACACAACCTAAAACCCTAATACGA

ACACAACCTAAAACCCTAATACAAC

Met-Forward

UnMet-Forward

GATCGTGATTATTTTGGTTAATACG

ATTGTGATTATTTTGGTTAATATGG

Met-Reverse

UnMet-Reverse

197 (M) and 196 (U)

154 (M) and 153 (U)

CTCACTACAAACTCTACCTCTCGAA CTCACTACAAACTCTACCTCTCAAA
SMG1

Met-Forward

UnMet-Forward

GCGTACGTGAATTTAAGGGTAC

GGTGTATGTGAATTTAAGGGTATGT

Met-Reverse

UnMet-Reverse

177 (M) and 178 (U)

AACAAAAAATCTCCACTACTACGAC AACAAAAAATCTCCACTACTACAAC
RUNX3 Met-Forward

CHFR

UnMet-Forward

ATTTTTTGAAGGGTTGAAAATTTTC

TTTTGAAGGGTTGAAAATTTTTG

Met-Reverse

UnMet-Reverse

CAAAACGATCAATAAAAAAACGTA

CCAAAACAATCAATAAAAAAACATA

Met-Forward

UnMet-Forward

TTTTGTGATAATATATTTTTTTCGT

TTTTTGTGATAATATATTTTTTTTGT

Met-Reverse

UnMet-Reverse

ATAATCTTAATCTCCTAACCTCGTA

ATAATCTTAATCTCCTAACCTCATA
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180 (M) and 178 (U)

165 (M) and 166 (U)

Results

Increased DNMT1a and DNMT3a expression in UMSCC-47 cells
As an initial characterization of epigenetic modifications associated with HPV-positive
HNC cells, DNA methyltransferase activity, and the global DNA methylation were quantified in
UMSCC-47 (HPV-positive) and UMSCC-1 (HPV-negative) cells. Significantly higher
expressions of DNMT1a and DNMT3a were found in HPV-positive UMSCC-47 cells as
compared to HPV-negative UMSCC-1 cells (Figure 27A). This result supports the finding that
shows up-regulation of DNMT1 and DNMT3a induced by HPV16 infection (119). However,
DNMT3b expression was decreased in the UMSCC-47 cell line. As expected, global DNA
methylation in UMSCC-47 cells was significantly higher compared to UMSCC-1 cells (Figure
27B). These results were consistent with a study done by Lechner et al. which showed
increased mRNA expression of both DNMT1 and DNMT3a in HPV-positive HNC cell lines
(213). Consistent results were also found in E6- and E7-transfected HNC cell lines (213).

Gene expression profiling of tumor suppressor genes in HPV-positive and negative
HNC cells
In this study, I selected 38 tumor suppressor genes, which were reported previously
to be altered in either cervical cancer or HNC; although it should be noted that HPV-specific
alteration in the expression of host genes has been poorly characterized and results varied
from one study to another. Some of these genes that were previously shown to be
hypermethylated and/or inactivated in HNCs are -- GRB7, CDH11, SFRP4 (212); CDH8,
CDH13, PCDH10 (213); PAX1 (125); SFRP4 (197); SMG-1 (214); MT1G (198); PHF21B
(199); RUNX3 (200); MGMT, RASSF1A (194); RASSF1 (201,202); CADM1/IGSF4 (203);
DAPK1 (202,215); S100A2 (206); CDH1, EDNRB, RARB, APC, DCC, NDRG2 (193); TUSC3
(207,212); TCF21 (211); GALC (209); EREG (195); FITH (195,210). There were genes that
were previously found to be hypermethylated and inactivated specifically in HPV-positive
HNCs (or were more hypermethylated in HPV-positive HNCs than HPV-negative HNCs); such
as CCNA1 (211,212) RUNX2, SPON2, PREX1, IRS1 (195), TIMP3, CHFR (215); GATA4,
IRX4 (104,208).
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The expression levels of these 38 tumor suppressors were analyzed in a custom
array plate that I designed. No significant changes in the expression of CCNA1, SPON2,
PREX1, IRS1, TIMP3, GATA and IRX4 were found between the HPV-positive (UMSCC-47)
and HPV-negative (UMSCC-1) cell lines. Nevertheless, six genes (GRB7, RUNX3, RUNX2,
CHFR, RARB, and EREG) showed significantly reduced expression in the HPV-positive HNC
cell line compared with the HPV-negative HNC cell line (Figure 28). In addition, one gene,
SMG-1 was marginally reduced in HPV-positive cell line as compared to HPV-negative cell
lines (p=0.08).

Figure 27: Relative expression of DNMT (A) and global methylation (B) in head and neck
cancer cell lines. HPV-positive cell line (UMSCC-47) showed significantly higher DNMT1 and
DNMT3a expressions and greater percentage global methylation than HPV-negative cell line
(UMSCC-1). (Significance level at *p<0.05, **p<0.01 and NS non-significant)
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Figure 28: Gene expression profile of six tumor suppressor genes that showed reduced
expression in HPV-positive cell line (UMSCC-47) as compared to that of HPV-negative cell
line (UMSCC-1). (Significance level at *p<0.05, **p<0.01, **p<0.001 and NS non-significant)

Determination of optimal de-methylation condition using 5-aza-dc treatment
Seven tumor suppressor genes showing decreased expression in HPV-positive HNC
cell line were selected to test whether their decreased expression corresponds with promoter
methylation using the de-methylation agent (5-aza-dc). Initially, I determined optimal
conditions for de-methylation using 5-aza-dc by testing cell viability and global methylation.
When cells are treated with 5-aza-dc (a nucleoside analog of cytidine), it gets incorporated
into DNA during replication forming azacytosine-guanine dinucleotide. DNA methyltransferase
(DNMT) recognizes this dinucleotide as a natural substrate for methylation and subsequently
gets covalently bound (i.e. trapped) to DNA, thereby inactivating its enzymatic function (217).
Since 5-aza-dc does not actively de-methylate the DNA, but rather inhibits the methylation of
new DNA during cell division, cells were treated with 5-aza-dc for a relatively long period of
time (4 days with re-treatment every day due to poor stability of the drug). Further, since
different cell lines vary in terms of toxicity to this drug, as well as their response in demethylation, I treated cell lines with different concentrations (0.5–30 μM) of 5-aza-dc. I found
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that treatment with 5 μM 5-aza-dc for 96 hours showed optimal de-methylation potency based
on global methylation (67% and 75% reduction in global methylation in UMSCC-1 and 47
respectively) with ~60 and 70% cell viability (Figure 29 and Figure 30).
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Figure 29: Cell viability of HPV-positive (UMSCC-47) and HPV-negative (UMSCC-1) cell
lines with increasing dosage of 5-aza-dc treatment for 96 hours.

Figure 30: Changes in global methylation (%) in HPV-negative (UMSCC-1) cell line (A) and
HPV-positive (UMSCC-47) cell line (B) after treatment with increasing dosage of 5-aza-dc for
96 hours.
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Changes in expression of candidate tumor suppressor genes in de-methylation
condition after 5-aza-dc treatment
To identify candidate genes whose expression is significantly increased upon demethylation, HNC cell lines were treated with 5 µM 5-aza-dc for 96 hours and expression of
the seven target genes was analyzed. As described in experimental procedures, the effect of
treatment was statistically analyzed for each gene on each cell type individually as well as
across the two cell types (i.e. Bonferroni corrected interaction), Figure 31. Out of 7 genes, 5
were less likely to be regulated specifically in HPV-positive HNCs. For example, SMG1 was
up-regulated upon de-methylation treatment only in HPV-negative UMSCC-1 cell line
(p=0.02), but not in HPV-positive UMSCC-47 cell line (p=0.795). Although the significant
change in expression of CHFR, RUNX3, and RARB was found on 5-aza-dc treatment, these
alterations were observed in both cell lines. The expression of the fifth gene, RUNX2 was
unchanged in both cell lines on 5-aza-dc treatment.
With a goal to identify a gene that is epigenetically regulated specifically in the HPVpositive environment, I found two genes, GRB7 and EREG that showed significant change on
de-methylation as putative targets of HPV-mediated promoter methylation. De-methylation
treatment significantly increased the expression of GRB7 and EREG in HPV-positive
UMSCC-47 cell line (p<0.05 and p<0.001 respectively) with no evidence of an effect in the
HPV-negative UMSCC-1 cell line (p=0.33 and p=0.21 respectively), Figure 31. When the
effect of 5-aza-dc treatment was analyzed across the two cell types (i.e. overall effect), I
found no significant effect on GRB7 and EREG expression across cell types (Bonferroni
corrected interaction p=0.26 and p=1.0, respectively). This result further confirms that 5-azadc treatment has an effect on GRB7 and EREG expression in cell-type specific manner but
not in overall interaction across the cell lines.

88

Figure 31: Changes in expression of tumor suppressor genes on de-methylation treatment (5
µM 5-aza-dc for 96 hours) in HPV-negative (UMSCC-1) and HPV-positive (UMSCC-47) cell
lines. Statistical bars represents the changes on gene expressions on each cell line
individually as well as Bonferroni corrected interaction of treatment across the two cell types
(Significance level at *p<0.05, **p<0.01, **p<0.001 and NS non-significant)

EREG promoter was methylated in the HPV-positive HNC cell line and was
hypomethylated after 5-aza-dc treatment
To further determine whether the silencing of EREG expression was due to promoter
methylation, I examined the methylation status of the EREG promoter region in HPV-positive
UMSCC-1 and HPV-negative UMSCC-47 cell lines using methylation-specific PCR (MSPCR), which covered the CpG island in the promoter region of EREG (Figure 32A). MS-PCR
assay revealed distinct differences in CpG methylation of the EREG promoter between
UMSCC-1 and UMSCC-47 cell lines. A methylated band (lanes indicated by M) was identified
in UMSCC-47 whereas an unmethylated band (lanes indicated by U) was observed in
UMSCC-1 (Figure 32B). To further confirm methylation-mediated transcriptional silencing of
EREG, cell lines were treated with a de-methylation agent (5-aza-dc). After 5 μM 5-aza-dc
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treatment, the unmethylated band (U) was observed in UMSCC-47 cells, while no change
was found in UMSCC-1 cells (Figure 32C). This suggests that the restoration of EREG
mRNA expression following 5-aza-dc treatment in UMSCC-47 was likely caused by demethylation of the hypermethylated CpG sites in the EREG promoter.

Methylation of GRB7 promoter in both HPV-positive and HPV-negative cell lines
Methylation-specific PCR analyses showed the presence of both methylated and
unmethylated GRB7 promoters in both cell lines, indicating partial methylation of GRB7 in
these cell types. Even on de-methylation treatment, there was no change in methylated and
unmethylated bands on the agarose gel (Figure 33B). The promoter of GRB7 contains CpG
sites (Figure 33A) but does not seem to contain CpG island as predicted by MethPrimer
software (Criteria used for CpG island prediction was Island size > 100 and GC% > 50.0).
Therefore, I further checked for the presence of an upstream promoter, which can possibly
affect the expression of GRB7. A study reported that methylation of CSF3 promoter
significantly correlates with GRB7 expression; both GRB7 and CSF3 are on chromosome 17q
and are commonly amplified together (218). Methylation-specific PCR of CSF3 promoter also
revealed similar results as observed from the GRB7 promoter. Both methylated and
unmethylated bands (lanes M and U respectively) of CSF3 promoter were seen in UMSCC-1
and UMSCC-47 cell lines (Figure 33D and 33C). This indicates that epigenetic regulation of
GRB7 may not be specific to the HPV-positive environment. This result reduces enthusiasm
for GRB7 as a candidate gene for epigenetic regulation in HPV-associated HNCs.
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Figure 32: Methylation status of EREG promoter (A) EREG promoter showing CpG island.
The locations where methylated and unmethylated methylation-specific PCR (MS-PCR)
primers anneal are indicated by the rectangular box; MF1-MR1 (methylated- forward and
reverse primers) and UF1-UR1 (unmethylated- forward and reverse primers). TSS indicates
transcription start site. (B) MS-PCR of EREG in bisulfite-modified DNA from HPV-negative
(UMSCC-1) and HPV-positive (UMSCC-47) cell lines. (C) MS-PCR of EREG after 5-aza-dc (5
µM for 96 hours) treatment. MS-PCR of β-actin serves as an internal control for bisulfitemodified DNA. No template DNA serves as negative control.
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Figure 33: Methylation status of GRB7 and CSF3 promoters. A) GRB7 promoter showing
CpG sites and the locations of methylated and unmethylated methylation-specific PCR (MSPCR) primers. MS-PCR of GRB7 (B) and CSF3 (C and D) in bisulfite-modified DNA from
HPV-negative (UMSCC-1) and HPV-positive (UMSCC-47) cell lines with or without 5-aza-dc
(5 µM for 96 hours) treatment. No template DNA serves as negative control. (Note: CSF3
promoter methylation is known to regulate GRB7 expression)

Discussion

Epigenetic changes are considered as important mechanisms in HNC progression,
but how these changes differ between HPV-positive and HPV-negative cancers are less
defined. I conducted a study that helps to identify an epigenetic mechanism that is specific to
HPV-positive HNCs. For this, I screened 38 tumor suppressor genes to identify a putative
candidate regulated by promoter methylation.
From gene expression profile of 38 tumor suppressors in the custom array, I selected
7 genes (GRB7, RUNX3, RUNX2, CHFR, RARB, EREG, and SMG-1) as the targets for
further studies, which showed reduced expressions in HPV-positive cell line than HPVnegative cell line (Figure 28). To determine whether the reduced expression of these genes
is due to promoter methylation, I treated cell lines with a de-methylation agent, 5-aza-2′deoxycytidine (5-aza-dc). It is shown that 5-aza-dc is able to re-express genes that are
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silenced by DNA methylation; although, this reactivation can vary from gene to gene and
different tissue/cell types (217). On 5-aza-dc treatment, I found different expression profiles of
tumor suppressor genes in two HNC cell lines. Out of 7 genes, only EREG and GRB7 genes
expression was significantly increased upon de-methylation treatment specifically in HPVpositive UMSCC-47 cell line. Although GRB7 expression was increased on 5-aza-dc
treatment only in UMSCC-47, without any significant change in expression in UMSCC-1,
GRB7 promoter was found to be methylated in both cell lines. This indicates that epigenetic
regulation of GRB7 may not be specific to the HPV-positive environment. Further analyses
quantifying the methylation status between UMSCC-1 and UMSCC-47 cell lines may help to
better understand the relationship between gene methylation and transcriptional regulation in
specific cell type.
In the case of EREG, I found a high correlation between gene expression and
promoter methylation. Methylated EREG promoter was detected in UMSCC-47 (Figure 32B)
where EREG was down-regulated (Figure 28). When these cells were treated with 5-aza-dc,
EREG expression was restored (Figure 31) and the unmethylated band was seen (Figure
32C). In contrast, higher expression of EREG was found in the UMSCC-1 cell line (Figure
28), which corresponded with its unmethylated promoter (Figure 32B). Also, 5-aza-dc
treatment showed no significant change in EREG expression in the UMSCC-1 cell line.
Consequently, these results suggest that EREG is regulated via promoter methylation
specifically in HPV-positive UMSCC-47 cell line. Subsequently, EREG was identified as a
putative candidate gene for being a driver of the carcinogenic process specific to HPVpositive HNCs. Consistent with my results, a genome-wide methylation study done using two
HPV-negative HNC cell lines (UMSCC-4 and UMSCC-74A) and an HPV-positive HNC cell
line (UMSCC-47) have shown enrichment in EREG gene for hypermethylation and decreased
expression in a UMSCC-47 (195). However, authors did not discuss the functional
characterization of EREG in their study.
EREG gene encodes for Epiregulin protein, which is a member of the epidermal
growth factor (EGF) family of proteins. Epiregulin was originally purified from the conditioned
medium of the mouse fibroblast-derived tumor cell line and identified as a tumor growth
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inhibitor, which induced morphological changes in HeLa cells (219). Epiregulin functions as
one of the ligands for the ErbB family receptors, namely EGF receptor (EGFR or ErbB1) and
ErbB4 (220). Studies suggested that epiregulin has dual biological activity (219,221,222). On
one hand, it stimulates proliferation of fibroblasts, hepatocytes, smooth muscle cells, and
keratinocytes (223-225) and EREG is overexpressed in many human cancers (226-228). On
the other hand, EREG inhibits the growth of several epithelial tumor cells (219,221,229) and
not all cancer cells have high levels of EREG expression (230). While the oncogenic function
of epiregulin is known to involve the activation of PI3K/AKT and MAP kinase cell signaling
pathways (228), little is known regarding the mechanism by which epiregulin functions as a
tumor suppressor in epithelial cancers. It is suggested that epiregulin inhibits the binding of
EGF (a potent mitogenic ligand of EGFR) to EGFR on epithelial tumor cells, which might be
the reason for growth inhibition of these cells (219).
Little is known about the role of EREG in the development of HNCs. A study showed
that epiregulin expression is higher in oral squamous cell carcinoma (OSCC) specimens than
in normal gingiva and oral dysplasia (231), thereby indicating that epiregulin expression may
be associated with cancer progression. Although authors did not determine HPV status of
these OSCC specimens, I would expect mostly HPV-negative because my study and others
(58,137) have shown that HPV prevalence is extremely low in OSCC. Another study done in
two HPV-negative HNC cell lines showed that increased transcription of epiregulin was
associated with the metastatic phenotype (232). Based on these findings, there is a high
possibility that increased EREG expression is related to HPV-negative HNCs, but not to HPVpositive cancers. My study and Sartor et. al (195) showed the promoter methylation and
transcriptional inactivation of EREG in HPV-positive HNC cell line, but not in HPV-negative
HNC cell lines. This opens up a possibility that EREG may act as a tumor suppressor in HPVpositive HNC and as an oncogene in HPV-negative HNC. Further studies on HPV-positive
and HPV-negative HNC cell lines and tissue specimens are required to confirm this
hypothesis. Additionally, further studies have to be conducted to elucidate the role of EREG in
HNC development.
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Studying the role of EREG in head and neck carcinogenesis would be beneficial for
the better application of treatment based on HPV status of a patient. Since HPV-positive HNC
patients have better therapy response than HPV-negative HNC patients, clinical trials are
undergoing to de-intensify the current treatment standards to reduce associated toxicities
(173,233). So, de-intensification of chemotherapy has been implemented by replacing with
cetuximab, a monoclonal antibody that inhibits EGFR. This is because EGFR is frequently
overexpressed in HNCs independent of HPV etiology (180,181). Interestingly, some studies
showed that the effect of cetuximab can be enhanced in cells with high levels of EGFR
ligands such as EREG (221,230). In colorectal cancer, patients with high EREG expression
benefit more from cetuximab therapy compared with low EREG expression (234). A study
done in HNC cell lines also showed that expression of epiregulin (along with other EGFR
ligands) is correlated with responsiveness to cetuximab (235). Because my study and Sartor
et. al (195) showed that HPV presence in HNC cell lines causes decreased EREG
expression, there is a possibility that HPV presence may decrease the efficacy of cetuximab
therapy in HPV-positive HNCs. The further in-depth study is required to address this highly
relevant issue and to determine whether 5-aza-dc induction of EREG expression increases
sensitivity to cetuximab in HPV-positive HNCs.
There is a growing interest to use 5-aza-dc (also called decitabine) as a therapeutic
agent for cancers in which epigenetic silencing of critical regulatory genes has occurred
(217,236). Consequently, decitabine has been used in clinical trials for hematological and
solid malignancies (237,238). The U.S. Food and Drug Administration (FDA) has approved
decitabine for the treatment of myelodysplastic syndrome, a pre-leukemic bone marrow
disorder (239). One group has investigated the efficacy of decitabine in combination with
cisplatin in HNCs (240). However, studies are not yet done to explore the possibility of
combinational therapy of a de-methylation agent decitabine and an EGFR-inhibitor cetuximab,
which may be an effective therapeutic strategy for treating HNCs; particularly HPV-positive
ones.
A major limitation of this study is that results were drawn based on two selected
model cell lines representing HPV presence (UMSCC-47) and HPV absence (UMSCC-1) in
HNCs. So, further studies are necessary using more HPV-positive/negative cell lines and
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human HNC specimens to confirm whether EREG epigenetic regulation is specific to HPVpositive HNCs. Moreover, since HPV E7 is known to increase DNMT1 and DNMT3a activity
(119), additional studies should be done by silencing E7 in HPV-positive cells or
overexpressing E7 in HPV-negative cells to determine whether epigenetic inactivation of
EREG is due to HPV E7 oncoprotein (see Appendix). Another limitation of this study is that
the effect in gene expression using 5-aza-dc in combination with histone deacetylases
(HDAC) inhibitor was not determined. Studies have indicated that 5-aza-dc in combination
HDAC inhibitors can produce a synergetic reactivation of some genes (241,242), so future
studies should be aimed using HDAC inhibitor alone or in combination with 5-aza-dc which
would provide a better picture of the genes regulated by promoter methylation in HNCs.
Overall, in this chapter, I attempted to better characterize the methylation differences
between HPV-positive and HPV-negative head and neck cancers. My finding concurs with the
observation of Sartor et. al (195) that promoter hypermethylation may possibly contribute to
down-regulation of EREG gene in the HPV-positive HNCs. This study should be continued to
determine whether epigenetic inactivation of EREG plays a role in HPV-associated head and
neck tumorigenesis.
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CHAPTER VI
CONCLUDING REMARKS

My dissertation identifies the potential biomarkers and genetic and epigenetic
mechanisms associated with HPV in head and neck tumors, as illustrated in Figure 35.

HPV-positive HNCs are characterized as a distinct entity from HNCs that are linked to
tobacco and alcohol use, and lack HPV-related etiology. Of note, HPV-positive HNC patients
are found to have more favorable treatment response and better survival than patients whose
tumors are HPV-negative. As HPV detection has huge diagnostic and prognostic significance,
there should be a suitable biomarker which precisely diagnoses HPV infection and a
personalized treatment regimen based on HPV status. For these reasons, the knowledge of
genetic and epigenetic profiles in HPV-positive HNCs is very important. This will help to
distinguish the underlying molecular basis between HPV-associated and –unassociated
carcinogenesis that may lead to the development of novel therapeutic strategies.
As the progression of HPV infection in premalignant lesions to HNCs is unknown, indepth clinical, histologic and molecular characterization of HPV-associated head and neck
tumors is needed. In chapter II, pathologically distinct tumors of the head and neck (benign,
premalignant and malignant) were characterized both histologically and molecularly. I found
that benign head and neck tumors i.e. multiple epithelial hyperplasias (MEH) are caused by
low-risk HPV types (126), whereas premalignant and malignant head and neck tumors are
caused by high-risk HPV types, predominantly HPV type 16 (127). Other benign lesions
called oral squamous papillomas were mostly HPV negative. Additionally, I found that
“mitosoid cells”, which were previously thought to represent an HPV-associated cytopathic
effect in benign MEH, can also be found in HPV-positive premalignant head and neck tumors
(127). My results strongly support that “mitosoid cells” in head and neck tumors are histologic
biomarkers for HPV infection.
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The identification of serum biomarkers of HPV infection is equally important, which
could lead to the development of early and non-invasive methods of HPV detection. In
chapter III, I assessed serum HPV E7 antibody titer as a potential serological biomarker. I
have shown for the first time that the combination of HPV E7 seropositivity and p16

INK4a

expression is a strong diagnostic biomarker for HPV-associated head and neck malignancy
(145). HPV E7 serology may be particularly useful in cases when a tissue specimen is not
INK4a

sufficient for histological tests (e.g. immunostaining of p16

or detecting mitosoid cells).

Further, serial monitoring of decline in HPV serology may be useful in predicting a patient’s
response to treatment.
In chapter IV, I extrapolated knowledge of HPV-induced oncogenicity in cervical
cancer to understand molecular determinants of HPV-associated HNCs. I analyzed whether
HPV DNA - integration and -methylation might play important roles in HPV-linked head and
neck carcinogenesis as seen in HPV-associated cervical cancers. I found that integration of
HPV DNA into the host genome appears to be essential for neoplastic transformation of
premalignant lesions; however, HPV DNA methylation might not play a role in the process of
HPV-induced head and neck carcinogenesis. I also suggest that Group 1 premalignant
lesions which contain diffuse mitosoid cells might have higher malignant transforming
potential, though further long-term follow-up studies are required to appropriately address any
trends towards malignant transformation.
Study of HPV epigenetics indicated that viral DNA methylation might not be involved
in head and neck carcinogenesis (Chapter IV). Therefore, in chapter V, I studied epigenetic
changes (i.e. promoter methylation and transcriptional inactivation) of host genes specific to
HPV- associated head and neck malignancy. For this, 38 tumor suppressor genes were
selected based on literature and screened to identify a putative candidate. I found that HPVpositive HNC cell lines showed promoter hypermethylation and transcriptional inactivation of a
candidate tumor suppressor gene EREG. It suggests that epigenetic regulation of EREG may
be specific to HPV-positive HNCs and may play a role in the development of HPV-associated
HNCs. This result needs to be put in a broader context using human cancer specimens and
understanding the role of EREG in head and neck carcinogenesis. The EREG gene encodes
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a ligand of the epidermal growth factor receptor (EGFR). Further studies on EREG gene
could provide insights into possible treatment strategies using EGFR inhibitors (i.e.
cetuximab, the Food and Drug Administration (FDA)-approved drug for HNC patients). Future
studies are also needed to explore the possibility of using combinational therapy of two FDAapproved drugs - cetuximab and decitabine (5-aza-dc) for treating HNCs, particularly HPVpositive cancers.
Overall, in this dissertation, I found variation in HPV presence among pathologically
distinct head and neck tumors. I also identified potential biomarkers of underlying HPV
etiology in head and neck malignancy. This study also provides better insights into the
putative genetic and epigenetic mechanisms by which HPV triggers head and neck
carcinogenesis, though further studies are required to explore this highly relevant issue.
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Figure 34: A schematic representation of a summary of the dissertation.
Different types of head and neck tumors were associated with the distinct type of HPV.
Benign tumors, particularly multiple epithelial hyperplasias (MEH) were caused by low-risk
HPV types. Pre-malignant (mainly Group1 lesions) and malignant (particularly oropharyngeal
cancers, OPC) were caused by high-risk HPV types. Potential serum and tissue biomarkers
for underlying HPV etiology were identified (shown in quotation marks). Mitosoid cells
represented not only an HPV-associated cytopathic effect in benign MEH but also a subset of
premalignant tumors. p16

INK4a

may serve as a surrogate marker only in Group 1 lesions

compared to other premalignant lesions. E7 serology complements p16 expression as a
strong biomarker for HPV-associated malignancy. Integration of HPV DNA and epigenetic
inactivation of host gene EREG may play a role in HPV-associated malignancy. But, viral
DNA methylation may not be required for transformation of premalignant lesions to malignant.
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APPENDICES
Introduction
During the course of my dissertation work, some supporting experiments were not
completed and some of the studies did not produce significant results. Therefore, I had to
change research aims and/or experimental focus. These results are not included in
dissertation chapters and therefore are shown in the appendix.

I.

Determine the presence of Fanconi anemia genes mutation(s) in HPV-positive
head and neck cancer specimens

Introduction
My original thesis proposal was to study whether a defect in Fanconi Anemia (FA) DNA repair system is associated with HPV-induced HNCs and whether this defect is linked
with improved prognosis in HPV-positive HNCs. This was based on the studies which have
shown a defect in FA-DNA repair pathway is implicated in hypersensitivity to DNA crosslinking agents (243) and HPV-induced HNC exhibit improved sensitivity to chemo/radio
therapies (244). While there is evidence for a DNA repair defect in HNCs, it is not well
documented whether this is specific to the HPV-positive environment. Sixteen proteins
encoded from 16 Fanconi anemia (FANC) genes are involved in a DNA-repair pathway
known as the Fanconi Anemia-DNA repair pathway (245) (Figure S1). Based on these
findings, I hypothesized that HPV-positive HNCs contain mutations in Fanconi genes that are
not present in HPV-negative HNCs and this defect in Fanconi anemia-DNA repair pathway is
implicated in improved prognosis in HPV-positive HNCs.
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Figure S1: Fanconi anemia (FA)-DNA repair pathway showing into three groups of FA
proteins: 1) Core complex proteins (FANCA, B, C, E, F, G, L and M); which in response to
DNA damage is required for mono-ubiquitination of 2) ID complex (FANCI and FANCD2);
and 3) DNA repair foci proteins [FANCD1/BRCA2, FANCJ/BRIP1, FANCN/PALB2, FANCO/
RAD51C, FANCP/SLX4 and FANCQ/XPF4/ERCC4] participate directly in DNA interstrand
crosslink repair. Accessory proteins such as MHF1/2 and FAAP24 (not shown here) help
FANCM to recruit core complex to the sites of DNA damage. The monoubiquitinated FANCD2
is the center of the pathway and a measure of functional FA pathway. BRCA1 is currently not
considered to be a true FA protein though it is an essential part of the FA-DNA repair
pathway.
Experimental Procedures
I had a plan to test all coding exons of 16 FANC genes (total 303 exons) by PCR-based
amplification using primers spanning intron-exon junctions. I had started with the amplification
and sequencing of 9 exons of FANCO/RAD51C; 14 exons of FANCL; 23 exons of FANCM;
14 exons of FANCG and 43 exons of FANCD2. Primers, PCR conditions and the target PCR
product for each exon of FANC genes were tested first by using HeLa cell DNA. By optimizing
PCR conditions, I amplified the respective exons in the HNC samples. Then, target PCR
products were excised from an agarose gel, purified, and sequenced.
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When a gene is known to produce multiple transcripts, the primers for shared exons and
primers unique for the spliced exon were designed. Multiple primer pairs were employed if the
coding exons were larger than 450bp. Primers were designed using Primer 3 software or IDT
PrimerQuest tool to cover at least 15bp at each 5’and 3’ sides of the exons. I ordered primers
(either forward or reverse) tagged with M13 primer (5’-GTAAAACGACGGCCAGT-3’) so that
all amplified products can be sequenced using a single M13 primer.
Data analysis
Sequencing data was analyzed for variant detection using Mutation Surveyor software
(SoftGenetics LLC., PA, USA). All sequences were compared to the related NCBI reference
sequences. The chromatograms of all the computationally determined variants were checked
manually for confirming the existence of those variants. SeqMan Pro program (Lasergene 12,
DNAstar Inc., Wisconsin) was used to align and compare the sequences from all the samples
analyzed. The identified variants were searched in NCBI dbSNP for Human to find their
related rs#, and those, which was not found, was considered as novel variants. Human
Splicing Finder website (http://www.umd.be/HSF/) was used to determine whether the
detected intronic and exonic mutations lead to splicing defects.
All insertion and deletions in the gene coding region, nonsense variants, and variants
located at the splice site consensus sequences were considered as potentially deleterious.
Missense variants first were searched in UniProt Database for determining their functional
effects. If their functional effect was not known, bioinformatics tools were utilized to predict
their effect. For predicting the functional effect of the missense variants, PolyPhen and SIFT
tools were used. Missense variants predicted to be deleterious by Polyphen or SIFT
algorithms and having a minimum allele frequency (MAF) >0.5% was considered as
potentially deleterious variants. The MAF > 0.5% was used to exclude singleton mutations
(private mutations seen in a single individual) which do not provide enough power for
analysis. The predicted potentially deleterious variants were planned to genotype in more
cases and controls.
Following mutational analysis, each putative mutation was independently re-amplified in
tumor DNA (to eliminate artifacts). I compared the sequencing results of each patient’s tumor
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to their matched tissue samples in order to eliminate background germline variations and to
focus on somatic alterations unique to the tumor genome. The comparison was done with
HPV-negative samples to establish a link between FANC mutation and HPV infection.

Results and Discussion
I analyzed two HPV-positive HNC samples with their matched normal tissues, and two
HPV− samples (altogether 6 samples). In 6 samples, I had sequenced 9 exons of
FANCO/RAD51C; 14 exons of FANCL; 23 exons of FANCM; 14 exons of FANCG and 43
exons of FANCD2. I was unable to get useful sequencing results from FANCD2 Exons 18, 19,
20, 22 and 26 amplified products. Although the primers were designed to target exons, some
intergenic and intron regions adjacent to exons were also amplified and sequenced. Variants
unique to HPV-positive HNC cases are shown in Table S1 and Table S2.
The majority of mutations that were observed were heterozygous synonymous. Mutations
that were heterozygous non-synonymous were mostly present in both tumor and normal
matched tissues, showing germline variations instead of somatic alterations unique to the
tumor genome. These mutations include FANCD2 c.2219C>CT (or p.P714PL); RAD51C
c.439C>CA (or p.Q133QK); FANCM ----c.437A>AC (or p.T118TP) c.5268C>CG (or
p.A1728AG) and c.5273C>CG (or p.Q1730QE); FANCG --- c.816G>GC (or p.E108ED),
c.923G>GC (or p.G144GA) and c.2197G>GC (or p.A569AP).
Heterozygous non-synonymous mutation of FANCG c.819G>GC (or p.Q109QH) and
heterozygous deletion of FANCM c.2379het_delT were found in HPV+ tumors but not in
matched normal. However, these mutations were not observed in additional HPV-positive
cases and FANCG c.819G>GC was also present in additional HPV-negative cases;
suggesting these alterations were not exclusively specific for the HPV-positive environment.
Most of the intronic variants were heterozygous and were also present in matched
normal. Heterozygous deletion of RAD51C c.947-74het_delG was found in one HPV-positive
tumor but there wasn’t predicted potential splice site, making this mutation non-significant.
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Table S1: Exonic variants identified in 5 FANC genes in DNA of only HPV-positive HNC
cases
No. Gene

Exon

Nucleotide
Change*

Amino Acid
Change

Mutation type

Total Samples

1

FANCD2

14

c.1200A>AG

p.V374VV

Heterozygous
synonymous

2 (tumor+ matched
normal)

2

FANCD2

17

c.1587C>CT

p.N503NN

Heterozygous
synonymous

2 (tumor+ matched
normal)

3

FANCD2

23

c.2219C>CT

p.P714PL

4

FANCD2

42

c.4176T>TG

p.L1366LL

Heterozygous nonsynonymous
Heterozygous
synonymous

2 (tumor+ matched
normal)
2 (tumor+ matched
normal)

5

RAD51C

2

c.439C>CA

p.Q133QK

6

FANCL

6

37214T>TG

p.G145GG

7

FANCM

1

c.437A>AC,

p.T118TP

8

FANCM

1

c.484T>TC

p.P133PP

Heterozygous nonsynonymous
Heterozygous
synonymous
Heterozygous nonsynonymous
Heterozygous
synonymous

9

FANCM

13

c.2379het_delT

2 (tumor+ matched
normal)
4 (tumors+ matched
normal)
4 (tumors+ matched
normal)
2 (tumor+ matched
normal)
1 (tumor)

10 FANCM

20

c.5268C>CG

p.A1728AG

11 FANCM

20

c.5273C>CG

p.Q1730QE

12 FANCM

21

c.5470T>TG

p.C1795CW

13 FANCM

21

c.5550T>TG

p.V1822VG

14 FANCM

21

c.5554T>TG

p.G1823GG

15 FANCM

23

c.6749A>AC

Heterozygous

16 FANCM

23

c.6880A>AC

Heterozygous

17 FANCM

23

c.6883T>TC

Heterozygous

Heterozygous deletion
Heterozygous nonsynonymous
Heterozygous nonsynonymous
Heterozygous nonsynonymous
Heterozygous nonsynonymous
Heterozygous
synonymous

4 (tumors+ matched
normal)
4 (tumors+ matched
normal)
2 (tumor+ matched
normal)
4 (tumors+ matched
normal)
3 (2 tumor+ 1 matched
normal)
3 (2 tumors+ 1 matched
normal)
4 (tumors+ matched
normal)
3 (2 tumors+ 1 matched
normal)
2 (tumor+ matched
normal)

Heterozygous nonsynonymous
Heterozygous non19 FANCG
4
c.819G>GC
p.Q109QH
2 tumors
synonymous
Heterozygous non2 (tumor+ matched
20 FANCG
4
c.923G>GC
p.G144GA
synonymous
normal)
Heterozygous
2 (tumor+ matched
21 FANCG
4
c.927G>GC
p.L145LL
synonymous
normal)
Heterozygous non2 (tumor+ matched
22 FANCG
13
c.2197G>GC
p.A569AP
synonymous
normal)
*A mutation in the mRNA region is prefixed with a “c” and a mutation in the protein sequence is prefixed
with a “p”.
18 FANCG

4

c.816G>GC

p.E108ED
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Table S2: Intronic variants identified in 5 FANC genes in only HPV-positive HNC cases
No. Gene

1

Intron
adjacent
to exon
FANCD2
5

Nucleotide
Change*

2

FANCD2

7

c.517-16A>AG

3

FANCD2

13

c.1068-38C>CG

4

FANCD2

16

c.1357-76A>G

5

FANCD2

17

1492-149A>AG

c.455+155T>TG

Mutation
type

Total Samples

Heterozygous 2 (tumor+ matched
normal)
Heterozygous 2 (tumor+ matched
normal)
Heterozygous 2 (tumor+ matched
normal)
Homozygous
1 (tumor)

Prediction using
Human Splicing
Finder
Potential donor splice
site
None
Potential acceptor
splice site
Potential donor splice
site
None

Heterozygous 2 (tumor+ matched
normal)
6. FANCD2
30
c.2938-4A>AC Heterozygous
3 (2 tumors+1
Potential acceptor
matched normal)
splice site
7. FANCD2
42
c.4263+33T>TC Heterozygous 2 (tumor+ matched
None
normal)
8 RAD51C
1
c.17C>CT
Heterozygous 2 (tumor+ matched
None
normal)
9 RAD51C
7
c.947-74het_delG Heterozygous
1 (tumor)
deletion
10 FANCL
6
c.537+27T>TG Heterozygous 2 (tumor+ matched
Potential acceptor
normal)
splice site
11 FANCL
6
c.537+97A>G
Homozygous 2 (tumor+ matched
None
normal)
12 FANCL
9
c.758-27A>C
Homozygous 2 (tumor+ matched
Potential acceptor
normal)
splice site
13 FANCM
9
c.1666+194het_delT Heterozygous 2 (tumor+ matched
Potential acceptor
deletion
normal)
splice site
FANCM
14
12
c.2245+97G>GA Heterozygous 4 (tumors+ matched
None
normal)
15 FANCM
21
c.5801+36T>G
Homozygous 4 (tumors+ matched Potential donor splice
normal)
site
16 FANCG
2
c.667+24G>GC Heterozygous 2 (tumor+ matched Potential donor splice
normal)
site
*A mutation in the mRNA region is prefixed with a “c”. A mutation that is called outside of an mRNA
region is assigned as plus or minus the number of bps by which it resides away from the closest
nucleotide of the mRNA

Next gene sequencing data
Next gene sequencing (NGS) using Ion AmpliSeq™ Comprehensive Cancer Gene
Panel (Ion Torrent, Thermo Fisher Scientific) was done in two samples (one HPV negative
HNC sample and one HPV positive HNC sample). This panel contained 7 FANC genes-namely FANCA, FANCC, FANCD2, FANCF, FANCG, BRIP1, and ERCC4.
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Table S3 shows SNPs (Single nucleotide polymorphisms) which were identified in the
HPV-positive sample. FANCD2 c.1179T>C and ERCC4 intronic mutations were found in both
HPV-positive and HPV-negative samples.
Interestingly, FANCD2 (c.1214A>G missense mutation) was seen only in an HPVpositive HNC sample, not in an HPV-negative sample. Sanger sequencing was conducted for
further verification. But, this mutation in that particular location was not observed in the same
sample. So, FANCD2 (c.1214A>G missense mutation) obtained from NGS seems to be a
false positive SNP. This is probably because Next Gene sequencer has problems in the
regions of repeated bases in the sequence. Indeed, the location of c.1214A>G mutation was
found in the region where there were repeats of A (the sequence was: aagaaataag).
Table S3: SNPs identified from an HPV-positive sample
†

Gene

Mutation* Classification

FANCD2 c.1214A>G

Suspected
Deleterious

Genotype Type Location

Coding

Amino acid

Variant

Change

effect

A/G

SNV

exonic

c.1214A>G p.Asn405Ser missense

FANCD2 c.1179T>C

Unknown

T/C

SNV

exonic

c.1179T>C

WT

synonymous

FANCD2 c.1170C>T

Unknown

C/T

SNV

exonic

c.1170C>T

WT

synonymous

ERCC4

Unknown

A/A

SNV

intronic

*A mutation in the mRNA region is prefixed with a “c”.
†
single nucleotide variants (SNVs)

Overall results obtained from mutational analysis of Fanconi-anemia-DNA repair genes
suggest that mutations in FANC genes may not be specific to HPV-positive head and neck
cancers, though further studies on larger number of specimens are required.
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II.

E7 knockdown or overexpression to determine whether viral oncoprotein E7
mediates promoter methylation and transcriptional inactivation of a candidate
gene EREG

Introduction:
The work presented in chapter V suggested a hypothesis that promoter methylation
and inactivation of EREG is mediated by HPV presence in head and neck cancers. Since
HPV16 E7 oncoprotein has been shown to upregulate DNMT1 and DNMT3a (119); I
rephrased the above hypothesis as − E7 oncoprotein causes promoter methylation of EREG.
To test this hypothesis, I attempted to perform lentiviral knockdown of E7 in HPV-positive
UMSCC-47 cell line and lentiviral-based overexpression of E7 in HPV-negative UMSCC-1 cell
line.
Experimental Procedures
Cloning and production of lentiviral plasmids for overexpression of E7: The E7 coding
region containing EcoRI and XhoI restriction sites was obtained from PCR-amplification of
HPV16 purified plasmid (i.e. a plasmid containing full genome of HPV16 cloned in the
pBR322 vector). Amplification was done using primers against the full length of E7 (forward
primer with EcoRI site: aaagGAATTCatgcatggagatacacctac and a reverse primer with XhoI
site: aaaaCTCGAGttatggtttctgagaacagatg). Amplified product was gel purified, digested with
EcoRI and XhoI and then ligated with a pLUTdNB lentiviral vector which was also digested
with the same restriction enzymes. This pLUTdNB vector is pTRIPZ base modified
doxycycline-inducible expression vector. pLUTdNB plasmid ligated with E7 cDNA was then
transformed into XL10-Gold Ultracompetent cells (Agilent Technologies, CA, USA) using βmercaptoethanol to increase transformation efficiency, according to the manufacture’s
protocol. After transformation, the plasmid was isolated and then sequenced to confirm the
cloning of full-length of HPV16 E7 cDNA into a pLUTdNB lentiviral expression vector.

Production of E7 overexpressing lentiviral particles: Lentivirus packaging protocol was
followed as described by Applied Biological Materials Inc. (Richmond Canada) with some
modifications. HEK 293T cells were co-transfected with the lentiviral constructs pVSV-G
(envelope vector) and psPAX2 (packaging vector) (Addgene) along with a pLUTdNB plasmid
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expressing full length of E7 (expression vector). Empty vector was used as a control and
transfected into HEK 293T cells. Transfections were carried out using TurboFect Transfection
Reagents in Opti-MEM® Reduced-Serum Medium (Thermo Fisher Scientific). Later, the
culture medium was centrifuged at 3,000 rpm for 15 mins at 4°C. The filtered supernatant was
used for lentiviral infection.
HPV16 E7 shRNA lentiviral particles: HPV 16 E7 shRNA lentiviral particles and control
shRNA lentiviral particles were purchased from Santa Cruz Biotechnology, Inc, USA. HPV 16
E7 shRNA lentiviral particles contain a pool of concentrated, transduction-ready viral particles
containing 2 target- specific constructs that encode 19-25 nucleotide shRNA designed to
knock down gene expression. Control shRNA Lentiviral Particles encodes for a scrambled
shRNA sequence suitable as a negative control for shRNA lentiviral transduction experiment.
Lentiviral particles transduction: A protocol for lentivirus particles transduction was
followed as described by Santa Cruz Biotechnology, Inc. Before lentiviral transduction, the
working concentration of puromycin was determined for the selection of transduced UMSCC1 (HPV-negative) or UMSCC-47 (HPV-positive) cell lines. For this, in a separate experiment,
UMSCC-1, and UMSCC-47 cells were treated with varying concentrations of puromycin
dihydrochloride (Santa Cruz Biotechnology, Inc) from 1 µg/ml to10 µg/ml. Then, an optimal
concentration of puromycin (2 µg/ml) was selected as the lowest concentration that kills 100%
of non-transfected cells in 2-3 days.
For lentiviral infection, cells were seeded in a 12-well plate 24 hours prior to viral
infection. Next day, media was replaced with Polybrene (Santa Cruz Biotechnology, Inc)
containing media to enhance binding of pseudo-viral capsid to the cell membrane. Then, cells
were infected with lentiviral particles (E7 over-expressing particles in UMSCC-1; and E7
shRNA lentiviral particles in UMSCC-104 cell lines). After cells underwent lentiviral
transduction, stably transfected clones were selected using 2 μg/ml puromycin. After antibiotic
selection, cells were expanded for stable E7 cDNA or E7 shRNA expression in UMSCC-1 and
UMSCC-47 respectively. Cells stably expressing control shRNA or control empty vector was
also isolated via puromycin selection.
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E7 mRNA expression: Total RNA was isolated and cDNA was synthesized following the
same protocol as described in chapter IV using primers against E7 by SYBR Green assay.
Western Blot Analysis: Cells were lysed and total protein was extracted using RIPA buffer
(Cell Signaling Technology) and protease inhibitors as per the protocol. Total protein
concentration was determined using the Bio-Rad Bradford protein assay reagent (Bio-Rad
Laboratories, USA) with bovine serum albumin (BSA; Pierce, USA) as a standard. Extracted
protein samples were mixed with sodium dodecyl sulfate (SDS) loading buffer (20% glycerol,
4% SDS, 100 mM Tris, pH 6.8, 0.002% bromophenol blue), and heated at 95°C for 5 min.
These proteins were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) gels
(NUPAGE 10% Bis-TRIS, Invitrogen, USA) and transferred to polyvinylidene difluoride
(PVDF) membrane (Immobilon-P transfer membrane, EMD Millipore, USA), which were
blocked with 5% nonfat dry milk in Tris-buffered saline containing 0.05% Tween 20 (TBST) for
1 h at room temperature. The membrane was then incubated with mouse monoclonal anti-E7
antibody (Abcam / Santa Cruz Biotechnology, USA) or rabbit polyclonal anti-β-actin (Genetex)
antibodies overnight at 4 °C. After washing with TBST for 3 times, membranes were
incubated with 1:5000 diluted secondary antibodies [horseradish peroxidase (HRP)conjugated goat anti-mouse IgG or HRP-conjugated mouse anti-rabbit IgG (Thermo Scientific
Pierce, USA)] for 1 h at room temperature. Proteins were detected by chemiluminescence
(SuperSignal West Dura Extended Duration Substrate; Thermo Scientific Pierce, USA) and
bands were visualized on X-ray film (CLXPosure Film, Thermo Scientific Pierce, USA) using
an SRX-101A processor (Konica Minolta Medical Imaging USA, Inc).

Results and Discussion
Cloning of E7 into lentiviral expression vector
HPV16 E7 cDNA was amplified and cloned into a pLUTdNB lentiviral expression
vector (Figure S2). After cloning, isolated plasmid was digested using EcoRI and XhoI, which
gave ~300bp product in an agarose gel, which corresponded to the full length of HPV16 E7
(Figure S2-D). For verification, the sequence of cloned vector was compared with other
sequence variants of HPV16 (such as AF402678.1, AF125673.1, AY686584.1, NC_001526.2,
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and KF954093.1) using SeqMan Pro program (Lasergene 12, DNAstar Inc., Wisconsin) and
NCBI BLASTN database. The obtained full-length nucleotide sequence was then translated
into an amino acid sequence using EditSeq (DNASTAR) software and compared with other
sequences using NCBI BLASTP database. 100% sequence identity was obtained between
the cloned sequence with protein sequences of HPV16 E7 (accession no. AAO85409.1),
suggesting the successful cloning of HPV16 E7 cDNA into lentiviral expression vector
pLUTdNB.

Figure S2: Cloning of E7 into a pLUTdNB lentiviral expression vector. A) Gel image showing
EcoRI and XhoI digested E7 DNA, which was initially PCR-amplified from HPV16 plasmid.
This DNA band was purified from the gel and used to ligate with digested pLUTdNB. B) Gel
image showing EcoRI and XhoI digested pLUTdNB vector, which was purified from the gel.
Restriction digested E7 and pLUTdNB DNAs were ligated and cloned into E. coli. C) Gel
image showing cloned E7-pLUTdNB plasmid DNAs (Lanes #1 and #3) isolated from
transformed E. coli. (Lane #2 showed the absence of cloned plasmid) D) Cloned plasmids
were digested with EcoRI and XhoI that produced the fragments of ~300 bp (shown by the
arrow), which corresponded to the full-length of E7.

Lentiviral knockdown of E7 in HPV-positive HNC cell line
After lentiviral transduction, puromycin selection was done to obtain UMSCC-47 cells
stably expressing E7 shRNA. Puromycin-resistant cells were obtained, indicating successful
lentiviral transduction. However, as shown in Figure S3, knockdown of E7 did not
significantly reduce E7 mRNA in UMSCC-47 cells as compared to cells stably expressing
scrambled control shRNA. To confirm above results, E7 protein levels was tested by
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immunoblotting, but could not be detected. Even a positive control (i.e. purified E7 protein)
was not detectable in the immunoblot. This may be due to the low quality of commercial E7
antibodies. However, the immunoblot was positive for house-keeping protein (β- actin). So,
further experiments have to be done to obtain effective knockdown of E7 in HPV-positive
UMSCC-47 cell line.

Figure S3: E7 expression in UMSCC-47 cells after the lentiviral shRNA-mediated
knockdown, showing unsuccessful knockdown of E7 compared to scrambled control shRNA.

Lentiviral transduction of E7 cDNA in HPV-negative HNC cell line
E7 overexpressing lentiviral particles were produced and then transduced in HPVnegative UMSCC-1 cell line. However, transduced cells started dying after treatment with 2
μg/ml puromycin (similar to non-transduced cells), indicating unsuccessful lentiviral
transduction. This may be due to the poor quality of lentiviral particles or due to other
reasons. So, experiments should be repeated troubleshooting the relevant issues.
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III.

Epigenetic changes in host tumor suppressor genes SMG1, RUNX3, and CHFR in
HNCs
In chapter V, I selected 7 genes (GRB7, RUNX3, RUNX2, CHFR, RARB, EREG, and

SMG-1) from 38 tumor suppressors as the targets for further studies and then focused on the
promoter methylation status of GRB7 and EREG, since they were the potential candidate
genes regulated in HPV-positive HNC cell lines. I have not included the promoter methylation
status of other genes as not to distract from the focus of the project, therefore have discussed
in this part of the appendix.

Correlation of DNA methylation status of SMG1, RUNX3 and CHFR promoters with their
expression
The methylation status of promoters of SMG1, RUNX3 and CHFR and the effect of
de-methylation treatment were analyzed using MS-PCR method. Both HPV-positive
(UMSCC-47) and HPV-negative (UMSCC-1) HNC cell lines contained methylated as well as a
unmethylated SMG1 promoter (Figure S4 A-B). RUNX3 and CHFR methylation status was
detected in both cell lines (Figure S4C-F). Even on de-methylation treatment, there was no
change in bands of all three genes- SMG1, RUNX3, and CHFR (Figure S4). These results
suggest that epigenetic regulations of SMG1, RUNX3 and CHFR may not be specific to HPVpositive HNCs.
Expressions of SMG1, RUNX3, and CHFR genes were higher in UMSCC-1 than
UMSCC-47 (Figure 28), but promoter methylation status was found similar in both cell types
(Figure S4). This result indicated that in the case of these 3 genes, the correlation between
increased promoter methylation and decreased expression tended to be low. There was also
no change in methylation status of the promoter of these genes even after de-methylation
treatment (Figure S4), although 5-aza-dc caused increased SMG1 expression in UMSCC-1,
and increased expression of RUNX3 and CHFR in both cell types (Figure 31).These results
additionally indicate that methylation-mediated gene silencing of SMG1, RUNX3, and CHFR
may not be cell-type specific.
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Figure S4: Methylation status of SMG1, RUNX3, and CHFR promoters. Promoter regions of
SMG1 (A), RUNX3 (C) and CHFR (E), showing CpG island and the locations of methylationspecific PCR (MS-PCR) primers. Agarose gel images showing MS-PCR of SMG1 (B),
RUNX3 (D) and CHFR (F) in bisulfite-modified DNA from HPV-negative (UMSCC-1) and
HPV-positive (UMSCC-47) cell lines with or without 5-aza-dc (5 µM for 96 hours) treatment.
No template DNA serves as negative control.
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LIST OF ABBREVIATIONS AND SYMBOLS
5-aza-dc

5-aza-2′-deoxycytidine

CIN

Cervical intraepithelial neoplasia

CpG

5'- Cytosine-phosphate-Guanine-3'

DNA

Deoxyribonucleic acid

DNMT

DNA methyltransferase

E2BS

E2 binding sites

E2F-TF

E2 factor family of transcription factors

EGFR

Epidermal growth factor receptor

EREG

Epiregulin

FFPE

Formalin-fixed, paraffin-embedded

hgOED

High-grade oral epithelial dysplasia

HN

Head and Neck

HNC

Head and Neck carcinoma/ cancers

HNSCC

Head and Neck squamous cell carcinoma

HPV

Human papillomavirus

H&E

Hematoxylin and eosin staining

IHC

Immunohistochemistry

ISH

in situ hybridization

LCR

Long control region

MEH

Multiple epithelial hyperplasia

MS-PCR

Methylation-specific PCR

OCSCC

Oral Cavity Squamous Cell Carcinoma

OPSCC or OPC

Oropharyngeal Squamous Cell Carcinoma

OPC

Oropharyngeal cancer

ORF

Open Reading Frame

PCR

Polymerase Chain Reaction

PV

Papillomavirus

qRT-PCR

Quantitative Reverse Transcription-PCR

Rb

Retinoblastoma

SCC

Squamous Cell Carcinoma

SNPs

Single nucleotide polymorphisms

TBP

TATA binding protein

TSG(s)

Tumor suppressor gene(s)

URR

Upstream Regulatory Region

132

CURRICULUM VITAE

Sujita Khanal
James Graham Brown Cancer Center
505 S. Hancock Street, CTR Bldg. Rm 242B
Louisville, KY 40202-1617, USA

ORCID ID: 0000-0003-3196-0058
sujita.khanal@louisville.edu
Tel: 502-292-8852

EDUCATION
Ph.D. Biochemistry and Molecular Genetics, University of Louisville, KY, USA

2012-2016

M.S. Biochemistry and Molecular Biology, University of Louisville, KY, USA

2012-2015

M.Sc., Biochemistry (85.26%), Jiwaji University, Gwalior, M.P, India

2009-2011

B.Sc., Biochemistry (cGPA 3.95), Purbanchal University, Nepal

2003-2008

GRANTS / FELLOWSHIP
2015 Commission on Diversity and Racial Equality (CODRE) / Graduate School Diversity
Research Grant,
University of Louisville, KY, USA (Spotlighted in CODRE Spring 2016 Newsletter)July 2015
(http://louisville.edu/codre/codre-publications/newsletters-1/codre-newsletter-spring-2016)
Graduate Student Council (GSC) Travel Fund, University of Louisville, KY, USA
July 2015
th
(To attend 30 International Papillomavirus Conference (HPV 2015) held September 17-21 in
Lisbon, Portugal)
Internal grant for oral and oropharyngeal cancer research
University of Louisville, KY, USA
IPIBS (Integrated Program in Biomedical Sciences) Fellowship
University of Louisville, KY, USA

July 2014- Aug 2016
2012- 2014

PUBLICATIONS
1.

Khanal, S., Cole, E. T., Joh, J., et al. (2015). Human papillomavirus detection in histologic
samples of multifocal epithelial hyperplasia: a novel demographic presentation. Oral Surg Oral
Med Oral Pathol Oral Radiol, 120(6), 733-743.
 Poster abstract published in Sep 2015 http://www.oooojournal.net/article/S22124403(15)00991-8/abstract

2.

Khanal, S., Joh, J., Kwon, A. M., et al. (2015). Human papillomavirus E7 serology and
association with p16 immunohistochemistry in squamous cell carcinoma of the head and neck.
Exp Mol Pathol, 99(2), 335-340.

3.

Khanal, S.*, Ferraris, E. D., Zahin, M., Joh, J., Ghim, S. J., & Jenson, A. B. (2015). Targeting
synthetic Human Papillomavirus (HPV) L2 disulfide-induced N-terminus conformational
epitopes for pan-HPV vaccine development. Exp Mol Pathol, 99(2), 330-334. (*corresponding
author)
 Paper featured in World Biomedical Frontiers http://biomedfrontiers.org/cancer-2016-3-3/

4.

Moore, A. R., Libby, A. L., Khanal, S., Ehrhart, E. J., 3rd, & Avery, P. (2015). Is this cell
hollow? Vet Clin Pathol.

5.

Zahin, M., Ghim, S. J., Khanal, S., Bossart, G. D., Jenson, A. B., & Joh, J. (2015). Molecular
characterization of novel mucosotropic papillomaviruses from a Florida manatee (Trichechus

133

manatus latirostris). J Gen Virol. 96 (12), 3545-3553
6.

Khanal S., Trainor PJ., Zahin M., Ghim SJ., Joh J., Rai SN., Jenson A., Shumway BS.
Histologic variation in high grade oral epithelial dysplasia when associated with high-risk
human papillomavirus. (Oral Surg Oral Med Oral Pathol Oral Radiol, Submitted, under
Revision)

Poster abstract published in Feb 2016 in International Journal of Radiation Oncology •
Biology • Physics, 94(4), 944. http://dx.doi.org/10.1016/j.ijrobp.2015.12.277

7.

Perez CA, Amsbaugh MJ,...Khanal S,…. Redman, R. High-Dose Versus Weekly Cisplatin
Definitive Chemoradiation Therapy for Human Papillomavirus–Related Oropharyngeal
Squamous Cell Carcinoma of the Head and Neck (2016). Poster abstract published in
International Journal of Radiation Oncology • Biology • Physics, 94(4), 895.
http://dx.doi.org/10.1016/j.ijrobp.2015.12.097

8.

Zahin M., Joh J., Khanal S., Husk A., Mason H., Warzecha H., Ghim SJ., Miller D.M., Matoba
N., Jenson A. Scalable Production of HPV16 L1 Protein and VLPs from Tobacco Leaves.
(PLOS ONE Submitted, under Revision)

9.

Vatsalya V, Khanal S., Jenson A., Srivastava S., Schwandt M., Ramchandani V.A. Role of
linoleic acid in the exacerbation of liver injury in treatment naïve HIV-diagnosed alcohol
dependent patients. (AIDS Research and Human Retroviruses Submitted, under Review)

AWARDS / SCHOLARSHIPS
University Topper Merit Award, Jiwaji University, M.P, India

2011

College Topper Award, Boston College for Professional studies, M.P, India

2011

Half Tuition Waiver, Boston College for Professional studies, India
(Scoring above 80% in every semester, M.Sc. Biochemistry)

2009-2011

Award of Excellence, Boston College for Professional studies, India
(First Position, creating decorative items from waste materials)

2009-2011

University Topper Award, Purbanchal University, Nepal

2007

Full Tuition Waiver, National College for Advance Learning, Nepal
(Highest Rank in every semester, B. Sc. Biochemistry)

2003-2007

Graduation Award, National School of Sciences, Nepal
(Distinction status, Higher Secondary Board Examination)

2002

Tuition Waiver, National School of Sciences, Nepal
(Highest Rank among female students, Higher Secondary Grade 11 & 12)

2000-2002

Aawhan Samuha S.L.C. Award, Aawhan Samuha, Kathmandu, Nepal
(Fourth among S.L.C. students of Kathmandu Metropolitan City, Ward # 7)

2000

Tanka Bdr. Pradhan Memorial Medal, Baba Boarding High School, Nepal
(Silver Medal, Second among the S.L.C. candidates)

2000

Tuition Waiver, Baba Boarding High School, Nepal
(Second position, scoring above 80% in final exams)

1998-2000

Peer Reviewer of Manuscripts
Currently serving as a peer reviewer for Cancer Informatics of Libertas Academica
Poster Presented at National and International Meetings


Multidisciplinary Head and Neck Cancer Symposium, Scottsdale, Arizona



30 International Papillomavirus Conference & Clinical Workshop (HPV 2015), Lisbon,
Portugal
Sep 17-21, 2015

th

134

Feb 18-20, 2016



Joint Annual Meeting of American Academy of Oral and Maxillofacial Pathology/American
Academy of Oral Medicine, San Diego, California
April 18-24, 2015



Postdoctoral Research Symposium, University of Kentucky, KY

June 12, 2015



Annual James Graham Brown Center Retreat, University of Louisville

Oct 2013,Oct 2014



Research! Louisville, University of Louisville

Oct 2013,Sep 2014



Graduate Research Symposium, University of Louisville

Nov 2014

ORAL PRESENTATIONS
1.

Dissertation Defense, Department of Biochemistry and Molecular Genetics
University of Louisville, Louisville, KY
July 15, 2016
“Molecular Characterization of Human Papillomavirus in Head and Neck Tumors”

2.

James Graham Brown Cancer Center Colloquia
University of Louisville, Louisville, KY
“Human Papillomavirus in Head and Neck Tumors”

Apr 6, 2016

3.

Three Minute Thesis Competition (Founded by the University of Queensland)
2016 Research Conference, University of Louisville, Louisville, KY
Apr 1, 2016
“Histologic variation in high-grade oral epithelial dysplasia when associated with HPV”

4.

Commission on Diversity and Racial Equality (CODRE) meeting
University of Louisville, Louisville, KY
Jan 14, 2016
“Human Papillomavirus Detection in Histological Samples of Premalignant Oral Lesions”

5.

Research Conference, Department of Biochemistry and Molecular Genetics
University of Louisville, Louisville, KY
Oct 28, 2015
“Molecular Characterization of Human Papillomavirus in different lesions of Head and Neck”

6.

Seminar, Department of Biochemistry and Molecular Genetics
University of Louisville, Louisville, KY
“Current Insights into HPV Integration-Driven Carcinogenesis”

Feb 23, 2015

POSTER PRESENTATIONS
1.

Khanal S, Shumway BS, Joh J, Zahin M, Ghim SJ, Redman R, Bumpous J, Jenson AB “Human
papillomavirus (HPV) prevalence and HPV DNA integration status in benign, premalignant and
cancerous lesions of the head and neck”
o Research Retreat –Department of Biochemistry and Molecular Genetics, August 21,
2015, University of Louisville, Louisville, USA
o Research! Louisville, Oct-2015, University of Louisville, Louisville, KY

2.

Khanal S, Trainor P, Rai SN, Zahin M, Ghim SJ, Joh J, Jenson AB, Shumway BS. “Histologic
Variation in High-Grade Oral Epithelial Dysplasia when associated with High-Risk Human
Papillomavirus”
o 30th International Papillomavirus Conference & Clinical Workshop (HPV 2015),
September 17-21, Lisbon, Portugal
o 2016 Multidisciplinary Head and Neck Cancer Symposium, which will be held February
18-20 in Scottsdale, AZ.

3.

Khanal S, Cole ET, Joh J, Ghim SJ, Jenson A, Rai SN, Trainor PJ, Shumway BS. “Human
Papillomavirus Detection in Histological Samples of Multifocal Epithelial Hyperplasia: a novel
demographic presentation”
o Joint Annual Meeting of American Academy of Oral and Maxillofacial Pathology
(AAOMP)/ American Academy of Oral Medicine (AAOM), April 18-24, 2015, San Diego,
California. http://www.oooojournal.net/article/S2212-4403(15)00991-8/abstract
o Postdoctoral Research Symposium, June 12, 2015, University of Kentucky, KY

135

4.

Khanal S, Joh J, Redman R, Bumpous J, Ghim SJ, Jenson AB “Correlation of HPV serology with
p16, smoking status and treatment response in oropharyngeal squamous cell carcinoma
patients”.
o Research! Louisville, Sept-2014, University of Louisville, Louisville, KY
th
o 14 James Graham Brown Center Retreat, Oct 17, 2014,University of Louisville,
Louisville, KY
o Graduate Research Symposium, Nov-2014, University of Louisville, Louisville, KY

5.

Khanal S, Ghim SJ, Davis KR, Ellis S., and Jenson AB. “A soybean peptide-lunasin suppresses
BPV-1 induced fibrosarcoma in mammalian cells”
o Research! Louisville, Oct-2013, University of Louisville, Louisville, KY
th
o 13 Annual James Graham Brown Center Retreat Oct 25, 2013, University of Louisville

6.

Zahin M, Ghim SJ, Khanal S, Jenson AB, Joh J. “Molecular characterization of two novel
mucosotropic papillomaviruses isolated from a Florida Manatee (Trichechus manatus latirostris)”.
th
o 14 James Graham Brown Center Retreat, Oct 17, 2014,University of Louisville,
Louisville, KY

7.

Zahin M, Joh J, Khanal S, Husk A, Mason H, Ghim SJ, Matoba N, Jenson AB. “Plant-based
Recombinant Vaccine: Purification of HPV16 L1 Protein And VLPs from Tobacco Leaves”
o PBVAB (Plant-Based Vaccines, Antibodies & Biologics) June 8-10 2015, Lausanne,
Switzerland
th
o 30 International Papillomavirus Conference & Clinical Workshop (HPV 2015),
September 17-21, Lisbon, Portugal

8.

Perez CA, Wu X, Amsbaugh MJ, Claudino WM, Yusuf M, Roberts T, Rios-Perez JA, Jain D,
Jenson A, Khanal S, Silverman CI, Tennant P, Dunlap NE, Rai S, Redman R. “High-dose versus
weekly cisplatin definitive chemoradiotherapy for HPV-related oropharyngeal squamous cell
carcinoma of the head and neck”
o 2016 ASCO (American Society of Clinical Oncology) Annual Meeting, June 3-7, 2016,
Chicago, Illinois
https://asco.confex.com/asco/2016/sci/papers/viewonly.cgi?username=166554&passwo
rd=766578
http://www.redjournal.org/action/doSearch?searchType=quick&searchText=khanal&occ
urrences=all&journalCode=rob&searchScope=fullSite

RESEARCH EXPERIENCE
Pre-doctoral research and other lab projects
Jan 2013- Aug 2016
Dr. Alfred Bennett Jenson and Dr. Steven R. Ellis (Supervisors), University of Louisville, KY
Dr. Jenson’s Lab, James Graham Brown Cancer Center, University of Louisville
 Molecular characterization of HPV-associated tumors of the head and neck, such as studies on
HPV DNA Integration, Methylation, Virus-induced epigenetic regulation and Fanconi AnemiaDNA repair Pathway
 HPV-serotyping and estimation of antibody titer in sera of head and neck cancer patients
 HPV detection in histological samples from benign and premalignant oral mucosal lesions
 Animal (Cat, Dog, Macaque, Manatee) papillomavirus infections
 Plant-based HPV vaccine development
 Determination of the effects of lunasin on BPV-1 induced fibrosarcoma in NIH 3T3 cells
 Papillomavirus isolation and purification by cesium chloride ultracentrifugation method
Lab Rotation
Sep-Dec, 2012
Dr. Schaner Tooley’s Lab, University of Louisville, KY
 Determine the effects of NRMT loss and/or inhibition of primary mammary epithelial cell growth
 Mouse mammary gland dissection, production of primary epithelial cells for culture, lentivirus
production, cell growth assays and immunofluorescence techniques
M.Sc. Dissertation
March-July, 2011
“Khanal, S., and Sharma, P.R. (2011) Anti-cancer activity of Withaferin A, an active compound from
Withania somnifera: Induction of apoptosis and inactivation of PI3K pathway. M.Sc. in Biochemistry
Dissertation, Indian Institute of Integrative Medicine, Council of Science & Industrial Research, Jammu,
India”
 Studied anti-cancer activity of withaferin A (WA, an active compound from Withania somnifera)
using scanning electron microscopy and fluorescent microscopy.

136
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